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T Testosterone
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TAM Tamoxifen
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Toluene [Carlo Erba -  F a rm ita l ia ,  I ]
Triamcinolone acetonide [Sigma, USA]
T r ich lo ro a ce t ic  acid [Carlo Erba -  F a rm ita l ia ,  I ]
Tris(hydroxymethyl)aminomethane
[Sigma, USA]
Trypan Blue [Sigma, USA]
Trypsin [Flow Laboratories In c . ,  USA]
Water (HPLC grade) [Omnia Res s r l , I ]
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[Runne, FRG]
Columns
a) Bond E lu t C2/500mg [Analytichem I n t . ,  USA]
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ZR75-1 [Dr. R.J.B. King, I .C .R .F .,  London, UK]
Endometrium
HEC-1A [Dr. R.J.B. King, I .C .R .F .,  London, UK]
HEC-50 [P ro f.  E. Gurpide, Mount Sinai H osp ita l,
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SUMMARY
This thes is  examines metabolism o f s te ro id s ,  
evaluated through conversion rates o f precursors ( l ik e  
oestrad io l (E2) and testosterone ( I ) )  in  " in  v i t r o ”' 
systems. Several long term c e l l  l in e s  derived from the 
endocrine re la ted  tumours o f breast, endometrium and 
prostate were used.
One o f the main goals was th a t o f re la t in g  the 
d i f fe re n t  conversion rates o f s te ro id  precursor(s) to 
the hormone s e n s i t i v i t y  s ta tus of c e l ls  defined by the 
presence or absence o f S ite  I receptors. To th is  end 
both responsive and unresponsive c e l l  l in e s  were 
s tud ied, i . e .  the mammary c e l l  l in e s  ZR75-1, T47-D, MDA- 
MB231, BT20 and PMC-42 and the endometrial c e l l  l in e s  
Ishikawa and HEC-1A. In both c e l l  types E2 conversion 
rates were inves t iga ted .
For prosta te  the c e l l  l in e s  under study were PC3 
and DU-145, o f human o r ig in ,  and CPA and CAPE from dog. 
Study o f these canine c e l ls  arose from the need o f a
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well estab lished c e l l  l in e  derived from normal prosta te  
ep ithe lium  which is  not re a d i ly  ava ilab le  among the 
human cel 1 1ines.
Cell l in e s  were characterized fo r  th e i r  content of 
s te ro id  receptors fo r  both oestrogens ( in  breast and 
endometrial c e l ls )  and androgens (p ro s ta te ) .  The 
stud ies on s te ro id  receptors were ca rr ied  out through 
the c lass ica l method o f dextran coated charcoal, in  
order to  d i f fe r e n t ia te  S ite  I ,  high a f f i n i t y  -  low 
capacity w ith a Ka o f >10(9)M from S ite  I I ,  s p e c i f ic  but 
lower a f f i n i t y  b ind ing.
S tero id  metabolic conversions in  v i t r o  showed 
p reva len t ly  an ox ida tive  metabolism of E2, in  some 
breast and endometrial cancer c e l l  l in e s ,  and o f T in  
prosta te  cancer . c e l l s .  Under id e n t ica l experimental 
cond it ions , other c e l l  l in e s  showed metabolic pathways 
in which reductive metabolism p re v a i ls .  For example, in  
some receptor negative breast and endometrial cancer 
c e l ls  (HEC-1A, PMC42, BT20 and MDA-MB 231) E2 was very 
qu ick ly  converted to  oestrone (E l ) .  Conversion ra tes
2
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were more than 50% in  the f i r s t  24 hr and s t i l l  g reater 
a f te r  96 hr.
However, in  the receptor p o s it ive  c e l l  l in e s  
Ishikawa, ZR75-1 and T47-D, E2 was very s low ly degraded 
and El formation was less than 10%, in  most cases, and 
never exceeded 40% even a f te r  96 hr. At the same time 
these c e l l  l in e s  showed very early  formation of 
catecholoestrogens (CCE) and o f o e s tr io l  (E3). The 
"o x id a t iv e "  c e l ls  (those which ra p id ly  convert E2 to  E l) 
showed very l i t t l e  i f  any, formation o f CCE and E3.
Thus, o v e ra l l ,  metabolic patterns o f several c e l l  
l in e s  re la te  to the hormone s e n s i t iv i t y  s ta tus  o f the 
c e l ls ,  as defined by s te ro id  receptor s ta tu s . These 
s ig n i f ic a n t  d if fe rence s , observed between c e l ls ,  appear 
to  be h igh ly  reproducib le , provided th a t both i n i t i a l  
c e l l  number and molar concentration of precursors are 
held constant. S im ila r  re su lts  were obtained in 
prosta te  normal and cancer, canine and human c e l l  l in e s .  
In fa c t ,  androgen receptor p o s it iv e  c e l ls ,  l i k e  canine 
cancer CPA and human cancer DU145 c e l ls ,  produced
3
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dihydrotestosterone (DHT) e a r ly ,  but only s low ly 
converted T. On the contra ry  unresponsive l i k e  human 
cancer c e l ls  PC3 and normal canine CAPE, very q u ick ly  
metabolize I  but no formation o f DHT was observed.
In the receptor negative prosta te  c e l ls  there was 
evidence th a t p re v a i l in g  o x id a t ive  metabolism was also 
observed when E2 was added as precursor. In conclusion, 
the d i f fe re n t  s te ro id  metabolic patterns observed in  
several long term c e l l  l in e s  appear to be an i n t r in s i c  
h igh ly  reproducib le property o f the c e l l  types, re la ted  
to  th e i r  s te ro id  hormone receptor content and, 
the re fo re , presumably to t h e i r  s e n s i t i v i t y  to  these 
s te ro id  hormones.
In v i t r o  systems o f fe r  many advantages i . e .  the 
p o s s ib i l i t y  to  study almost pure e p i th e l ia l  c e l ls  
w ithout in te r fe r in g  actions o f stromal c e l ls  or 
e x t ra c e l lu la r  s tru c tu re s . On the other hand, stromal -  
e p i th e l ia l  in te ra c t io n s  and e x t ra c e l lu la r  s tru c tu re s  are 
in teg ra l parts o f the tissues in  v ivo . As a consequence 
th is  study was expanded to  study the t issue  content o f
4
SUMMARY
oestrogens ( in  both normal endometria and breast cancer 
t issues) to  obta in  some in d ic a t io n  on s te ro id  metabolism 
in  v ivo .
The study included: a) oestrogen concentrations in  
normal endometrium, in  both ea r ly  p r o l i f e r a t i v e  and 
la te  secretory menstrual cycle phases; b) the 
concentration o f oestrogens in  breast cancer t issues and
c) the free  oestrogen content in  breast cyst f l u id  
(BCF). From these stud ies emerged evidence th a t two 
d i f fe re n t  oestrogen patterns e x is t .  Again, the 
d if fe rences can be associated w ith the hormone 
s e n s i t iv i t y  s ta tus  o f the tissues as determined by 
receptor content. In BCF there was c lea r evidence th a t 
a number o f selected parameters o f oestrogens were 
s ig n i f i c a n t ly  associated w ith  the d i f fe re n t  potassium 
(K+) to  sodium (Na+) ra t io s .
A ll these observations were cons is ten t w ith  the 
view th a t ,  in  v i t r o  or in  v ivo , ox ida tive  metabolism of 
s te ro ids  is  associated w ith  receptor negative, hormone 
in se n s it ive  tissues and, on the con tra ry , reductive
5
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metabolism is  associated w ith  receptor p o s i t iv e ,  hormone 
se ns it ive  t issues*
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1 . INTRODUCTION
1 .1 . Steroid Hormones
Oestrogens have been long inves t iga ted , but 
understanding o f the processes involved in th e i r  
fo rmation, metabolism and the outcome of th e i r  
b io lo g ica l e f fe c ts ,  is  s t i l l  l im i te d .
Because of the complexity inherent in  the chemistry 
of these hormones, the abundance o f c lose ly  re la ted  
compounds in  nature, the extremely low steady-sta te  
concentrations of many o f the key intermediates in most 
human tissues and the very rapid tu rn -over rates o f some 
o f them, oestrogen studies are complex.
These problems are compounded by the lack o f 
soph is t ica ted  methods to  permit a complete separation 
and a reproducib le q u a n t i f ic a t io n  o f ind iv idu a l 
metabolites.
Some o f the ea r ly  experimental data come from crude 
and u nsa t is fac to ry  methodological approaches and cannot
7
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be re l ie d  on.
A number o f fa c to rs  con tr ibu te  to ove ra l l  oestrogen 
metabolism, e.g. ovarian and adrenocortica l fu nc t ion s , 
modulation and/or regu la tion  by centra l nervous system 
hormones, plasma leve ls  o f c a r r ie r  p ro te in s , periphera l 
aromatiza tion , rates o f in t ra t is s u e  conversion, 
production rates of conjugated compounds and excre tion
rates and ra t io s  o f end-products. Moreover, a t le a s t
some of these aspects must be considered in terms o f
comparative b iochemistry.
Oestrogen metabolism was, u n t i l  rece n t ly , poorly 
understood compared w ith other s te ro id  pathways, l i k e  
those o f Androgens or C o rt ico s te ro ids . A d d it io n a l ly ,  
in te re s t  has mainly focused on the three c la ss ica l
oestrogens. Thus, very l im i te d  a t te n t io n  has been paid
to the m a jo r ity  o f intermediate oestrogen compounds. 
Nevertheless, the lack o f experimental work on the ro les  
played by the intermediate oestrogens does not ind ica te  
lack of metabolic fu nc t ion .
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1.2 . H is to r ic a l  Rela tionsh ip  Between Hormones and Cancer
Growth
The re la t io n s h ip  between hormones and cancer is  
s t i l l  an open question, a t lea s t fo r  a number o f 
aspects, despite the large l i t e r a tu r e  [Henderson et a l . ,  
1982; James and Reed, 1980; Kelsey e t a l . ,  1981;
Kirschner e t a l . ,  1982; Thomas, 1978; Zumoff, 1981; 
Zumoff, 1982]. These con tr ibu t io n s  have been o f great 
value both in  terms o f the th e o re t ica l basis in  
understanding cancer growth^and in the p ra c t ica l  care of 
cancer p a t ien ts .
A fte r  S ir  Astley Martin observation in 1835, 
f i r s t l y  Beatson [1896] showed a re la t io n sh ip  between the 
ovaries and breast cancer, but the f i r s t  d i re c t  
experimental evidence o f s te ro id  action  in  ta rg e t 
tissues did appear over 60 years la t e r .  In 1959 two 
biochemists revealed accumulation o f lab e l le d  hexoestrol 
in  reproductive tissues o f immature sheeps and goats. 
This was the f i r s t  real evidence fo r  oestrogen receptors 
(ER) [Glascock and Hoekstra, 1959].
9
INTRODUCTION
In 1960 Bui brook published experimental re su lts  
showing th a t measurement o f 17-Hydroxy-Corticostero ids 
(170HCS) and Aetiocholanone excre tion  values improved 
se lec t ion  o f breast cancer pa t ien ts  fo r  hormone-therapy 
[Buibrook e t a l . ,  I960 ].
These two contemporany experimental achievements 
created the background from which several subsequent
stud ies were founded and from which apparently
dichotomous research trends s ta r te d . Thus, many attempts 
have been made to  u t i l i z e  Stero ids as biochemical 
markers of human breast and other endocrine-re la ted  
cancer.
A fte r  the BulbrOok’ s d isc r im inan t fu n c t io n , Lemon 
introduced th a t o f o e s tr io l  (E3) quotien t [Lemon et a l . ,  
1966], concerning the excre tion  r a t io  values o f
c lass ica l oestrogens. La te r, th is  was used to  study the 
epidemiology o f breast cancer in  Asian and North—
American women [HacMahon e t a l . ,  1971]. In 1971 Dao 
presented a c r i te r io n  fo r  p re d ic t in g  successful response 
to adrenalectomy o f breast cancer p a t ie n ts ,  based on the
10
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evaluation o f sulphokinase a c t i v i t y  w ith in  the tumour 
(as sulphates synthesis ra tes , i . e .
Dehydroepiandrosterone (DMA) :17f$--oestradiol (E2) ra t io )  
[Dao and Libby, 1971].
In 1975 a tte n t io n  moved to other s te ro id  excre tion  
leve ls  and ra t io s ,  inc lud ing  progestins and 
c o r t ic o s te ro id s  [Kodama et a l . ,  1975]. Oestrogen
excretion  p ro f i le s ,  inc lud ing  less common oestrogens -  
the ’"unusual”  oestrogens -  were inves t iga ted  in  our 
labora to ry  [Castagnetta e t a l . ,  1977; Castagnetta et 
a l . ,  1981] The importance o f the minor metabolites was 
stressed by Dao [1979] who championed the study o f 
metabolism and e spec ia lly  of the more po lar oestrogens.
Studies on minor s te ro id  metabolites inc lud ing  
those on catecholoestrogens [Martucci and Fishman, 
1976], on s te ro id -su lpha tes  pool [Poortman e t a l . ,  1973] 
and on peripheral aromatization [Nimrod and Ryan, 1975] 
were performed but s tud ies on metabolism of these 
compounds have developed in  recent years.
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1 .3 . Oestrogens and Cancer
In stud ies on oestrogens in  re la t io n  to  cancer 
growth, a number o f hypotheses e x is t .  These a c tu a l ly  
range between the c lass ica l " th ree  oestrogens" 
hypothesis and the "conjugate oestrogens" hypothesis; 
p a r t ic u la r  conjugates are the sulphates (S) and the 
l ip o id a l  oestrogens. On the other hand, must be 
remembered the importance o f some minor oestrogen 
metabolites, l i k e  e s te tro l  [Martucci and Fishman, 1977], 
lba-hydroxy-oestrone (16aOH~El), on which L. Bradlow and 
coworkers [1986a] have recently  concentrated, and the 
more investiga ted  catecholoestrogens.
For example a number o f biochemical actions are now 
known to  be played by catecholoestrogens and th e i r  
metabolites and more is  known about the b io syn th e t ic  
processes o f these compounds. Also the ro le  o f some 
other metabolites ( l i k e  16ceOH~El) as r is k  fa c to rs  fo r  
breast cancer in  humans is  being inves t iga ted .
Concomitantly, several enzymatic a c t i v i t i e s  have 
been studied in  the attempt to  b e tte r  c l a r i f y  oestrogen
12
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metabolism and production ra tes. Aromatase, catechol — 
oxy-methyl-transferase (COMT) several hydroxylases, 
sulphotransferases and sulphatases, and o rn ith in e  
decarboxylase (ODC) have a l l  been studied [A bu l-H a jj e t 
a l . ,  1979a; Amr et a l . ,  1980; Assicot e t a l . ,  1977;
Edman et a l . ,  1978; Fishman, 1982; Folkerd and James, 
1982; Fournier et a l . ,  1982; Gurpide and Marks, 1981; 
King e t a l . ,  1981; Kreitman e t a l . ,  1979; Kreitman et 
a l . ,  1980; Li e t a l . ,  1976; Mauvais-Jarvis et a l . ,  1986; 
Newton and James, 1985; S i i t e r i  and MacDonald, 1973; 
S i i t e r i ,  1982; Tseng and Gurpide, 1975; Tseng et a l . ,  
1977; Tseng e t a l . ,  19813.
In v i t r o  system stud ies demonstrate how e p i th e l ia l  
cancer c e l ls  can qu ick ly  convert E2 to E2-S [Hata et 
a l . ,  1987]; the same c e l ls  can also ra p id ly  produce
large amounts of l ip o id a l  oestrogens. Conjugate 
formation, prev ious ly  considered as s p e c if ic  fo r  
metabolism of s te ro ids  by l i v e r ,  is  now recognized to 
happen to a large extent also in  periphera l ta rg e t 
t issues . This is  very re levant because conjugate
13
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oestrogens are considered as long acting s te ro id s ,
S tero id  metabolism in cancer biopsies may be a 
r e f le c t io n  o f the disease s ta te .  Consequently, 
a t te n t io n  should be focused on the s te ro id  pa tte rns 
during the ea r ly  premalignant s ta te  to get an in s ig h t  
in to  the changes which enhance carcinogenic a c t i v i t y  
and/or cancer progression. These cons idera tions, 
combined w ith  improving methodologies, have perm itted us 
to obta in  new data about s te ro id  metabolism. For 
example, very recen tly  convincing evidence has arisen 
[Vandewalle e t a l . ,  1985] fo r  a s p e c if ic  receptor fo r  
catecholoestrogens, d i f f e r e n t ly  loca l ized  from the well 
characterized 178-E2 receptor; i t  suggests th a t a 
b io lo g ica l and/or biochemical ro le  played by 
catecholoestrogens may be more important than prev ious ly  
be lieved. This supports the data from our Lab, showing 
th a t very large concentrations o f catecholoestrogens can 
be found in breast or endometrial cancer t issues or th a t  
they are early  formed by breast and endometrial cancer 
c e l ls  in  v i t r o  [Castagnetta et a l , ,  1986a; see also
Section 3 ,1 . ] .
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1 . 3 . 1 . 16«-hydroxy1at ion
Much evidence has rec en t ly  ar isen suppor t ing  an 
impor tant  ro le  in  carcinogenesis f o r  16a'0H~El, 16a-
hyd roxy la t ion  being o r i g i n a l l y  thought to  be much 
h igher than 2 -hyd ro x y la t io n  in  var ious animal and human 
t is s u e s .  However, more s e n s i t i v e  techniques have shown 
th a t  the ex ten t  o f  2 -hy d rox y la t ion  is  between three and 
fou r  t imes more than 16a -hydroxy la t ion  [Schneider et  
a l . ,  1982].
Looking at  d i f f e re n c e s  between 2- and 16a- 
hyd roxy la t ion  o f  E2 in  o ther  species l i k e  pr imates and 
experimental  animals i . e .  d i f f e r e n t  mice s t r a i n s ,  i t  can 
be seen t h a t ,  the ex ten t  o f  2 -hyd ro x y la t io n  is  much 
h igher  (ranging from 2 to  10 f o ld )  [Bradlow e t  al . ,  
1986a]. There is  also some evidence th a t  females e x h i b i t  
h igher  le v e ls  of  2 -hy d rox y la t ion  w i th  respect to  males 
(also in  humans, but exc luding  some rodents -  ra ts  and 
m ice ) .
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Brad1owf s group studied 2- and 16a~hydroxylation in 
normal women and in  breast cancer p a t ie n ts .  No
d if fe rences in  the extent o f 2~hydroxylation were found. 
On the con tra ry , 16a~hydroxy1ation was greater (about 
50% more) in cancer pa t ien ts  and there was v i r t u a l l y  no 
overlap between the re su lts  in  breast cancer pa t ien ts  
group w ith respect to  the contro l subjects [Schneider e t 
a l . ,  1982]. A s im i la r  increase was observed in  women
with endometrial cancer [Fishman et a l . ,  1984]. These 
re su lts  were obtained using a very o r ig in a l  rad iom etric  
technique. A fte r  the adm in is tra t ion  o f labeled E2,
t r i t iu m  release from the metabolic reac tive  s i te  was
measured in the body water pool [Fishman et a l . ,  1980].
I t  is  o f in te re s t  to note th a t 2 -hydroxy la t ion  and
16a-hydroxy1ation show minimal v a r ia b i l i t y  w ith  age and
menopausal s ta tus  [Fishman e t a l . ,  1980]; though some 
reduction was observed in humans between pre- (39%) and 
post-menopause (33%) in the extent o f 2 -hydroxy la t ion , a 
n o n -s ig n if ica n t v a r ia t io n  between pre (10.7%) and post 
(8.5%) menopausal subjects was reported fo r  16a- 
hydroxy la tion .
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A series o f experimental re su lts  were obtained by 
studying and comparing the extent o f 16a-hydroxy1ation 
in d i f fe re n t  mice s tra in s  having d i f fe re n t  mammary 
tumour incidence [Bradlow et a l . ,  1986b]. C lea r ly  the 
16a-hydroxylation extent was h igh ly  re la ted  to s tra in s  
burdened by higher tumour incidence; C3H/0uJ and 
C3H/HeJ, having 100% tumour incidence, showed about 20% 
o f 16o:-hydroxyl a t io n ,  w h i ls t  C57B1/6J or C57L/J (having 
less than 1% of tumour incidence) showed g re a t ly  reduced 
16a~hydroxylation a c t i v i t y .  C57Br/CdJ has no tumour 
evidence at a l l  and e x h ib i ts  a very low 16a- 
hydroxy la tion  a c t i v i t y  (3.8%), i . e .  6-7 times less than 
th a t observed in s t ra in s  having higher incidence o f 
tumour. In mice aging d id not change l i k e  sex, the 
percent o f th is  reac tion . These authors concluded th a t 
E2 16o:-hydroxylation is  h igh ly  co rre la ted  w ith  tumour 
incidence and th a t th is  is  p a r t i a l l y  influenced by mouse 
mammary tumour v irus  (MMTV) and regulated by genetic 
fa c to rs .  The authors observed th a t no d if fe rences  
occurred in  the extent o f the reaction in  d i f fe r e n t
17
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males of the same mice s t ra in .  They suggested th a t a 
dominant autosomal gene must regulate E2 16a~ 
hydroxy la t ion . The extent o f th is  reaction fo r  E2 is  
lower than th a t  of several androgens and p rogestins i 
16a-hydroxylation o f E2 is  about 2.0 or less in 
d i f fe re n t  s t ra in s  o f mice; i t  is  between 3.0 and 6.0 fo r  
testosterone (T), between 1.5 and 10.9 fo r  
dehydroisoandrosterone; i t  is  much higher fo r  
progesterone (Pg), ranging from 13.8 to about 30.0, and 
also h igher, between 5.5 and 21.5, fo r  pregnenolone. 
However th is  s ig n i f ic a n t  increase in the main metabolic 
pathway o f E2 could play a major ro le .  The authors 
pointed out th a t the powerful 16o:OH-El, a product of 
th is  reac tion , is  able to cova len tly  bind to  aminogroups 
on pro te ins  and nucleotides and, thus, i t  is  capable of 
achieving an extended residence time in  the nucleus 
[Bucala e t a l . ,  1982; Yu and Fishman, 1985].
1 .4 . B iologically  Available Steroids and Cancer
In te re s t  in  free  f ra c t io n s  re la t iv e  to s te ro ids  in 
blood, comes from previous work by Pardridge e t a l .
18
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[1980 ].
A general b e l ie f  e x is ts  th a t free  s te ro id  f ra c t io n  
is  more b io lo g ic a l ly  ava ilab le  to t issues.
S i i t e r i  e t a l . [1980] i n i t i a l l y  suggested th a t r is k  
o f breast and endometrial cancer may be re la ted  to the 
b io lo g ic a l ly  a va ilab le  f ra c t io n  o f E2. This led to  an 
in te re s t  in  the d is t r ib u t io n  o f E2 among plasma 
p ro te ins .
Evidence has been presented th a t  both non p ro te in -  
bound and albumin-bound E2 are able to cross the blood- 
bra in  in  ra ts ,  whereas E2 bound to  S tero id  Hormone 
Binding Globulin (SHBG) does not. This suggests th a t  E2 
may be considered as b io lo g ic a l ly  ava ilab le  unless bound 
to  SHBG [ S i i t e r i  e t a l . ,  1981].
1 .4 .1 . Breast cancer
In some s tud ies , plasma E2 was measured in normal 
and breast cancer postmenopausal women (see Tab. 1 .01). 
They showed th a t free  E2 was s ig n i f i c a n t ly  increased in
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Table 1.01.
Summary of data from several Authors comparing 
plasma free  oestrad io l in  normal and breast 
cancer postmenopausal women.
Reproduced from Reed and James [1987].
PERCENTAGE OF FREE OESTRADIOL IN PLASMA 
FROM NORMAL POSTMENOPAUSAL WOMEN AND 
FROM POSTMENOPAUSAL WOMEN WITH BREAST CANCER
Free Oestradiol (%)
Normal B Ca Reference
1.72 2 .1 9 - [Moore et a l . ,  1982]
1.52 1 .8 5 - [Reed et a l . ,  1983]
1.96 2.22- [Lang!ey e t a l . ,  1985]
1.47 1.54 [Bruning et a l . ,  1985]
•p<0.05, •-pcO.OOl (from Reed & James [1987])
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breast cancer group [Langley et a l . ,  1985; Moore e t  a l . ,  
1982; Reed e t a l . ,  1983]. However, some other authors 
fa i le d  to  obta in s im i la r  evidence [Bruning et a l . ,  
1985]. In fa c t ,  from Bruning 's paper, comparable 
increase in  free  E2 was not observed, although higher 
increased plasma concentration o f E2 was found in women 
with breast cancer. Moreover, i t  has been suggested 
very recently  th a t s te ro ids  bound to  both albumin and 
SHBG (the two major plasma transport p ro te ins  of 
s te ro ids )  may also be e a s ily  a va ilab le  to  ta rg e t t issues 
[Pardridge e t a l . ,  1980; Petra e t a l . ,  1983; S i i t e r i  e t 
a l . ,  1982].
Another series o f data was obtained by studying 
the albumin-bound f ra c t io n  o f E2, which is  about 20 
fo ld  greater than the free  E2 concentration in  plasma 
[Reed et a l . ,  1983], These stud ies may be e a s ily
misleading because of the observed wide f lu c tu a t io n s  
over a 2A hr period in  the albumin-bound E2 [Reed et 
a l . ,  1986a].
Comparing Japanese and B r i t i s h  women, a s ig n i f i c a n t
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d if fe rence  was shown concerning the albumin-bound E2 
f ra c t io n  [Moore e t a l . ,  1983]. Bui brook observed th a t 
normal Japanese women e x h ib i t  qu ite  d i f fe re n t  
p roportions o f to ta l  E2 bound to  SHBG in blood with 
respect to B r i t i s h  women. Japanese women have a reduced 
r is k  o f developing breast cancer w ith  respect to  B r i t i s h  
ones [Armstrong and D o l l ,  1975]. D iet has been 
im plicated in development o f breast cancer; e .g . fa t  
consumption is  much lower among Japanese than B r i t i s h  
women [Moore e t a l . ,  1983].
Some stud ies have shown th a t ,  " in  v i t r o " ,  l i p id s  
can increase the ava ilab le  f ra c t io n  o f to ta l  plasma E2 
[Reed et a l . ,  1986b]. The suggestion was made th a t an 
increased r is k  of developing breast cancer may be 
associated w ith a high fa t  d ie t ,  because o f the supposed 
increase in  the ava ilab le  E2 plasma f ra c t io n .  However, 
curren t epidemiological stud ies can f in d  no d ire c t  
c o r re la t io n  o f breast cancer w ith f a t  in take , only w ith 
to ta l  c a lo r ic  intake [Reed e t a l . ,  1986b].
An important question is  to  what extent p ro te in -
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bound s te ro ids  are b io lo g ic a l ly  a va ila b le .  This is  a 
debated matter and experimental co n tr ib u t io n s  to  th is  
po in t are s t i l l  today not p a r t ic u la r ly  s a t is fa c to ry .  
For example, plasma d is t r ib u t io n  o f testosterone (T) is  
modified a f te r  adm in is tra t ion  o f 31-Thyronine (T3) 
(3Q0pg/day), which was shown to increase the SHBG plasma 
leve ls  [Ruder et a l . ,  1971]. A large r is e  in the 
b inding capacity  o f SHBG, a f te r  adm in is tra t ion  of 
t r i io d o - th y ro n in e  fo r  three weeks, was observed. This 
increase was p a ra l le le d  by a f a l l  in  both free  and 
albumin-bound T. However, the re s u lt in g  increase of 
SHBG-bound T was mainly couterbalanced by a f a l l  in  
albumin-bound T (% reduction o f free  T was from 2.5 to 
less than 1.0%, th a t o f albumin-bound T changed by more 
than 40% to about 10%, re s p e c t ive ly ) .  I t  is  to be noted 
th a t  adm in is tra t ion  of T3, 300pg/day fo r  3 weeks, 
resu lted in  a very large increase o f SHBG content (from 
less than 1 to  more than 2.2pg/100ml) .
Results from d i f fe re n t  s tud ies ind ica te  an abnormal 
d is t r ib u t io n  of plasma to ta l  E2 in  women w ith  breast
22
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cancer, but these changes, s p e c ia l ly  the increment o f 
f ree  E2 concentra tion , are very l im i te d .  The 
s ign if ica nce  o f th is  small r ise  o f free s te ro ids  in 
re la t io n  to tumour development is  the re fo re  not 
p a r t ic u la r ly  convincing, s ince i a) the reported increase 
appears to be very small, a t le a s t in  re la t io n  to  th a t
o f SHBG observed in  the same experiments; b) the ro le
and the reduced a v a i l a b i l i t y  of free  and conjugate 
s te ro ids  is  s t i l l  unclear -  the re la t iv e  proportion  of 
free  and conjugate f ra c t io n s  appears to  be very low.
In ea r ly  stud ies concerning the plasma binding of 
E2 in breast cancer p a t ie n ts ,  p re lim ina ry  evidence 
suggested th a t plasma E2 a v a i l a b i l i t y  was greater than 
predicted from plasma SHBG leve ls  in  these pa t ien ts  
[Si i t e r i  et a l . ,  1981].
The report by S i i t e r i  [ S i i t e r i  e t a l . ,  1986],
concerns evaluation o f to ta l  E2, free  E2, to ta l  El and
SHBG leve ls  in  both women w ith benign or malignant 
breast diseases and con tro ls  (Tab. 1 .02), The analys is  
o f re s u lts ,  concerning Caucasian women, showed the
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Table 1.02.
Comparison o f pre and postmenopausal women with 
breast cancer and con tro ls  fo r  th e i r  plasma 
values of oestrone (E l) , oestrad io l (E2), free 
E2 and s te ro id  hormone binding g lo b u lin  (SHBG). 
Reproduced from S i i t e r i  e t a l . [19861.
SERUM ESTROGENS, FREE E2 FRACTION AND SHBG LEVELS 
(MEAN ± SD) IN PRE- AND POSTMENOPAUSAL WOMEN 
WITH BREAST CANCER AND CONTROLS
Premenop. women Postmenop. women
C ontro l Cancer C on tro l Cancer
Tota l E l°  82+36 105+77 35+19 36+16
Tota l E2° 110+84 124+85 14±8 16±9
Free E2° 2 .0+1 .5  2 .0 + 1 .4  0 .2 + 1 .0  0 .3 ±0 .2
SHBG* 44+19 52+24 44±24 45±20
n-36 n~36 n=38 n=38
°p g /m l; *pmoles/ml
(from S i i t e r i  e t  a l . ,  [19 86 ])
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expected inverse re la t io n sh ip  between plasma SHBG 
binding capacity and body weight, on one hand, and tha t 
o f the percentage o f free  E2 in  pre- and postmenopausal 
women, on the o ther. No s ig n i f i c a n t  d if fe rences  were 
observed when selected groups o f e i th e r  pre- or 
postmenopausal breast cancer pa t ien ts  were matched w ith 
appropria te  co n tro ls ,  tak ing in to  account age and body 
weight.
S i i t e r i  observes th a t these re su lts  are s tron g ly  in 
con tras t w ith previous reports from h is  own lab . He adds 
th a t the mean values o f con tro ls  appear to be higher 
than values reported e a r l ie r .  A very in t r ig u in g  
suggestion is  thus given concerning the in f luence o f  
sample storage; i t  was very short fo r  the la te s t  
re s u lts ,  but much longer fo r  the previous ones (two 
months mean storage o f frozen sera in  la s t  reports  vs 
6-8 years in  previous s tu d ies ) .
To te s t  th is  p o s s ib i l i t y ,  experiments were ca rr ied  
out by S i i t e r i  e t a l . [19863 to  compare e f fe c ts  o f long 
vs short term storage o f sera in  re la t io n  to  % values o f
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free  E2. Results ind ica te  th a t % of free  E2
s ig n i f i c a n t ly  increased in sera having long term (38 
months) w ith respect to  th a t  having short term (2 
months) storage. This increase appears to  be
s ig n i f ic a n t  in  sera o f cancer p a t ie n ts ,  although i t  was 
not s ig n i f ic a n t  comparing sera o f co n tro ls .  S i i t e r i  et 
a l . conclude th a t there is  no support fo r  the view th a t 
the development o f breast cancer may be l inked  to  a 
s p e c i f ic  defect in  oestrogen tran spo rt .  Nevertheless, 
i t  should be noted th a t the number o f cases in the la s t  
experiments was r e la t iv e ly  small and tha t these s tud ies , 
ca rr ied  out on breast cancer p a t ien ts ,  were
re trospec t ive , such th a t bias fa c to rs ,  r is in g  from many 
sources, have not been completely excluded.
In general terms, a l l  these studies can be 
in te rp re ted  so th a t some inherent d if fe rence  e x is t  in  
breast cancer p a t ien ts  fo r  SHBG values and also th a t 
some breast cancer p a t ien ts  e x h ib i t  an increased 
a v a i l a b i l i t y  o f plasma E2. An in te re s t in g  comment is  
given by S i i t e r i  in re la t io n  to the extent to which 
plasma oestrogen measurement re f le c ts  the hormonal
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m ilieu  o f the breast i t s e l f .
1 .4 .2 . Endometrial cancer
Less in formation regarding the re la t io n s h ip  between 
the free  s te ro id  pool and growth of endometrial cancer 
is  a va ila b le .  A re la t io n sh ip  between age, obesity  and 
endometrial cancer was f i r s t l y  suggested by S i i t e r i ,  on 
the basis of an increased periphera l oestrogen synthesis 
in  obese postmenopausal women together w ith  enlarged 
a v a i l a b i l i t y  o f plasma E2 [Davidson e t a l . ,  1981;
S i i t e r i ,  1981]. The hypothesis given was th a t 
c h ro n ic a l ly  elevated oestrogens, unopposed by 
progesterone, appear to promote endometrial cancer. 
However, S i i t e r i  observed th a t most postmenopausal women 
having a very s im i la r  oestrogenic s ta tus  do not develop 
any cancer, suggesting th a t other fa c to rs ,  such as 
enviromental carcinogens, may be invo lved. Very 
recently  S i i t e r i  [ S i i t e r i  et a l . ,  1986] postu la ted a 
necessary but in s u f f i c ie n t  ’V o le ”  o f oestrogens in 
cancer development, suggesting th a t some c r i t i c a l  le ve ls
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of these hormones may a c t iva te  those c e l ls  th a t have 
been already primed through another mechanism.
Reed and James [1987] studied a small number of 
women having endometrial cancer or benign hyperp las ia . 
The free  f ra c t io n  o f E2 was found to be s ig n i f i c a n t ly  
increased w ith  respect to  normal age-matched 
postmenopausal con tro ls  (values o f 1.94±0.36% observed 
in endometrial cancer pa t ien ts  were s ig n i f i c a n t ly  h igher 
(p<0.02) than those observed in  normal c o n tro ls ,  these 
la s t  being 1.52±0.33%). However, other authors found no 
d if fe rences in these s te ro id  f ra c t io n s  between normal 
women and pa tien ts  w ith endometrial cancer [Davidson et 
a l . ,  1981]. O vera ll,  the d if fe rence  in free  E2
concentrations between normal and endometrial cancer 
women was in  most stud ies very l im i te d .  Moreover* the 
ro le  th a t the increase o f free  s te ro id  f ra c t io n  may play 
in  the development or growth o f cancer tissues remains 
unclear.
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1 .5 . Prospective Studies of Hormones in Aetiology of
Human Cancer
To b e tte r  define the ro le  played by hormones in 
ae tio logy of the human cancer, prospective case-control 
s tud ies are necessary so one can evaluate s te ro id  
plasma and/or excre tion  leve ls  before the onset of 
disease. Some of these p ro jec ts  s ta rted  very re ce n t ly ,  
l i k e  QRDET study in  I t a l y  [Berr ino  e t a l . ,  1988].
P re lim inary re su lts  have been reported by Bui brook 
from h is  prospective study on the Guernsey Is land 
population [Buibrook et a l . ,  1986], showing th a t the 
m a jo r ity  of cases had lower leve ls  o f non-prote in  bound 
E2 w ith respect to th e i r  contro l ranges. This 
d is t r ib u t io n  was s ig n i f ic a n t ,  despite the considerable 
v a r ia t io n s  reported not only among precancer cases but 
also in contro l groups. Expressing data from co n tro ls  
as a % of the value fo r  precancer cases, i t  was 
emphasized th a t the m a jo r ity  o f the con tro ls  exh ib ited  
free  E2 f ra c t io n  values lower than those o f precancer 
cases (115 out of 139). However Bui brook po in ts  out 
th a t the magnitude o f the abnormality in  precancer cases
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is  small: about 70% of the contro l values lay  w ith in
±20% of the normalized precancer values. I t  was noted 
also th a t albumin-bound E2 leve ls  in  precancer cases, 
were not s ig n i f i c a n t ly  d i f fe re n t  from co n tro ls ;  on the 
con tra ry , precancer cases exh ib ited  E2 bound to  SHBG to 
a lesser extent than con tro ls  and th is  d if fe re nce  was 
s ig n i f i c a n t .  The SHBG capacity was lower in  the 
precancer cases group than in  co n tro ls ,  although no
s ig n i f ic a n t  d if fe rences were observed. In summary, 
re su lts  o f th is  case-control study showed a higher 
proportion  o f serum E2 in the ava ilab le  f ra c t io n  in
precancer cases.
The proportions of blood E2 in f re e , albumin-bound, 
and SHBG-bound f ra c t io n s  a l l  appear to be h ig h ly  
co rre la ted  w ith SHBG capac ity . As SHBG capacity  
increases, the p roportions o f e i th e r  free or albumin-
bound E2 decrease.
Concerning the observed r ise  o f the p roport ion  of 
SHBG-bound s te ro id ,  however, Bui brook observes th a t 
some fa c to rs ,  other than SHBG capacity , may a f fe c t
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th is  b ind ing, since the c o e f f ic ie n ts  of determ ination 
appear to  be in  the order o f 20%. Considering 
separate ly pre- and postmenopausal women, the 
re la t io n sh ip  between SHBG binding and capacity was about 
the same in premenopause, but postmenopausal women 
showed a c o r re la t io n  between binding capacity and free  
E2 f ra c t io n  only.
Bui brook reports  also th a t weight is  only 
margina lly  co rre la ted  w ith the free E2 f ra c t io n s  and is  
unrelated to the albumin or SHBG-bound f ra c t io n s .  
Considering Q uete le t’ s index (a measure o f f a t  con ten t) , 
i t  was observed th a t  there is  no c o r re la t io n  w ith  any of 
the three oestrogen f ra c t io n s  s tud ied. However i t  was 
also shown th a t the re la t io n s h ip  between weight and free  
E2 is  mainly accounted by the postmenopausal group. In 
conclusion, there is  a h ig h ly  s ig n i f ic a n t  re la t io n s h ip  
between weight increase and the decrease in the SHBG 
capacity . Note th a t ,  in  Bulbrook's study, pre- and 
postmenopausal women e x h ib i t  very s im i la r  values in the 
d i f fe re n t  parameters o f the free  and bound E2 f ra c t io n s
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in  blood.
I n i t i a l l y ,  Bui brook concluded th a t the precancer 
group was characterized by higher p roportion  o f e i th e r  
free  blood E2 and albumin-bound E2 (the "b io a v a i la b le  
f ra c t io n s " )  or by a reduced SHBG-bound E2 f ra c t io n .  I t  
was moreover observed th a t the to ta l  SHBG capacity  of 
th is  pa tien ts  group was not s ig n i f i c a n t ly  lower than 
co n tro ls . Both body weight and SHBG capacity  were 
excluded as fa c to rs  in f luenc ing  b io a v a i la b i l i t y  o f E2. 
Bulbrook considers, a t the end, the p o s s ib i l i t y  th a t 
SHBG capacity is  completely unrelated to  possib le 
increases in  E2-bioavai1able f ra c t io n s  [see Moore e t 
a l . ,  1982], since in the study concerning Guernsey
Is la n d ’ s population th is  was not apparent and the same 
was in  the study which compared B r i t i s h  and Japanese 
women [Moore et a l . ,  19833. Bulbrook notes also th a t  
increase in  the p roportion  o f a va ilab le  blood E2 
f ra c t io n s  in  precancer cases (10 to 15% fo r  the non 
protein-bound and 5% fo r  the albumin-bound f ra c t io n )  is  
small and asks whether so small an increment could be o f 
any b io lo g ica l s ig n if ica n ce . Later fo l low -up  shows th a t
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the d if fe rences  between pre-cancer cases and con tro ls  
eventua lly  disappear. This suggests th a t high le ve ls  of 
free  plasma E2 simply ind ica te  those w ith ra p id ly  
growing cancers. I t  is  not an ove ra l l  index o f r is k  fo r  
breast cancer [Bulbrook, personal communication].
1 .6 . Steroids in the Aetiology of Human Breast Cancer
Most hypotheses on the ae tio logy of human breast 
cancer include a ro le  fo r  the s te ro id  hormones. 
Steroids have been id e n t i f ie d  e ith e r  as d i re c t  e f fe c to rs  
or mediators o f actions by other hormones and growth 
fa c to rs .
Risk has been a t t r ib u te d  to  (1) excess o f to ta l  
oestrogens, (2) imbalance among several oestrogen 
fra c t io n s  and (3) excess o f oestrogens not 
counterbalanced by progesterone. The d i f fe r e n t  
hypotheses, put forward on hyperoestrogenism, have been 
well reviewed by Zumoff [Zumoff et a l . ,  1975; Zumoff, 
19813.
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Several experimental observations suggest th a t 
oestrogens are s trong ly  involved in the aetiopathology 
of human breast cancer. Heilman [Heilman e t a l . ,  1971]
and Thijssen [1974] detected increased oestrogen leve ls  
in  breast cancer, whereas Horreal [Morreal e t al . ,  
1979] showed the reverse. Arguelles [A rgue lles e t a l . ,  
1973], Cole [Cole et a l . ,  1978] and Sherman [Sherman et 
a l . ,  1979] observed oestrogen leve ls  not s ig n i f i c a n t ly
d i f fe re n t  from normal co n tro ls . Other observations 
ind ica ted also a reduction in  oestrogen le v e ls  or in  
some oestrogen f ra c t io n s  [Lemon et a l . ,  1966]. On the 
con tra ry , in  endometrial cancer, Oilman and coworkers 
[1968] showed th a t a large increase in minor oestrogens 
was associated w ith  cancer growth.
S ig n i f ic a n t ly  increased oestrogen excre tion  le ve ls  
have been observed in  breast, endometrium and prosta te  
cancer pa t ien ts ,  though a bimodal expression o f s te ro id  
excre tion  patterns in cancer pa tien ts  can be observed 
[Castagnetta et a l . ,  1977? Castagnetta, 1980;
Castagnetta et a l . ,  1981; Castagnetta e t a l . ,  1985;
Castagnetta et a l . ,  1986b]. Rather than measuring to ta l
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oestrogens, some stud ies suggest th a t d i f fe re n t  
oestrogen metabolites must be d is t ingu ished  in  re la t io n  
to th e i r  possib le d i f fe re n t  b io lo g ica l p rope rt ie s .
1 .6 .1. The o e s tr io l  hypothesis
Three main hypotheses were made. The o e s tr io l  
hypothesis suggests th a t E3 has a b io lo g ica l action  
completely d i f fe re n t  and counteracting th a t o f E2 and 
E l; E3 thus acts as an antioestrogen. The E3 quotien t 
hypothesis, subsequently disproved by experimental 
resu lts  from other authors [C lark e t a l . ,  1977] was
f i r s t l y  created by Lemon [Lemon et a l . ,  1966] and
followed by ep idem io logists [MacMahon et a l . ,  1974] in  
order to  study possible d if fe rences  in s te ro id  excre tion  
between Asian and North American women, in  whom the 
incidence o f breast cancer was s ig n i f i c a n t ly  d i f fe r e n t .
More recent stud ies [Lipmann, e t a l . ,  1977] showed 
tha t E3 has to  be considered oestrogenic and e x h ib i ts  
exactly  the same b io lo g ica l a c t i v i t y  as E2 and E l, 
provided th a t adm in is tra t ion  o f E3 is  given more
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frequen t ly  than the two other oestrogens.
Huggins and Jensen [1958] and, la t e r ,  Lemon [Lemon 
et a l . ,  1966] postu lated the theory o f "impeded
oestrogens" on the basis th a t ,  during pregnancy, "E3 
q uo t ie n t"  appeared to  be h igher. Pregnancy is  known to 
reduce r is k  o f breast cancer. Elevated E3 was found in 
Japanese women, in  whom incidence o f breast cancer is  
s ig n i f i c a n t ly  lower w ith respect to North American or 
North European women. However, other authors 
demonstrated th a t ,  during pregnancy, c i r c u la t in g  
oestrogen le v e ls ,  p a r t ic u la r ly  E3 le v e ls ,  are not 
predominant and, more p re c ise ly ,  th a t the higher E3 
ra t io  observed in Japanese women is  mainly due to 
de fective  El and E2 leve ls  more than to ,an excess o f E3 
[Zumoff, 1981]. A l l  these hypotheses r e f le c t  the common 
b e l ie f  th a t  breast cancer should e x h ib i t  higher 
oestrogen leve ls  or E3 ra t io s  re la t iv e  to co n tro ls .
1 .6 .2 . The oestrone hypothesis
Another more recent hypothesis was developed by
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S i i t e r i  [ S i i t e r i  e t a l . ,  1981], I t  was o r ig in a l l y
applied to endometrial cancer and subsequently extended 
to  breast cancer. The assumption is  th a t  E l, qu ite  
d i f f e r e n t ly  from E2 and E3, has more carc inogenetic  
power; i t  is  based mainly on two d i f fe re n t  experimental 
observations. F i r s t l y ,  breast or endometrial cancer are 
more frequent in  postmenopausal women, where El is  
c e r ta in ly  the main c i r c u la t in g  oestrogen [Grodin e t a l . ,  
1973]? secondly, experimental observations suggest th a t 
breast cancer r is k ,  as fo r  endometrial cancer, is  higher 
in obese women; fu r th e r ,  ju s t  in  the obese women, a 
higher conversion o f Delta4-androsten-3,17-dione 
(de lta4 ” A) to El has been observed. S i i t e r i f s 
hypothesis is  based mainly on the plasma le ve ls  o f El 
ra ther than on the u r ina ry  excre tion  pa tte rns . Some 
c r i t i c is m  can be made on the value o f both plasma and 
excre tion  leve l s i  they may re f le c t  free  oestrogens 
ra ther than t issue  content, which is  s t i l l  high in 
postmenopausal uterus, fo r  example.
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1 .6 ,3 . The free~oestrad io l hypothesis
The th i r d  hypothesis is  l inked  to the experimental 
observation th a t in  breast cancer c i r c u la t in g  leve ls  o f 
free  E2 appear to  be higher than in normal con tro ls  and, 
then, suggesting fo r  an excess o f free  E2 is  responsible 
fo r  the disease. This excess was f i r s t l y  suggested by 
S i i t e r i  [ S i i t e r i  et a l . ,  1981] and then i t  received 
experimental support by other authors [Moore e t a l . ,  
1982; Reed e t a l . ,  1983; Bruning, e t a l . ,  1985].
A complement to  the f i r s t  hypothesis, on the excess 
of to ta l  oestrogens, is  the hypothesis by which the same 
excess is  co rre la ted  to  a d e f ic ie n t  production of 
progesterone. Progesterone is  believed and observed as 
an antagonist of oestrogens mainly in  stud ies coming 
from physiology of human endometrium, where a balance 
between oestrogens and progestins modulates and 
regulates phys io log ica l menstrual cycles.
Maximum DNA synthesis in  breast t issu e s , during the 
ovarian cyc le , occurs in  the lu te a l  phase [Anderson et 
a l . ,  1982], in  con tras t to  endometrial e p i th e l ia l  c e l ls
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where DNA synthesis is  in h ib i te d  as soon as progesterone 
leve ls  r is e .
1.7. The A n ti-oes trogen ic  Role o f Progesterone and 
re la ted  hypotheses
The an ti-oes trogen ic  ro le  of progesterone 
represents the basis o f three ' separate hypotheses. 
These are the hypotheses of the anovulatory cyc les , of 
the lu te a l in s u f f ic ie n c y  and o f oestrogen window.
1 .7 .1 . The anovulato ry  cyc les hypothesis
The f i r s t  one, the anovulatory cycles hypothesis, 
was developed by G ra tta ro la , R. [19643. This author 
observed tha t the endometrial pa tterns in breast cancer 
were s ig n i f i c a n t ly  d i f fe re n t  from normal co n tro ls .  Less 
than 20% of breast cancer pa tien ts  showed, in  fa c t ,  a 
progesta tive  endometrium, w ith respect to  the 70% of 
normal contro l women; about 40% of breast cancer 
pa tien ts  exh ib ited  a p ro ! i fe ra t iv e  endometrium, 
presumably in d ic a t in g  anovulatory cycles, w h i ls t  the
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remaining 40% exh ib ited  adenomatous hyperplasia or 
a typ ica l hyperp lasia , sure ly  suggesting anovulatory 
cycles. G ra tta ro la , in  the same paper, suggested th a t 
oestrogenic s tim u lus, unbalanced by progesterone,
produced anovulatory cyc les. The author supported h is  
experimental observations w ith a previous paper by
Sommers [1955] who observed a higher incidence o f 
endometrial and breast ep ithe lium  hyperplasias in
au top tic  m ateria ls  from pa tien ts  who died o f breast 
cancer. The experimental evidence, gained w ith 
au top tic  materia l by both G ra tta ro la  and Sommers, have 
not yet been disproved.
1 .7 .2 . The lu te a l in suf f ic ie n c y  hypothesis
The hypothesis o f lu te a l  in s u f f ic ie n c y  s ta rted  from 
the G ra tta ro la  observation. Sherman and Korenmann
[1974] l inked  a number o f r is k  fa c to rs  fo r  breast cancer
( l ik e  la te  pregnancy, n u l l i p a r i t y ,  obes ity , la te
menopause and ea r ly  menarche) to anovulatory cycles. 
These authors modified the theory o f "anovulatory 
cyc les”  w ith th a t of " lu te a l  in s u f f ic ie n c y " ,  in  other
39
INTRODUCTION
words w ith in s u f f i c ie n t  progesterone production to  
counteract oestrogenic s t im u l i .  In the attempts to 
v e r i f y  th is  hypothesis, through progesterone assays, two 
authors only showed experimental evidence of lu te a l 
in s u f f ic ie n c y  [Kodama, e t a l . ,  1977; Secreto e t a l », 
1984], but some others published normal c i r c u la t in g
progesterone leve ls  [Swain et a l . ,  1974; England et a l . ,  
1975; Malarkey e t a l . ,  1977; Sherman e t a l . ,  1979].
1 . 7.3. The oestrogen window hypothesis
Another hypothesis is  th a t of the "oestrogen 
window", suggested by Korenmann [Korenmann et a l . ,  
1980] as a change to  the o r ig in a l  " lu te a l
in s u f f ic ie n c y " .  This l a t t e r  hypothesis suggests the 
p o s s ib i l i t y  th a t there e x is t  two periods during women’ s 
l i f e ,  l inked  to  puberty and menopause, in '  which
progesterone secre tion  is  l im i te d .  This hypothesis was 
based mainly on the basis of epidemiological
observations th a t the incidence of breast cancer 
appeared to  be raised amongst Hiroshima women a f te r  the
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atomic bomb, but only in  those women who were 10-14 
years o ld a t the time o f exposure to ra d ia t io n s . This 
is  the time corresponding to the f i r s t  supposed window; 
Korenmann again suggests th a t breast cancer is  
associated to  ea r ly  puberty and to  la te  menopause, 
because these should be l inked  to  a large dura tion  of 
both windows. Some experimental observations weaken the 
hypothesis. F i r s t  o f a l l ,  there are no reports  on 
increases o f breast cancer in  Hiroshima women during the 
menopausal window (women aged 45-50 at the time of 
exposure). Precocious puberty is  associated w ith ea r ly  
evidence of ovu la tory  cyc les, as reported by Wallace 
[Wallace e t a l . ,  1978]; th is  disproves the concept o f a 
large f i r s t  oestrogen window suggested by Korenmann.
1 .8 . In V itro  Studies on Endometrial and Breast Cancer 
Cells
1 .8 .1 . The long term c e l l  l in e s
Responsive and unresponsive human breast cancer 
c e l l  l in e s  have been estab lished and characterized fo r  
th e i r  optimal condit ions o f growth by several authors
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[Engel e t a l . ,  1978; Horwitz e t a l . ,  1978]. At the same 
time n u t r i t io n  needs fo r  mammalian c e l ls  in  t issue  
cu ltu re  were prev ious ly  valuated [Eagle, 1955; R ichter 
e t a l . ,  1972; Katsuta and Takaoka, 1973; Hayashi and 
Sato, 1976; Lippman et a l . ,  1976; A lleg ra  and Lippman, 
1978; Hayashi e t a l . ,  1978; Horwitz e t a l . ,  1978;
Lippman et a l . ,  1979; A llegra  and Lippman, 1980].
The s te ro id  receptor content and respons iv ity  o f the 
several human breast cancer c e l l  l in e s  have been also 
tested . This includes the responsive c e l ls  MCF7, ZR75-1, 
T47D, R27 and MDA-MB361; a l l  of them were reported to  be 
progesterone receptor (PgR) p o s i t iv e ,  g lu co co r t ico id  
receptor (GcR) p o s i t iv e ,  androgen receptor CAR) p o s it iv e  
and endowed o f nuclear ER. Also several hormone 
unresponsive, i . e .  MDA-MB175, MDA-MB231, MDA-MB436, 
HBL100, BT20, EVSA-T and PMC42 were s tud ied.
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1 ,8 ,2 . Breast cancer c e l l  l ines 
The MCF-7 c e l l  l in e
Looking a t the oestrogen responsive human breast 
cancer c e l ls  in  long term c u ltu re ,  the most popular MCF7 
were estab lished by Brooks e t a l . [19731 ; subsequently 
they have been p a r t i a l l y  characterized [Soule et a l . ,  
1973], This c e l l  l in e ,  as reported by Lippman and Bolan
[1975], is  able to  synthesize a-1actalbumin and to 
produce 7.05 pmoles lactose/30 min/pg p ro te in .  Those 
authors studied the e f fe c ts  o f E2 on DNA synthesis in  
th is  c e l l  l in e  and showed th a t there is  a b iphasic 
response to oestrogens. In f i r s t  experiments they used 
E2 at lower molar concentra tion ( in  the range o f 10(~9) 
-  10(~7)M); as l i t t l e  as 10(-11)M E2 added to  c e l ls ,
trea ted  w ith serum str ipped  by several charcoal 
passages, induced reproducib le increases in 
macromolecular synthesis and s ig n i f i c a n t ly  higher leve l 
o f 3H-Thymidine (3H-Thy) inco rpo ra t ion . No augmentation 
o f nucleoside inco rpo ra t ion  and o f macromolecular 
synthesis, was noted when the E2 was added j o i n t l y  w ith
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non s tr ipped  serum. When molar concentration higher than 
10(~7)M were used, there was a strong decrease in  both 
3H-Thy inco rpo ra t ion  and macromolecular synthesis. This 
noticed d i f fe r e n t  response by MCF7, s trong ly  suggests 
th a t the same population o f c e l ls  may be s tim ula ted by 
E2 at lower concentration and in h ib i te d  by E2.at higher 
concentrations.
To more c le a r ly  i l l u s t r a t e  the response to 
oestrogens and oestrogen dependence fo r  growth by these 
c e l ls  these authors used 10(~7)M Tamoxifen (TAM). At
such concentrations TAM s ig n i f i c a n t ly  depressed DNA
synthesis ; there was a TAM in h ib i t io n  o f e i th e r  
macromolecular synthesis and incorpora t ion  o f 14C— 
leuc ine ; these e f fe c ts  were reversed by simultaneous 
add it io n  o f 10(~8 )M E2. This in h ib i to r y  e f fe c t  is  shown 
w ith in  about 10 h r ; macromolecular synthesis f a l l s  to 
about one th i r d  of contro l le ve ls  by 24 hr and recovery 
by these phenomena is  completely achieved a f te r  10 hr of 
E2 a dd it io n . These authors also observed th a t when the
hormone responsive MCF7 c e l ls  are l e f t  in  TAM alone most
c e l ls  begin to "round up, detach from the surface and
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d ie ”  a f te r  about 4 h r. However th is  phenomenon, named 
"Tamoxifen k i l l i n g " ,  is  in v a r ia b ly  reve rs ib le  when E2 is  
added to the medium, even though the anti-oestrogen 
remains in the medium. Also in the experiments ca rr ied  
out in  serum-free cond it ions , i . e .  to ta l  lack of 
oestrogens in the medium, TAM was s t i l l  able to i n h ib i t  
the c e l ls  below contro l le v e ls .  In th is  c e l l  l in e  
Lippman and Bolan detected about 770 fmoles ER/mg 
so lub le p ro te in ,  w ith  an apparent Kd o f about 
5 x lO (- l l )M , a value which was in  reasonable agreement 
w ith  th a t prev ious ly  reported by Brooks et a l . [1973].
In these experiments they compared the MCF7 w ith other 
oestrogen unresponsive c e l l  l in e s ,  l ik e  K ie l t y ,  611, 
HT39 th a t were shown to be n e ithe r  stimulated by 10(-8)M 
E2, nor in h ib i te d  by TAM. However they were reported to 
be k i l l e d  by 10(-5)M E2; th is  is  a very in te re s t in g  
observation. Two other human breast c e l l  l in e s ,  EVSA-T 
and EVSA-E, both developed in  authors* lab , showed to  be 
able to respond to  10 (-8 ) M E2, w ith the accumulation of 
a-Lactalbumin, w ithout however a s ig n i f ic a n t  increase in 
general macromolecular synthesis.
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Demonstration o f MCF7 c e l l  growth s t im u la t io n  by 
oestrogens and growth in h ib i t io n  by antioestrogens, was 
ca rr ied  out w ith c e l ls  maintained in  medium supplemented 
w ith charcoa l- trea ted  c a l f  serum; the experiments on 
growth s t im u la t io n  were performed under serum free  
cond it ions . There was a d ire c t  evidence th a t  the use of 
charcoa l- trea ted  c a l f  serum permit low concentration of 
oestrogens and is  very useful fo r  metabolic experiments, 
but th a t serum free  condit ions do not support prolonged 
c e l l  growth. Conversely, many la b o ra to r ie s  have fa i le d  
to show an in v i t r o  e f fe c t  of oestrogens [Sonnen e t a l . ,  
1980; Shafie, 1980]; one common hypothesis to expla in  
th is  was th a t oestrogens only in d i r e c t ly  ac t, v ia  the 
l ib e ra t io n  o f growth f a c t o r s , . i . e .  estromedins release 
from other tissues [Sirbasku and Benson, 1979]. To th is  
proposal we have to  remember th a t both, c e l l  c u ltu re  
condit ions and the exclusion of endogeneous oestrogens 
by c e l ls ,  may be c r i t i c a l  [Vignon e t a l . ,  1980; Strobl 
et a l . ,  1980]. For instance, charcoa l-trea ted  c a l f
serum s t i l l  may contain high leve ls  o f E1S and, as we
46
INTRODUCTION
know, [Pasqualin i e t a l . ,  1989] th is  may be a c t iv e ly
i
metabolised by e p i th e l ia l  c e l ls ,  also on in  v i t r o  
cond it ions.
The ZR75-1 c e l l  l in e
ZR75-1 c e l ls  were estab lished in 1978; they were 
also ex tens ive ly  described to contain ER, AR, PgR and 
GcR [Engel e t a l . ,  1978]; strong biochemical,
morphological and chromosomal evidence o f th e i r  human 
breast cancer o r ig in  has been given. Studies on ZR75-1, 
ca rr ied  out in  serum free  condit ions or w ith hormone 
supplemented media, were also run [A l leg ra  and Lippman, 
1978]. As prev ious ly  sta ted by Katsuta and Takaoka 
[1973] and f i r s t l y  suggested by Hayashi [Hayashi et 
a l . ,  1978] these c e l l  l in e s  are able to grow in serum
free  cond it ions . Lippman's group [Lippman et a l . ,  1976] 
studied the e f fe c ts  o f both E2 and TAM,in an environment 
t o t a l l y  devoid of oestrogens. The same authors using a 
system where, although c e l ls  are serum fre e , they are 
10(-11) -  10(-7)M; E2 concentrations in  the order o f
(10(—10)M) produced maximal e f fe c ts .  Another time i t  was
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shown th a t ,  in  c e l ls  depleted o f E2 fo r  14 days, the 
readd it ion  o f 10(-9)M E2 led to a marked increase in 
thymidine, u r id in e ,  leucine and acetate inco rpo ra t ion . 
Also i t  was shown th a t TAM exert a s p e c i f ic  cy to to x ic  
e f fe c t  on c e l l  growth: th is  e f fe c t  was dose dependent 
and reve rs ib le  by E2.
The T47D c e l l  l in e
The T47D c e l ls  were p rev ious ly  estab lished by 
Keydar [Keydar et a l . ,  1979] and defined as
unresponsive; subsequently, respons iv ity  and receptor 
content of th is  c e l l  l in e  were reported by Horwitz.
They were fu r th e r  characterised and have been shown 
to have mammary e p i th e l ia l  c h a ra c te r is t ic s  and to 
contain mainly nuclear ER, moreover they are able to 
synthesize casein [Horwitz et a l . ,  1978]. These c e l ls  
however, a f te r  several days in  modified medium and 
growth cond it ions i . e .  by using 5% heat ina c t iva ted  
Fetal Calf Serum (FCS) plus phys io log ica l in s u l in  
le v e ls ,  but no c o r t is o l  or E2, showed a very low leve l
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of soluble ER. In s p ite  of these cu ltu re  cond it ions the 
c e l ls  were s t i l l  able to  maintain a considerable number 
o f PgR, roughly 300,000 progestin binding s i te s  per 
c e l l ,  as reported by the authors. The same authors 
remind th a t th is  is  roughly ten fo ld  greater than 
usua lly  seen in E2 stim ula ted tissues [Milgrom et a l . ,  
1973; Mester and Baulieu, 1977].
In a very elegant manner Horwitz and colleagues 
demonstrate th a t in  T47D the PgR are not under the 
contro l of oestrogens [Horw itz , 1981; Horwitz e t a l . ,  
1982], in fa c t  e i th e r  E2 or na fox id in  were completely 
in e f fe c t iv e ;  the possib le hypothesis th a t PgR were a 
c o n s t i tu t iv e  product o f gene t ra n s c r ip t io n  was showed to 
be not t ru e , because when c e l ls  were c u l t iv a te d  in  the 
presence o f butyra te  10 mM, PgR leve ls  f e l l  o f 30% in 24 
hr and 55% in 36 h r, meanwhile c e l l  growth was 
unaffected by bu ty ra te . Butyrate has been shown to 
exert a number of biochemical ac tions, a l te r in g  the 
leve l o f histone a ce ty la t io n  and having e i th e r  
s t im u la to ry  as well as in h ib i to r y  e f fe c ts  on gene
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induction [Samuels et a l . ,  1980; Leder and Leder, 1975].
So there was d ire c t  evidence th a t :  t ra n s c r ip t io n  of 
PgR genes in T47D c e l ls  is  not c o n s t i tu t iv e ,  but remains 
la rg e ly  regulated; th a t i t  is  independent by c e l lu la r  
p r o l i f e r a t i v e  a c t i v i t y  and s u rp r is in g ly  i t  is  not 
modulated by oestrogens, as commonly happens fo r  the 
most pa rt o f responsive c e l ls  [Horwitz and McGuire, 
1978a]. In T47D the leve l o f ER were s trong ly  in h ib ite d  
when p ro te in  synthesis was in h ib i te d  [Horwitz and 
McGuire, 1978b].
In these c e l ls  at steady s ta te  the ER content is  
low, however th e i r  growth can be s trong ly  in h ib i te d  by 
anti-oestrogens as TAM. I t  should be noted th a t th is  
may be explained on the basis o f reported evidence by 
some authors [Brandes e t a l . ,  1985; Sutherland e t a l . ,  
1980] th a t antioestrogen are d is t in c t  from oestrogen 
high a f f i n i t y  binding s i te s .  Following previous reports 
[Horwitz e t a l . ,  1982; Mockus e t a l . ,  1982], in
p a r t ic u la r  cu ltu re  cond it ions , ” PgR in T47D c e l ls  are 
e n t i r e ly  independent o f oestrogen ac t io n ; oestrad io l is
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not required fo r  progesterone receptor syn thesis , and 
anti-oestrogens cannot suppress PgR le ve ls  or c e l l  
growth” . For the above reasons these c e l ls  should be 
c la s s i f ie d  as oestrogen unresponsive.
Current views are th a t in  v i t r o  systems may be 
e ith e r  oestrogen dependent or oestrogen responsive; in  
both cases they are considered hormone se n s it iv e .  In my 
experience, based on both in v i t r o  and in v ivo s tud ies , 
cancer c e l ls  may e x h ib i t  oestrogen s e n s i t iv i t y  not 
accompanied by oestrogen dependence or responsiveness. 
Thus, we may consider the hypothesis th a t any system 
might be oestrogen se n s it ive  even when i t  is  ne ithe r  
dependent nor responsive.
1 .8 .3 . The induced pro te ins
Another very in te re s t in g  observation on in v i t r o  
system is  th a t oestrogens induce the secre tion  o f 
p a r t ic u la r  p ro te ins  [Chalbos et a l . ,  1982; Westley and 
Rochefort, 1980].
In t h e i r  papers Rochefort and colleagues showed
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induced p ro te ins  by MCF7, ZR75-1 [Westley and 
Rochefort, 1980] and by T47D [Chalbos et a ] . ,  1982], In 
the la s t  study i t  was observed: th a t the more hormone 
se n s it ive  and receptor endowed clone 11 was much more 
able to  induce a 6QK p ro te in ;  th a t th is  p ro te in  was 
induced by phys io log ica l 10(~10)M - 10(-9)M
concentration o f E2 and tha t th is  induction precedes the 
c e l l  growth e f fe c t  observed la te r  on. In the same paper 
also these authors showed th a t a d i f fe re n t  E2 s tim ula ted 
c e l l  growth can be observed in  d i f fe re n t  clones, having 
d i f fe re n t  receptor content, respec t ive ly  clones 8 and
11. Moreover i t  was noticed th a t the E2~stimulated 
growth showed a biphasic e f fe c t  -  maximal growth was 
induced by less than 10(~9)M E2 concentra tion ; the 
e f fe c t  on growth was lower a t higher E2 molar 
concentration and there was in h ib i t io n  of growth a t very 
high molar concentration o f E2. This biphasic e f fe c t  is  
probably a more complex phenomenon than be lieved, since 
i t  is  not observed on the induced pro te ins  but mainly 
concerns the c e l l  growth ra te . However as fo r  E2 
s t im u la t io n  o f growth ra te and p r o l i f e r a t iv e  a c t i v i t y  o f
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c e l ls ,  d i f fe re n t  clones having d i f fe re n t  leve ls  o f ER, 
produced d i f fe re n t  induced p ro te in s : clone 11 was
producing mainly 60K, 2-3 fo ld  more than c o n tro ls ;  in 
clone 8 , on the con tra ry , having low le ve ls  o f ER, E2 
add it ion  did not increase s ig n i f i c a n t ly  the to ta l  amount 
o f p ro te ins  released in to  the medium. Also in  the 
presence of E2, production o f the 60K p ro te ins  in clone 
8 was s ig n i f i c a n t ly  lower than in clone 11. S tim u la t ion  
of 55K component and some in h ib i t io n  of 48K p ro te ins  
were also observed, in  the same c e l ls .
Several hypotheses can be made on the fa i lu r e  by
some authors to  demonstrate in  v i t r o  e f fe c ts  by E2 on
c e l ls ;  among these, Chalbos et a l . [1982] reported
th a t in  large f la s k  the c e l ls  grew two fo ld  more than in 
m u lt iw e ll  cond it ions , but no explanation fo r  th is
observation was given. Other possible explanation is  
th a t the c e l ls  may be not p o te n t ia l ly  responsive to
oestrogens, th is  should be the case of the c e l ls  lack ing  
of func tiona l ER and o f any hormone s e n s i t iv i t y ;  another 
is  th a t the concentration of ER and the modulation of
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biochemical ac tion  exerted by oestrogens, should be 
decreased by several fa c to rs .  An example in  p o in t is  
tha t o f in s u l in ;  evidence th a t in s u l in  lowers the ER 
content in  MCF7 c e l ls  has been reported [Moore, 1981; 
B u tle r  et a l . ,  1981]; i t  has also been shown tha t
in s u l in  reduces the e f fe c t  o f TAM on c e l l  growth and
decreases the s e n s i t i v i t y  of a t lea s t c e l ls  (T47D) to 
oestrogens [Chalbos e t a l . ,  19823. However in  the 
absence o f E2, in s u l in  increased the growth ra te  o f the 
c e l ls ,  which is  cons is ten t w ith i t s  known mitogenic
e f fe c t  [King and Khan, 1981] a t lea s t at concentration
there used i . e .  50 pg/m l. Other than the induced 
p ro te ins , yet mentioned, inc lud ing  g lycopro te in  46K of 
Westley and Rochefort [1980] th a t  are s tim ula ted by E2 
and in h ib ite d  by antioestrogens, several other p ro te ins  
l i k e  thymidine kinase [Bronzert et a l . ,  1981] and
plasminogen a c t iv a to r  [B u t le r  e t a l . ,  1979] are also 
regulated by oestrogens.
The same c e l l  l in e  MCF7 estab lished in  1973 by Soule 
et a l . [1973], as shown by Brooks et a l . [1973] and by 
Chong and Lippman [1980], when subcultured, produced
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d i f fe re n t  clones; a new subline o f MCF7, TAM re s is ta n t  
and E2 independent in  growth was established [Nawata et 
a l . ,  1981a; Nawata e t a l , ,  1981b],
1 ,8 ,4 , Endometrial cancer c e l l  l in e s  
I s h i k a w a c e l l 1ine
j
The Ishikawa c e l l  l in e  was established from a well 
d i f fe re n t ia te d  endometrial adenocarcinoma by Nishida et 
a l . [1985], I t  has been shown to respond to  ad d it io n  of 
10(“ 9) to 10(—7) molar E2 in v i t r o .  The response 
resu lted in  increases of PgR le v e ls ,  of the a c t i v i t ie s  
o f a lka l in e  phosphatase and also of DNA polymerase-a 
[Holinka e t a l . ,  1986a; Gravanis and Gurpide, 1986; 
Holinka e t a l , ,  1986b],
A c lea r e f fe c t  o f E2 on Ishikawa ce ll  p r o ! i fe ra t io n  
was demonstrated but only when the number o f c e l ls ,  to  
which E2 10(-8)M was added, were compared w ith  co n tro ls  
a f te r  dishes reached plateau values [Holinka e t a l . ,  
1986a], In th is  case, c e l l  d ens it ie s  obtained 20 days
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a f te r  seeding, in  the presence of E2, were about 3 
times la rg e r  than those in contro l dishes. Experiments 
were ca rr ied  out w ith  2.5x10(5) c e l ls ,  in  6 cm. d ish, 
changing medium every two or three days. The e f fe c t  was 
counteracted by 4-hydroxy-TAM at 10(-6) molar 
concentra tions; furthermore add it ion  of E2 in  contro l 
cu ltu re s , a t approximately maximal c e l l  dens ity , 
resu lted in  resumption o f c e l l  p ro l i f e r a t io n .
No s ig n i f ic a n t  d if fe rences  between growth curves of 
contro l c e l ls  and c e l ls  exposed to E2 were noted up to 
10 days a f te r  seeding. Exponential growth was apparent 
from days 1 to  5; in  th is  case the doubling time was 27 
hrs. I t  was s l ig h t l y  reduced from days 5 to  7 (doubling 
time o f 36 hrs) and markedly slower a f te r  day 7; in 
fa c t ,  doubling time was o f 110 hrs from day 7 to  10. 
Cell dens ity , in  cu ltu re  w ithout E2, reached plateau 
values a f te r  about 10 days (approximately 7x10(6) 
c e l ls /d is h ) ,  but the cu ltu res  conta in ing 10(-8)M E2 
reached a density  of 20x10 (6 ) c e l ls /d is h  by day 2 2 ; i . e .  
they showed a continued growth a f te r  day 10th  wheras no 
s ig n i f ic a n t  changes were noted in  co n tro ls .  So, i t  may
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be concluded th a t the E2 e f fe c ts  on c e ll  p ro ! i te ra t io n  
i . e .  re s p o n s iv i ty , in  Ishikawa c e l l  l in e  have been well 
documented, by comparing c e l l  d e ns it ie s  a f te r  contro l 
cu ltu res  have reached plateau le v e ls ,  but non
s ig n i f ic a n t  e f fe c ts  by the hormone were noted during the
i n i t i a l  expos it ion  (exponential growth phase). In 
another paper Gurpide and collogues [Holinka et a l . ,
1986c] studied the p roportion  o f the c e l l  population in 
the quiescent (non p ro ! i fe ra t iv e )  and in the
p ro l i t e r a t iv e  f r a c t io n ,  j o i n t l y  w ith the colony forming 
e f f ic ie n c y  o f Ishikawa c e l ls .  They showed th a t the
add it ion  o f E2 to the medium did not a f fe c t  colony 
formation e f f ic ie n c ie s ;  in  con tras t
D if luo rom ethy lo rn ith ine  s trong ly  in h ib i te d  colony 
formation, but th is  e f fe c t  was la rg e ly  counteracted by 
putrescine. In th is  la s t  paper they also studied DNA 
polymerase a and o rn ith in e  decarboxylase (ODC) 
a c t i v i t ie s  as l i k e  as ER le ve ls  at various times a f te r  
seeding.
S ig n i f ic a n t  p o s it iv e  c o r re la t io n s  between ODC and
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DNA polymerase a a c t i v i t i e s  (c o r re la t io n  co e f f ic e n t  =
0.8) and ER and DNA polymerase a a c t i v i t y  (c o r re la t io n  
co e f f ic e n t  = 0.76) were observed; the c o r re la t io n  found 
between the a c t i v i t ie s  o f DNA polymerase «, ODC a c t i v i t y  
and ER leve ls  s trong ly  suggest th a t common fa c to rs  
a f fe c t  the a c t i v i t ie s  o f these growth-re la ted enzymes 
and the leve ls  of s p e c i f ic  oestrogen binders involved in 
hormone ac t ion . In th is  study a lso, Holinka e t a l . 
[1986c] conclude th a t reasons why c e l ls  reach maximal 
density  in  contro l cu ltu re  shouldn’ t  be the lack o f 
n u tr ie n ts  or oxygen depr iva tion  re la ted  to the 
accumulation of c e l l  laye rs , since the simple a dd it ion  
of E2 provokes the resumption of growth. More l i k e l y ,  
in  th e i r  op in ion, E2 may a f fe c t  the balance o f autocrine 
growth s t im u la to ry  or in h ib i to r y  fa c to rs  produced by the 
same c e l ls .  Release o f such fa c to rs  has been described 
fo r  other c e l l  l in e s ;  the dependence o f e i th e r  colony 
formation e f f ic ie n c y  or c e l l  dens ity , found in th e i r  
s tud ies , supports the hypothesis th a t Ishikawa c e l ls  
produce autocrine growth s t im u la to ry  fa c to rs  [Sporn and 
Todaro, 1980; Sporn and Roberts, 1985].
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1 .9 . In V itro  Oestrogen Metabolism by Cell Lines
In a recent study Gurpide and colleagues [Hata et 
a l . ,  1987] approached the metabolism of E2 added to  the 
Ishikawa c e l ls ,  a t d i f fe re n t  molar concentra tions, in 
short term incubation (3 to 24 h r ) .  At very near to 
phys io log ica l concentration (10 ( - 8 )M) the most pa rt of 
3H-E2 was qu ick ly  converted to E2-S, a t 24 h r; smaller 
proportion  o f E1S and free  E2, but no free  El fo rmation, 
were reported. At higher molar concentration (1 0 (-6 )) 
the p roportion  of formation by precursor o f conjugate E2 
was much reduced (to  less than 10%). In th is  case, 
a f te r  24 h r, no E1S at a l l ,  but in  con tras t more than 
10% of non conjugated El were detected; the most part of 
3h-E2 precursor (more than 70%) was s t i l l  unconverted. 
Almost the same p ic tu re  was reported a f te r  10(-5)M 3H-E2 
adm in is tra t ion ; an intermediate p ic tu re  was seen at 
1Q(-*7)M concentra tion . So, there was a c lea r evidence 
th a t the most part o f precursor is  qu ick ly  converted 
under conjugate form by Ishikawa c e l ls ;  at 10(-8)M 3H~
E2 the sulphate formation s ta r ts  very e a r ly ,  more than
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50% conversion was observed as soon as a f te r  6 h r.
However in  d i f fe re n t  cond it ions , i . e .  a f te r  add it ion  of 
10(-8)M or 10(-7)M 3H-E2 the most part o f recovered
ra d io a c t iv i t y  was represented by free  E2 (over 80%), 
very scant amount o f 3H-E2-S were observed. In a l l
experiments large formation o f El from E2 can be
excluded. So, in  conclusion, in  the stud ies o f Gurpide 
and collegues, there are m u lt ip le ,  c lea r and complete 
observations in Ishikawa c e l ls :  one being th a t E2 is  
not qu ick ly  converted to  El in  any experimental 
cond it ion ; another is  the large v a r ia t io n  reported 
concerning the fa s t  formation of sulphates in  re la t io n  
to molar concentration o f precursor used; another is  the 
early  E2-S formation, using low molar concentra tion , 
th a t can be explained by the low Michaelis-Menten 
constant p rev ious ly  reported fo r  human endometrial 
oestrogen sulphotransferase [Tseng and L iu , 19813. The 
observed dependence in the su lphation o f 3H-E2 ind ica tes  
sa tu ra t ion  o f the enzyme at low le ve ls  o f E2. Note th a t  
the amount o f El product increases enormously, w ith  
respect to  the amount o f produced E2-S, as the
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concentration o f E2 becomes h igher; the authors 
emphasize the relevance o f studying pa tte rns of 
metabolism a t near to  phys io log ica l concentrations.
More recen tly  lorge Pasqualini [1989] in  Paris
showed also th a t responsive breast cancer c e l ls  l in e s  
MCF-7, R-27, T47D were able to  q u ick ly  convert E2-S, 
El-S and E3-S in to  free  E2, El and E3 and other 
oestrogens in normal cond it ion  cu ltu res . Very l i t t l e  or 
no conversion was found in the hormone-independent 
breast cancer c e l l  l in e s  MDA-MB 231 and MDA-MB 436. In 
conclusion, from these la s t  stud ies there is  evidence 
th a t ,  e i th e r  breast or endometrial cancer c e l ls  in
c u ltu re ,  have both enzyme a c t i v i t i e s ,  i . e .  
sulphotransferase and sulphatase, which q u ick ly  can 
transform precursor in  conjugate metabolites and also
transform sulphate oestrogens in free  m etabolites.
Ten years ago Strobl and Lippman [1979] showed a
prolonged re ten tion  o f e s trad io l by human breast cancer 
c e l ls  in  t issue  c u ltu re .  These breast cancer responsive 
c e l ls ,  MCF7 were showed to  maintain high leve l o f
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precursor E2 w ith l im i te d  conversion to both El and E3 
fo r  several hours. There was a d ire c t  demonstration 
th a t E2 is  not qu ick ly  converted to  E l, a t lea s t fo r
th is  breast cancer hormone responsive c e l l  l in e .
I t  is  o f some in te re s t  to  note th a t  in these 
s tudies Gurpide and colleagues [Hata e t a l . ,  1987] used 
EMEM (Eagle Minimum Essential Medium) w ith E a r le 's  s a l t
i . e .  w ith phenol red and b) th a t the detection  of 3H-E2 
metabolites were ca rr ied  out e xc lus ive ly  on the cu ltu re  
medium. So, they did not take in to  account the
in t r a c e l lu la r  oestrogens to de tect, fo r  instance,
formation, accumulation and degradation of less po lar
/
metabolites, p rev ious ly  described as l ip o id a l  E2
d e r iva t ives  [Schatz and Hochberg, 19815 Mel 1on~Nussbaum 
e t a l . ,  1982] and recen tly  reported by Adams et a l .
[1986] to occur in  MCF7 c e l ls ,  since oestrogen f a t t y  
acid esters are not released in to  the medium.
The Adams' hypothesis is  th a t oestrogen f a t t y  acid 
esters could act as regu la to rs  o f in t r a c e l lu la r  E2 
leve ls  by accumulating the hormone and re leasing i t
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slowly by ac tion  of esterases. Such a process may 
s ig n i f i c a n t ly  con tr ibu te  to  the in t r a c e l lu la r  pool of 
E2. In a very recent paper, Vandewalle and Lefebvre 
[1989] studied the e f fe c ts  of E2 and 20HE1 on growth of 
the hormone se n s it ive  breast cancer c e l ls ,  MCF7, and a 
new c e l l  l in e  VHB1, estab lished by the same authors 
[Vandewalle et a l . ,  1987]. Cell growth was assessed by 
c e l l  counts and t ra n s fe r r in  receptor le v e ls ,  c e l l  
d i f f e r e n t ia t io n  was assessed by secreted p ro te ins  such 
as a-lacta lbum in and GCDFP-15 o f Haagensen. In these 
c e l l  l in e s ,  both responsive and endowed o f ER, they 
observed opposite e f fe c ts ,  exerted by E2 and 20HE1, 
resp ec t ive ly . F i r s t l y ,  as also observed prev ious ly  in 
MCF7 c e l ls  by Horwitz and McGuire [1978a], E2 s t im ula ted 
PgR synthesis in  both c e l l ' l i n e s ,  but th is  e f fe c t  was 
not exerted by 20HE1, in  so showing the lack of 
oestrogenic e f fe c t  o f th is  compound. This supports the 
previous f in d in g  o f Bradlow's group th a t 20HE1 may play 
an an t ies trogen ic  ro le  [Schneider et a l . ,  1984].
Furthermore a-Lactalbumin as l i k e  GCDFP-15 secre tion  was 
s ig n i f i c a n t ly  stimulated by 20HE1 and s ig n i f i c a n t ly
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reduced by E2, w ith respect to the contro l le v e ls ,  in 
both VHB1 and in  MCF7 c e l ls .  Also o f some in te re s t  was 
the evidence tha t 20HE1 (10(-7)M) was able to reduce 
c e l l  number (the decrease ranged between 20% and 30%) 
s im i la r ly  to th a t observed fo r  4~hydroxy~TAM (10(-6)M) 
th a t in h ib i te d  c e l l  growth to 30-40%. Moreover they 
observed th a t adding simultaneously E2 and 20HE1, i t  was 
evident th a t 20HE1 was able to lower s t im u la to ry  e f fe c t  
induced by E2; 2QHE1 e f fe c ts  were also observed to  be 
dose dependent. Much more in te re s t in g  was the evidence 
th a t almost 40% of ra d io a c t iv i t y  added to the cu ltu re  
medium, was a f te r  24 hr detected as E2 metabolites and 
as in t r a c e l lu la r  r a d io a c t iv i t y .  These rad ioac t ive  
metabolites were mainly E l, 2-hydroxy and 2-methoxy 
d e r iva t ive s  o f El and o f E2. A ltogether almost the 25% 
of catecholoestrogens* metabolite  formation (hydroxy + 
methoxy) was observed in  MCF7, approximately the 20% in 
VHB1.
In h is  more recent stud ies Adams et a l . [1989]
report th a t Km fo r  e s te r i f i c a t io n  o f s te ro ids  is  very
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high; the order of magnitude is  o f 25pM. Consequently, 
the add it ion  of higher molar concentration o f precursor 
y ie ld s  much higher le ve ls  o f l ip o id a l  conjugate formed. 
Moreover, in  these stud ies Adams and collegues report 
th a t l ip o id a l  E2 formation was higher in MDA-MB 231' w ith 
respect to  the MDA-MB 330; much higher in  these two MDA- 
c e l l  l in e s  than in MCF7 or ZR75-1. Of great in te re s t  
also the fa c t  th a t several unresponsive, receptor- 
negative, c e l ls  more q u ick ly  converted E2 to  El than did 
the responsive, re c e p to r-p o s i t ive , ce l l  l in e s  (mean 
values observed were fo r  receptor p o s it iv e  4.5 and fo r  
receptor negative 32 .6 ), moreover the receptor-negative  
c e l ls  exh ib ited  lower E1S formation. These data 
s trong ly  support the idea th a t several c e l l  l in e s ,  
d is t ingu ished  on the basis o f th e i r  hormone-responsivity 
and/or s e n s i t i v i t y  or o f th e i r  receptor s ta tus , may 
produce qu ite  and s ig n i f ic a n t  d i f fe re n t  proportions o f 
conjugate, i . e .  sulphate and l ip o id a l ,  and o f free  
oestrogens.
In other words a d i f fe r e n t  hormone se n s it ive  s ta tus  
o f cancer c e l ls  may switch . on d i f fe re n t  metabolic
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pathways o f s te ro ids  and consequently express d i f fe re n t  
accumulation leve ls  o f s te ro id  metabolites w ith in  cancer 
t issues or c e l ls .
1.10. Androgen Metabolism in Normal Prostate, Benign 
Prostate Hyperplasia and Prostate Cancer Tissues 
and Cells
I t  is  a very common b e l ie f  th a t a l l  the androgen 
se n s it ive  periphera l t issues and c e l ls ,  l i k e  p ros ta te , 
kidney, sebaceous gland, seminal vesc ic les and so on, 
have the a b i l i t y  to  metabolize T. Two main pathways are 
well recognized: a) the f i r s t  one is  the conversion o f T 
in to  5a-androstan-173-ol-3-one (d ihydro testosterone - 
DHT) and in 5a~androstan-3a,JL73-diol (3 a -d io l)  and 
5a-androstan~33,173-diol (33~d io l) .  This conversion 
needs of an enzymatic complex which includes a 
5a-reductase and two 3a~ and 33-hydroxy s te ro id  
dehydrogenase (HSD). The 5a reduction of r ing  A, to  
convert T to  DHT as l i k e  as the importance o f these 5a~ 
reduced T metabolites as mediators o f androgenic a c t io n , 
has been demonstrated by many in ve s t ig a to rs  [Anderson
66
INTRODUCTION
and Liao, 1968; Baulieu et a l . ,  1968; Bruchowsky and 
Wilson, 1968; Giorgi e t al . ,  1971; Farnsworth and Brown, 
1963] and reviewed by Wilson [1972].
The other possib le pathway is  the conversion o f T 
in to  androstenedione (de lta4 -A ), Ba-androstanedione (5cf- 
A) and aridrosterone (A). This la s t  metabolic pathway 
has been ascertained in  human and canine prosta te  but i t  
s t i l l  con trovers ia l in  the ra t  prosta te  [Djoseland et 
a l . ,  1981; Robe! et a l . ,  1971]. In fa c t  many reports 
suggested th a t the s i tu a t io n  in  the human and canine 
prostate may well be d i f fe re n t  from ra t  p ros ta te , 
[Djoseland e t a l . ,  1983; Krieg e t a l . ,  1981; Krieg et 
a l , ,  1983; Lathonen et a l . ,  1983; Orlowsky e t a l . ,  1983; 
W ilk in  e t a l . ,  1980].
Possible androgen pathways are shown in  F ig. 1.01.
The "main pathway”  is  considered a p re re q u is i te  fo r  
the m u lt ip le  action exerted by T on ta rg e t s truc tu res  
[Wilson and Gloyna, 1970); Robe! et a l , ,  1971; M a r t in i ,  
1982; Bruchowsky and Wilson, 1968],
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Figure 1.01.
Oxidative and reductive metabolic pathways 
androgens.
Reproduced from Laev e t a l . [1971].
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Concerning the "o the r pathway” , T conversion in to  
de1ta4-A, 5a-A and A, several reports have demonstrated 
th is  in  e ith e r  dogs [G iorg i et a l . ,  1972; Isaacs, 19833 
and in man, e ith e r  in  normal or patho log ica l prostate 
[Chamberlain et a l . ,  1966; Isaacs et a l . ,  1983; Krieg et 
a l . ,  1979; Shimazaki e t a l . ,  19663.
In a previous paper, Robel et a l . [1971] showed
th a t the explants of ra t  p ro s ta t ic  t issue  do not form 
de lta4 ” A from T; c o n tro v e rs ia l ly  Djoseland and coworkers 
[19813 have found th a t e i th e r  delta4-A e i th e r  5a~A or A 
are present in  the prosta te  of adu lt male ra ts ,  a f te r  
the in  v ivo adm in is tra t ion  o f T. In a recent work o f L., 
M artin i and coworkers [19863, there is  c lea r evidence 
th a t the prosta te  of normal young ra ts  is  able to 
convert T in to  high amount o f DHT and of the d io ls ,  but 
also substan tia l amounts o f delta4~A, 5a~A and o f A have 
been detected.
Moreover data from several authors demonstrate th a t  
when delta4-A is  used as substra te , th is  s te ro id  may be 
reduced by the ra t  prosta te  to  y ie ld  e ith e r  5a~A or A as
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shown respect ive ly  by M art in i e t a l . [1986] on ra t
minced prostate t issu es , by Roy e t a l . in  ra t  [1972] and 
by C o l l in s  e t a l . in  humans [1970]. In a dd it ion  
Djoseland and coworkers [1983] found th a t folTowing in 
v ivo in je c t io n  o f T, the content of delta4~A in  the 
ventra l p rostate is  higher in  old than in young ra ts ;  so 
there is  evidence th a t a d i f f e r e n t ia l  accumulation of 
delta4-A happens w ith  changing age, a t leas t in  ra ts .
M art in i and coworkers [1986] showed also th a t w ith 
ageing there is  a decrease o f Ba-reduced metabolites of 
the 17-hydroxy series but th a t the age doesn’ t  decrease 
the formation o f the 5«~reduced metabolites o f the 17- 
keto se r ies ; on the contrary the formation o f these 
metabolites appears to  increase with advancing age. In 
another series of experiments M art in i et a l . [1986]
showed th a t a f te r  add it ion  o f 40H-4-androsten-3,17-dione 
to minced prostate t issues there was a s ig n i f i c a n t  
decrease in the conversion of the T in to  DHT and in to  
the d io ls ;  but no action  was exerted on the formation of 
the 5a~reduced metabolites o f the 17-keto se r ies  in 
fa c t ,  s ig n i f i c a n t ly  increased formations of the delta4-A
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and of h is  5a~reduced metabolites were observed.
1 .10.1. 5g-reductase enzymes
Very recen tly  L. M art in i et a l . [1986] have
reported stud ies on the possible existence o f two 
Ba-reductases. These authors concluded th a t  in  ventra l 
p rosta te  o f the ra t  there are two d i f fe re n t  Ba-reductase 
isoenzymes: the f i r s t  one is  se n s it ive  to  age and to
in h ib i to r y  e f fe c t  o f 40H-4-androsten-3,17-dione; the 
second one which appears in se n s it ive  to the age and to 
the e f fe c ts  o f 40H-4-androsten-3,17-dione. The f i r s t  
one should be responsible fo r  the Ba~reduced metabolites 
o f the 17-hydroxy se r ies , i . e .  conversion o f T in to  DHT 
and the d io ls ,  the o ther, which a ffe c ts  the conversion 
o f de lta -4 -A , should be responsible fo r  the Ba~reduced 
metabolites o f the 17-keto se r ies , i . e .  Ba~A and A. 
Also Rennie e t a l . [1983] reported evidence o f at le a s t 
two d is t in c t  Sa-reductases in human benign p ro s ta t ic  
hypertrophic t issues and poss ib ly  of several Sa- 
reductase isoenzymes in  the p ros ta te . They have studied
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the enzyme k in e t ic s  o f these two d i f fe re n t  a c t i v i t i e s  
and the response o f the two isoenzymes to Testosterone-
2-methylene, a competit ive in h ib i t o r .  Suggestion was 
given th a t the two d is t in c t  enzymes were lo ca l ize d  in 
the stroma and in  the ep ithe lium , re spec t ive ly . Also 
Djoseland e t a l . [1983] suggested two (stromal and
e p i th e l ia l )  forms of p ro s ta t ic  5«-reductase both 
induc ib le  by large doses o f DHT, having d i f fe r e n t  Km 
values. In th e i r  stud ies M art in i and coworkers do not 
separate the stroma from the ep ithe lium  so they haven’ t  
studied the metabolism of labeled T and o f delta4~A in 
the two t issue  components, separate ly. However, in  
th e i r  b e l ie f  the hypothesis o f Rennie appears a remote 
one, since they report th a t d i f f e r e n t ly  from the human 
and the canine prosta te  [Krieg et a l . ,  1981; Krieg et 
a l . ,  1983; Lahtonen e t a l . ,  1983; W ilk in  e t " a l . ,  1980],
in the ra t  prosta te  the 5ct-reductase a c t i v i t y  appears to 
be equally  present in  both compartments [see Orlowsky et 
a l . ,  1983; Djoseland e t a l . ,  1983].
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1.10*2. I n  v i t r o  testosterone -  de lta4 --androstenedi one
interconvers ions
In 1968, at the John Hopkins U n ive rs ity ,  Becker and 
Snipes [1968] studied the metabolic in te rconvers ion  o f T 
and de1ta4-A. Minces o f testes o f guinea p ig were 
incubated w ith 14C-delta4~A or simultaneously 14C-T 
under steady-sta te  e qu il ib r ium  condit ions (F ig . 1 .02).
I t  was evident th a t the e qu il ib r ium  between delta4-A 
and T s h if te d  from favouring the oxid ized compound when 
minces o f immature te s t i s  were used, to favouring the 
reduced form, in  the presence of minces o f mature 
t e s t i s .  Also Inano and Tamaoki [1966] found a greater 
reduction o f double bond o f the A-r ing  of androgens by 
homogenates of immature ra t  t e s t i s ,  than by homogenate 
o f mature t e s t i s .  They also reported a more rapid 
disappearance o f pregnenolone a f te r  incubation w ith 
f ra c t io n s  o f mature te s t i s ,  than w ith  those o f immature 
t e s t i s .
The relevance o f s tud ies on metabolism of both 
delta4-A and T in  guinea pig t e s t i s ,  also ca rr ied  out in
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a whole c e l l  preparation [Snipes et a l . ,  1965], is  tha t 
s te ro id  concentra tions, seen by these authors in  plasma 
of male guinea p igs, are s im i la r  to  th a t in  human adu lt 
male. These f in d in g s  give support to the hypothesis of 
Lindner and Mann [1960] th a t androgenization a t puberty 
is  in  part due and/or expressed as changes in  the 
proportions o f androgens synthesized by t e s t i s :  a T to
delta4-A ra t io  from less than 1 to  1, a t up 3 months of 
age, to greater than 10 to  1, in  animals aged more than 
9 months was reported. S im ila r  changes in androgen
ra t io s  w ith age, through the study o f re la t iv e  androgen
concentrations, were seen f i r s t l y  by Lindner [1959] in
bovine tes tes . Change in ra t io s  o f androgens a t or
a f te r  puberty has been found in e i th e r  the ra t  and in 
human blood [F raz ie r  and Horton, 1966] and, more 
recen t ly ,  in  bound-T during prepuberty in  boys 
[Belgorosky and R ivaro la , 1987].
Following Becker and Snipes [1968] the steady s ta te  
cond it ions they used would e lim ina te  the p o s s ib i l i t y  of 
simple sa tu ra t ion  e f fe c t  due to  a d if fe rence  in  the 
endogenous content o f the two androgens. In th e i r
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Figure 1.02.
Metabolism of Androstenedione (a -  top) and 
Testosterone (T) (b -  bottom) in guinea pig 
tissues o f mature and immature t e s t i s .
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opinion the approach they adopted would suggest th a t the 
s h i f t  in  the p roportion  of the two androgens, they 
observed in  immature and mature guinea pig testes 
re sp ec t ive ly , is  not due to  a fu r th e r  metabolism of 
e i th e r  delta4-A or T to  some other s te ro ids .
1 .10.3. The prosta te  cancer c e l l  l in e s
Many other stud ies have been ca rr ied  out on 
prosta te  cancer c e l ls  in  v i t r o ,  however they concern 
mainly the is o la t io n  and ch a rac te r iza t ion  o f these c e l l  
l in e s  and th e i r  growth c h a ra c te r is t ic s  much more than 
the androgen metabolism in v i t r o .
For instance, Berns e t a l . [1984] studied the
fluo rescen t androgen d e r iva t ive s  in  re la t io n  to th e i r  
a b i l i t y  to  d isc r im ina te  androgen-responsive and 
unresponsive c e l ls ,  Berns et a l . [1986] studied also the 
growth regu la tion  and s p e c i f ic  p ro te ins  release by the 
same LNCaP, Hasenson e t a l . [1985] studied the e f fe c ts  
o f hormones on growth and ATP content o f LNCaP, Smith e t 
a l . [1985] valuated the regu la t ion  o f growth o f
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androgens se n s it ive  R3327H tumor c e l l  l in e s ,  studied 
also by Heston e t a l . [1979].
Several new c e l l  l in e s  have been estab lished and 
stud ied. Eaton and P ie rrep o in t [1982a; 1982b]
established and characterized neoplastic  e p i th e l ia l  CAPE 
and f ib ro b la s to id  CAPF c e l l  l in e s ,  derived from the 
canine p ros ta te , and studied th e i r  p r o l i f e r a t io n  in 
response to hormones; Gallee e t a l . [1986] studied the 
monoclonal antibod ies against PC82 c e l l  l in e ;  Iizumi et 
a l . [1987] estab lished another p ro s ta t ic  androgen
responsive TSU-PR1 c e l l  l in e ;  Okada and Schroeder [1974] 
established a new e p i th e l ia l  c e l l  l in e s  EB33 and, 
subsequently [Okada e t a l . ,  1976], studied the clonal 
se lec t ion  and androgen dependence of th is  new c e l l  
1i nes.
A number o f authors ca rr ied  out s tud ies on primary 
c e l l  cu ltu res  and c u l t iv a t io n  methods of prosta te  c e l ls  
[Brehmer e t a l . ,  1972; Chapdelaine and Chevalier, 1984; 
Chen, 1981; Cowan e t a l . ,  1977; Heston e t a l . ,  1979;
Isaacs e t a l . ,  1986; Kawamura and Ich ihara , 1987;
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Mackeen et a l . ,  1984], For example, Bologna et a l .
[1984] studied the s t im u la t io n  o f dome formation by 
d imethylsulphoxide also in PC3 c e l l  l in e .  MacMahon et 
a l « [1972] studied the morphological responses to  T;
Schroeder and MacKeens [1974], Shipman et a l . [1975] and 
Sinowatz e t a l . [1977] studied the u l t r a s t ru c tu ra l
m od if ica tion  by T, DHT and 5a-A-3o:,17o;“ d io l on the
canine c e l ls  [see also Stone e t a l . ,  1975 and 1976; Syms 
et a l . ,  1982; Webber, 1979]. Several authors studied 
also he te ro -transp lan ts  in  animals o f these c e l ls  and 
the re la t iv e  growth of tumors in  animal models [Dunning, 
1963; Isaacs e t a l . ,  1978; Isaacs e t a l . ,  1981; Isaacs 
and Coffey, 1981; Lazan et a l . ,  1982; Lowe and Isaacs,
1984; Mickey e t a l . ,  1977; Shain et a l . ,  1984; Wake et
a l . ,  1982].
1 .10.4. Androgen content of human prostate
Looking at androgen content o f human p ros ta te , a 
major accumulation o f androgen in the p ros ta te , 
s ig n i f i c a n t ly  higher than in  ske le ta l muscle has been
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reported [Tveter and Attramadal, 1968; Tveter and
Attramadal, 1969]. This p re fe re n t ia l  androgen uptake
is  believed due to cytoplasmic and nuclear receptor 
p ro te in  [Fang e t a l . ,  1969; Unhjem e t a l . ,  1969; Unhjem 
and Tveter, 1969; Unhjem, 1970], So tha t the suggestion 
th a t DHT content o f prosta te  cancer t issues may be 
p re d ic t ive  of the hormone responsiveness have also been 
made [G e lle r  and A lb e r t ,  19853.
From other stud ies the DHT has been extracted 
separately from ep ithe lium  and stroma of benign 
p ro s ta t ic  hypertrophy and of human normal prosta te  and 
q u an t if ie d  by radioimmunoassay (RIA) [Bartsch e t a l . ,
1982]. Concerning benign p ro s ta t ic  hypertrophy, the DHT 
was mainly observed in  the nuclear f ra c t io n  o f 
ep ithe lium  and stroma, whereas 3cc~diol was o f a 
completely extranuclear o r ig in .  In the nucle i derived 
from stroma of benign p ro s ta t ic  hypertrophy the DHT 
content was s ig n i f i c a n t ly  higher than in the nucle i 
derived from benign p ro s ta t ic  hypertrophy ep ithe l ium ; 
moreover DHT content in  the nuclear f ra c t io n  of 
ep ithe lium  and stroma was s ig n i f i c a n t ly  lower in  human
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normal prosta te  when compared w ith benign p ro s ta t ic  
hypertrophy t issues . In conclusion the data from 
Bartsch et a l . [1982] and Krieg e t a l . ,  1981 ind ica te
th a t the stroma o f benign p ro s ta t ic  hypertrophy is  a 
p re fe re n t ia l  ta rge t t issue  fo r  androgen metabolism or 
th a t the DHT is  p re fe re n t ia l ly  accumulated in to  the 
nucle i of benign p ro s ta t ic  hypertrophy stromal c e l ls  in 
humans. Autoradiographic re s u lts ,  however, have 
ind ica ted a p re fe re n t ia l  lo c a l iz a t io n  of androgens 
w ith in  the ep ithe lium  of the prosta te  and seminal 
vescic les in ra ts  [Tveter and Attramadal, 1968 and
1969].
S ig n i f ic a n t ly  higher production of DHT from T were 
observed by other authors [Djoseland et a l . ,  1977], in  
benign p ro s ta t ic  hypertrophy, much more than in human 
normal prosta te  or in  PCa t issues . A fte r  incubation o f 
minced t issue  w ith 3H-T fo r  2 h r, several androgen 
metabolites were id e n t i f ie d :  T, de1ta4-A, 5a~A, DHT, 3a~ 
d i o l , 33-d io l and A. Noteworthy the authors reported 
th a t ,  meanwhile in  normal human prosta te  and benign
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p ro s ta t ic  hypertrophy t issues , the incubated 3H-T is
metabolized a t 40% and 65%, re sp ec t ive ly , the PCa
tissues metabolized T only a t 20%, o f which 50% was
present as DHT. Moreover the formation o f the 5a~
reduced metabolites of 17-keto series was approximately 
the same, independently from th a t in  several prosta te
tissues higher or lower 5a~DHT production were observed.
This suggests th a t the 5a-reduction o f 17-hydroxy
and 17-keto se r ies , resp ec t ive ly , is  qu ite  independent 
from one another and th a t production o f the 5a-reduced 
17-keto metabolites is  not inve rse ly  proportiona l to the 
DHT conversion le v e ls .  These authors concluded th a t  the 
very low metabolic conversion of T in PCa tissues should 
be examined fu r th e r  in  re la t io n  to  tumour 
d i f fe r e n t ia t io n  and c l in ic a l  e f fe c t  o f endocrine 
therapy.
More recently  a t te n t io n  has been focused on the 
formation o f the conjugate, sulphate and glucuronide 
s te ro id s ; stud ies on long term c e l l  cu ltu re  o f human 
PCa, in  L ab r ie 's  labs, showed th a t the LNCaP c e l ls  were 
able to convert androgens in to  s ig n i f ic a n t  amounts o f
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glucuronides, thus showing the presence o f g lucuronide 
transferase a c t i v i t y .  On the contrary e i th e r  DU145 or 
PC3 c e l ls  never produced appreciable amounts o f 
glucuronide m etabolites. The same authors [Lacoste et 
a l . ,  1989] showed th a t DU145 c e l ls ,  when incubated w ith 
T ex tens ive ly  transformed precursor in to  DHT and E2, 
thus in d ic a t in g  the presence o f high leve l o f 5a~
reductase and aromatase a c t i v i t i e s .  Lower leve l of 
a c t i v i t y  by these enzymes were reported fo r  PC3 c e l ls .
1.11. S tero id  Content o f Human Normal and Cancer Tissues
A growing number of stud ies have shown th a t the
le ve ls  of some s te ro ids  are co n s is ten t ly  and 
s ig n i f ic a n t ly  increased, w ith respect to plasma values, 
in  both normal n ipp le  asp ira tes and in breast cyst 
f lu id s  (BCF). The observed r ise  in  s te ro id
concentrations includes th a t o f androgen sulphates
[Bradlow et a l . ,  1983; M i l le r  and Fo rres t, 1983], of 
DHA-S [M i l le r  et a l . ,  1980], o f E3S in BCF [Raju e t a l . ,  
1981] and o f free El and E2 together w ith  p ro la c t in
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[Wynder and H i l l ,  1977], Mechanisms fo l lo w in g  which 
s te ro ids  accumulate in  BCF are s t i l l  not defined: a)
s te ro ids  may enter breast f lu id s  from blood; b) they may 
be lo c a l ly  synthesized from precursors, The observation 
th a t there is  a weak but s ig n i f ic a n t  c o r re la t io n  between 
free  plasma, ra ther than t o t a l ,  El or E2 and breast 
f l u id  content of these hormones, may support evidence 
fo r  the f i r s t  hypothesis [ S i i t e r i  e t al . ,  1986],
Several in ve s t ig a t io n s  showed a simple l in e a r  
c o r re la t io n  between plasma and t issue  concentrations of 
s te ro ids  [Batra e t a l . ,  1979; Cortes-Gallegos et a l , ,  
1975; Wiegering e t a l . ,  1983], A d d it io n a l ly ,  several in  
v i t r o  stud ies have suggested the p o s s ib i l i t y  of a r ise  
in  the loca l b iosynthesis of E2 (oestrogens) [A b u l-H a j j ,  
1979; Desphande et a l . ,  1976], Meanwhile, some reports  
compare s te ro id  b iosynthesis by normal and malignant 
t issues in v ivo [Vermeulen et a l . ,  1985; lames e t a l . ,  
19863.
Very in te re s t in g  data have been recen tly  reported 
by Thijssen and coworkers, on both endometrial and 
breast cancer [Wiegerinck et a l . ,  1983; Alsbach e t a l . ,
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1983], They studied both t issue  content and su b ce l lu la r  
d is t r ib u t io n  o f f i v e  d i f f e r e n t  s te ro ids , namely DHA and 
DHA-S, de lta5 -A ndros tend io l(33,173), E2 and E l. These 
stud ies were ca rr ied  out in  normal, hypertroph ic  and 
cancer t issues o f both pre- or postmenopausal women. 
Accumulation o f DHA-S was not observed in  normal, 
hypertroph ic , or cancer breast t issues . This was true  
fo r  pre- and postmenopausal samples. In p a r t ic u la r ,  
median values reported fo r  cancer tissues (from e i th e r  
pre- or postmenopausal women) were less than one h a l f  of 
minimal value of in te rq u a r t i le  ranges observed in 
plasma, fo r  DHA-S. In te re s t in g ly ,  the DHA-S median 
values observed in premenopausal cancer t issues were 
less than one f i f t h  w ith  respect to normal or benign 
t issues ; in  postmenopusal cancer t issues they 
represented one fo u r th  o f the normal t issue  content. 
Conversely, fo r  the other two androgens studied (DHA and 
de lta5 -Androstend io l) ,  the median to ta l  concentrations 
were higher in cancer samples w ith respect to  the 
plasma le ve ls  (e .g. two times more than th a t observed in 
plasma fo r  DHA in both pre- and postmenopausal
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neop lastic  t is s u e s ) .  However, median to ta l  t issue  
content of androgens observed in cancer samples was 
between two and three times lower than th a t observed in 
normal or benign tissues in premenopause and was not 
s ig n i f i c a n t ly  d i f fe re n t  from normal tissues in post 
menopausal cancer. As to  5 -androstenedio l, the median 
concentrations observed in  cancer t issues were in the 
range o f plasma values ( fo r  both pre- and postmenopausal 
samples); these values were also lower than in  normal or 
benign to ta l  t issue  concentrations in  premenopause, but 
almost at the same leve l fo r  postmenopause.
For both DHA and de lta5 -A ndros tend io l, the study of 
su b ce l lu la r  d is t r ib u t io n  showed higher concentrations in  
nuclear f r a c t io n .  This was true fo r  normal, 
hypertrophic and cancer t issue  from e i th e r  pre- or 
postmenopausal pa t ien ts  (except fo r  the 5-androstenediol 
content o f postmenopausal cancer t is su e s ) .
Tissue content o f two oestrogens (El and E2) appear 
qu ite  d i f fe re n t  from those p rev ious ly  observed fo r  
androgens. F i r s t l y  the median values of cancer t issu e
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concentrations were higher than respective median plasma 
values; th is  was true  fo r  both pre- and postmenopause. 
For instance, El median concentrations were eleven and 
s ix  times h igher, re spec t ive ly , fo r  pre- and post­
menopausal cancer t issues . For E2, le ve ls  were two 
times higher (median values) in  premenopausal cancer 
t issue  but almost t h i r t y  times more o f to ta l  
concentrations in postmenopausal cancer samples. In 
general, there was s t r ik in g  evidence th a t t issue  
concentrations were, in  almost a l l  cases, much higher 
than respective plasma values. The only exception was 
E2 content in  premenopausal samples, where normal or 
benign tissues exh ib ited  roughly the same leve ls  as in 
plasma. Subce llu la r s tud ies detected higher 
concentrations in cytosol f ra c t io n s  than in nuclear ones 
and th is  was true  fo r  El (roughly 80% of samples), in 
both normal and cancer t issues and in  p re- and 
postmenopausal samples. This was less evident fo r  E2 
(roughly 60%), but co n s is te n t ly  in  normal, benign and 
cancer premenopausal t issu es , and in  normal and cancer 
postmenopausal samples. Thus, both these oestrogens
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exh ib ited  higher cancer t issue  concentrations than 
benign or normal t issues ; E2 content was two times more 
fo r  premenopausal samples and over two times more fo r  
postmenopausal ones. The t issue  to  plasma E2 ra t io s
ranged from 10, fo r  normal postmenopausal samples, to 
more than 25, fo r  cancer postmenopausal samples.
1 .11.1. S tero id  content of breast cyst f l u id
Breast c y s t ic  disease a f fe c ts  mainly premenopausal 
women (between 30 and 50 years o ld) and is ,  fo r  the most 
p a r t ,  represented by gross c y s t ic  disease, i . e .  cysts 
la rg e r  than 3 mm of diameter as defined by Haagensen e t 
a l . [19813. Women w ith gross c y s t ic  disease seem to
have increased r is k  (from 2 to 4 times more than
con tro ls )  of breast cancer [Haagensen e t a l . ,  1981;
Azzopardi, 19793.
Breast c y s t ic  disease is  thought to be caused by 
m u lt i fa c to r ,  endocrine and/or biochemical d iso rders . 
E p ith e l ia l  a typ ica l hyperplasia also seems to  increase 
the r is k  o f cancer. For th is  reason, in te re s t  fo r
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breast cyst f lu id s  developed during the la s t  15 or 20 
years.
From recent s tud ies , breast cysts can be 
categorized by potassium (K+) and sodium (Na+) 
concentrations and by K+ to  Na+ ra t io s  of BCF [Bradlow 
et a l . ,  1985], Cation ic  pa tte rn  associated, s ig n i f ic a n t  
s te ro id  accumulations have been reported. For example, 
increased p ro te in  and s te ro id  hormone le ve ls  were 
detected [Bradlow et a l . ,  1979 and 1983], At the same 
time a r ise  in  th y ro id  hormones was observed [Angeli e t 
a l . ,  1984]. Above a l l ,  increased DHA-S amounts appeared 
re la ted  to the apocrine metaplasia by e p i th e l ia l  c e l ls  
l in in g  cys ts . [Dixon e t a l . ,  1983]. This evidence
agrees well w ith apocrine e p i th e l ia l  contro l by 
androgens, so th a t DHA-S can be considered as a marker 
o f apocrine secre tion  in cyst f lu id s  [Labows e t a l . ,  
1979? Scheurch e t a l . ,  1982],
S im ila r  increase o f in t ra c y s t ic  amounts has been 
reported fo r  some growth fa c to rs  ( l ik e  EGF), fo r  other 
p ro te in  hormones ( l i k e  fi- human chorion ic  gonadotropin,
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3-HCG) and fo r  some tumour markers or oncofetal antigens 
( l i k e  e p i th e l ia l  membrane antigen [C o l le t te  et a l . ,
1986], carcinoembryonic antigen (CEA) [O l iv a t i  e t al 
1986] and CA-125 [D o g l io t t i  e t a l . ,  1986a]). Several
g lycopro te ins have been shown to r ise  in  BCF, 
p a r t ic u la r ly  an a - fe to p ro te in ,  named Gross Cystic 
Disease F lu id  Prote in  15 (GCDFP15) [Haagensen e t a l . ,
1979; Haagensen and Mazoujian, 1983]; th is  la s t  could be 
an androgen dependent apocrine secretion  marker 
[C o l le t te  e t a l . ,  1986; Mazoujian e t a l . ,  1983; D i l le y  
et a l . ,  1983; Bradlow et a l . , '1 9 8 5 a ] and was observed as 
p a r t ic u la r ly  increased in  both breast cyst f lu id s  and 
cancer t issues [Bradlow et a l . ,  1985b; M i l le r  et a l . ,
1988]. Other substances l i k e  in s u l in - l i k e  growth 
fa c to rs  and CA-15.3 and some p ro te in  hormones ( l ik e  
p ro la c t in )  showed s ig n i f ic a n t  decrease.
3-HCG was p a r t ic u la r ly  increased in cyst f lu id s  
[Greenblatt and Mahesh, 1986], the Haagensen’ s GCDFP15 
p ro te in  was also detected by Mazoujiyan and D i l le y  in  
BCF ( in  more than 50% of cases) and in  metasta tic  breast
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cancer [D i l le y  et a l . ,  1983] in  b iopsies from more than 
60% of p a t ien ts .
More in general, a marked fea ture  of BCF is  the 
enormous increase of e i th e r  s te ro id  or p ro te in  hormones, 
fo r  the most part in  b io lo g ic a l ly  ac tive  forms ( i . e .  
f re e ) ,  because o f the in t ra c y s t ic  reduction o f the 
s p e c if ic  transport p ro te in s . In general terms, the 
p ro te in  content of cyst f lu id s  is  about one th i r d  of the 
corresponding plasma values.
Looking at s te ro id s , high leve ls  o f 17-oxo- 
s te ro id s , El or E3, and of androgen metabolites (mainly 
sulphated) are very commonly reported: DHA-S content was 
studied in  re la t io n  to the K+/Na+ ra t io .  Categoriz ing 
cysts on the basis o f th e i r  K+ and Na+ content, i t  was 
observed tha t DHA-S was in  a p o s it iv e  c o r re la t io n  w ith 
K+ content and in negative c o r re la t io n  w ith Na+ content 
[D o g l io t t i  et a l . ,  1986b]. By subdiv id ing cysts on the 
basis of th e i r  c a t io n ic  pa tte rns , most belong to  type I 
(high K+ -  low Na+) and to  type I I  (high Na+ -  low K+), 
w h i ls t  a l im i te d  percentage, roughly 10%, was a t t r ib u te d
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to  an intermediate type I I I ,  having almost equimolar 
concentrations of K+ and Na+ [D o g l io t t i  e t a l , ,  1986b],
Three observations have been reported o f some 
in te re s t :  f i r s t  of a l l ,  c a t io n ic  patterns seem to  be not 
modified fo l low ing  f o l l i c u l a r  or lu te a l  phases o f the 
menstrual cyc le ; secondly, pa t ien ts  having m u lt icys ts  
show nearly the same e le c t ro ly te  pa tte rn  in  almost a l l  
the cyst f lu id s ;  t h i r d l y ,  th is  pattern  is  completely 
modified in postmenopause, in  which the percent of cases 
having type I cysts is  much lower and the percent o f 
p a t ien ts  having type I I  cysts is  much higher (Tab, 
1 .03).
This ind ica tes th a t there is  a s ig n i f i c a n t ly  
d i f fe re n t  d is t r ib u t io n  o f cyst types among 
postmenopausal compared w ith  menstruating p a tien ts  
[Orlandi e t a l . ,  1987], This view is  in  agreement w ith  
previous re su lts  by Scheurch e t a l , [1982], who reported 
a strong reduction o f apocrine metaplasia 
c h a ra c te r is t ic s  in  b iopsies of benign breast les ions 
from pa tien ts  aged over 50 years.
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Table 1.03,
D is t r ib u t io n  o f cyst types categorized on the 
basis o f potassium (K+) and sodium (Na+) 
content. F o l l i c u la r  vs lu te a l  = NS; f o l l i c u l a r  
vs menopause p<0.001; lu te a l vs menopause 
p<0.001 (Chi square te s t ) .
Reproduced from D o g l io t t i  et a l . [1986a],
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These data were obtained through c u t - o f f  values 
which were s l ig h t l y  d i f f e r e n t  w ith respect to those 
proposed by Bradlow et a l . [1983] and by M i l le r  et a l . 
[1983], i . e .  K+ to  Na+ ra t io  more than 3 fo r  type 1 and 
less than 1 fo r  type 2.
Evidence is  accumulating th a t p a t ien ts  in  whom 
apocrine changes occur more frequen t ly  are associated to 
an increased r is k  o f breast cancer, [W ellings e t a l . ,  
1975; Scheurch e t a l . ,  1982; Mazoujian et a l . ,  1983].
I t  was also observed th a t  m u lt ip le  cysts are associated 
w ith higher incidence of apocrine metaplasia and w ith  a 
greater frequency of developing fu r th e r  cysts [Dixon et 
a l . ,  1985]. These l a t t e r  reports come out from a
prospective study ca rr ied  out on over 100 cases in  which 
the authors observed th a t pa t ien ts  presenting w ith  type 
I cys ts , mainly having apocrine ep ithe lium , developed 
fu r th e r  cysts f i v e  times more frequen t ly  than those 
presenting w ith type I I  cysts ( f la t te n e d  e p ithe l iu m ). 
This was also the opinion of Haagensen, who reported 
th a t m u lt ip le  cysts are associated w ith  a higher r is k  o f
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developing breast cancer [Haagensen e t a ! . ,  1981].
I t  has been observed th a t the c a t io n ic  pa tte rns , 
ca tegoriz ing  cysts f l u id s ,  are s trong ly  associated with 
pH values of these f l u id s .  Such stud ies were ca rr ied  
out recently  by two d i f fe re n t  groups [Dixon et a l . ,  
1984; Bradlow et a l . ,  1987]. In the study of Dixon, the 
pH c u t -o f f  value was 7.4, w ith  type I -  high K+ f lu id s  
having values below 7.4 and type I I  -  high Na+ f lu id s  
more than 7.4. The more recent study o f Bradlow stated 
a pH c u t - o f f  value at 7.0. In summary, he showed th a t 
type I cysts co n s is ten t ly  have pH le ve ls  less than 7.0, 
together w ith increased amounts o f organic acid and low 
leve ls  o f carbon d ioxide (C02) and ch lo r ide  (C1-). Type 
I I  cysts un iform ly have pH values over than 7.0. In 
add it ion  the more a c id ic  cysts type I tend to have a 
much greater loss in  C02 than th a t observed in type I I  
cys ts . In conclusion, from Bradlow's stud ies there is  
evidence th a t eva luation o f pH values must be ca rr ied  
out c a re fu l ly ,  by avoiding exposure to  a i r  during 
measurements, since the much higher tendency to  loose 
C02 by one cyst group very qu ick ly  leads to v a r ia t io n
91
INTRODUCTION
(range of 0 .3 -0 .5 ) o f pH values.
Studies aiming to  es tab lish  the t issue  content of 
s te ro ids  in human cancer should have two goals. F i r s t ,  
they should consider as large a range as possib le 
pa tte rn  o f s te ro id  metabolites.- secondly, the r a t io  of 
plasma to t issue  le ve ls  should be determined. For 
example, E2 content o f cancer tissues and a t the ra t io  
o f plasma to  t issue  E2 values, together w ith the leve ls  
o f E2 conjugates, should be determined. For both 
reasons, i t  seems essentia l th a t  several metabolites and 
classes o f s te ro ids  may be id e n t i f ie d  and q u a n t if ie d  by 
appropriate methodologies.
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2. MATERIALS AND METHODS
2,1 . Cell Cultures
Cell l in e s  were maintained in Dulbecco's Modified 
Eagle Medium(DMEM)/Ham*s F10 (50:50 v :v )  supplemented 
w ith fe ta l  c a l f  serum (FCS) 10% (v /v ) ,  L-glutamine 200 
mM and a n t ib io t ic s  ( p e n ic i l l i n  100 U/ml, streptomycin 
100 pg/m l, fungizone 2 pg/m l, kanamycin 50 pg/ml) .  A l l  
l in e s  were tested fo r  b a c te r ia l  (b ra in  heart in fus ion  
broth and Saboraud f l u id  medium) and mycoplasma (Hoechst 
33258- Flow k i t )  contamination ro u t in e ly  before
th e i r  u t i l i z a t i o n  fo r  metabolism s tud ies.
Cells  growing in log phase were tryp s in ize d  and 
counted w ith  a Burker chamber under a l i g h t  microscope. 
Cells  a t a concentration o f about 1x10(6) were 
subsequently p lated on P e tr i  dishes (0 60 mm). For
s te ro id  metabolic stud ies 5 ml of Biggers (BJG, phenol- 
red and FCS free ) as the incubation medium and 
rad ioac tive  precursors were used. A separate P e tr i  dish 
is  set as an external contro l in  the presence o f the
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same ra d io in e r t  precursor at the same molar 
concentrations used, in  order to  monitor c e l l  growth and 
v i a b i l i t y  fo r  the s ing le  set of time course experiments. 
V ia b i l i t y  was determined w ith the Trypan-Blue (0.5% v /v ) 
exclusion method (see Fig, 2 .01).
Cells  were allowed to p la te  down fo r  24 or 48 hr in  
a C02 (5%) incubator a t 37°C and then incubated under
experimental cond it ions fo r  various times ranging from 
as short as 30 min up to 96 hr.
The experiments have been ca rr ied  out using e i th e r  
constant rad ioac tive  precursor concentrations or
constant cel 1/p recursor molar ra t io  as reported in the 
f low chart (F ig . 2 .02).
In order to  monitor the d i f fe re n t  d is t r ib u t io n  of
metabolites between c e l ls  and medium, e x tra c t ions  o f
c e l ls  and medium separate ly or c e l ls  plus medium were 
ca rr ied  out,
At the end of incubation period the medium is  
co llec ted  separate ly and c e l ls  are harvested in
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Figure 2.01.
V ia b i l i t y  te s ts  on HEC-1A C e lls . Values of 
v iab le  (open) and dead (hatched) c e l ls  at 
d i f fe re n t  steps; 1) before adding serum free 
BJG medium; 2) ju s t  before the add it ion  of 
rad ioac tive  precursor; 3) at the end of 
incubation time.

Figure 2.02,
Flow chart of various steps fo r  measurements of 
s te ro id  conversion rates by in v i t r o  systems.
CELL L IN E S  MAINTENANCE 
In  D u l b e c c o ' s  m o d i f i e d  E a g l e  m ed ium  (DMEM) /  H a m 's  F IG  
w i t h  FCS 107., L —g l u t a m i n e ,  a n t i b i o t i c s  a nd  a n t i m y c o t . i c s
HARVESTING AND ALIQUOTING 
C e l l s  s u s p e n d e d  i n  T r y p s i n - E D T A  and  p l a t e d  ( x ~ l x 1 0 ( 6 ) ± 5 x 1 0 ( 4 ) )  
i n  s e r u m —f r e e ,  p h e n o l  r e d - f r e e  D i g g e r s  BJG m e d ium  
on 5 ml P e t r i  d i s h e s  f o r  2 4h
INCUBATION
A t  d i f f e r e n t  t i m e s  ( u s u a l l y  f o r  2 4 ,  7 2  a nd  96  h) 
u s i n g  o ne  o r  t w o  r a d i o a c t i v e  p r e c u r s o r s  3 H - E 2 ; 14 C - E 1 ; 3 H - T
( u s u a 1 1 y a t  1 0 ( - 9 )  t o  1 0 ( - 8 ) M)
CELL HOMOGENIZATION
A t  4 °C  i n  f r e s h  B i g g e r s - B J G  m ed ium  
( i n  p r e s e n c e  o f ' a s c o r b i c  a c i d  f o r  o e s t r o g e n s )  
u s i n g  a g l a s s - g l a s s  h o m o g e n i s e r  p r e c o a t e d  s y s t e m
EXTRACTION
I n  g l a s s  v i a l s  p r e c o a t e d  w i t h  t h e  same r a d x o i n e r t  p r e c u r s o r
f r o m  c e l l s  a n d / o r  m e d iu m  o f :
/  \
OESTROGEN m e t a b o l i t e s  ANDROGEN m e t a b o l i t e s
w i t h  d i e t h y l  e t h e r : a c e t o n e  ( 9 s 1) w i t h  d i e t h y l  e t h e r
i n  p r e s e n c e  o f  a s c o r b i c  a c . ? i n  p r e s e n c e  o f  NaOI-l 2  M
(1 0  m g / m l ) (2 0  p i / m l )
E x t  r  a c t s  d r  i  e d u n d e r  n .i t  r  o g e n a nd  s  t  o r e d  a t  4 0 C i n  t h e  d a r  k
D r  y  e t  r  a c t  s  r  e s  u s p e n d e d w i  t  h 3 0 u 1 o f  A c e t  o n i  t  r  i  1 e j u s t  b e f  o r  e
HPLC ANALYSIS
i n  r e v e r s e  -  p h a s e  mode 
i n  i s o c r a t i c  c o n d i t i o n  a t  1 . 0  m l / m i n  
w i t h  on l i n e  UV and  r a d i o m e t r i c  d e t e c t i o n s
7  \OESTROGENS v  ANDROGENS
Mob i  1 e~p  h ase s  Mob i  1 e -phase? :
a c e t o n i  t r . i  1 es c i  t r i c  a c .  w a t e r : a c e t o n i t r i 1 e : t e t r a h y d r o f u r a n
0 . 1  M (40s  6 0 )  ( 5 5 : 3 3 . 7 s 1 1 . 3 )
MASS SPECTROMETRY/ANALYSIS 
A u t o m a t e d  f  r a c t i  oh c o l  1 e c t  .i on 
o f  i n d i v i d u a l  m e t a b o l i t e s  
f o r  m a s s - f r a g m e n t o g r a p h i c  p a t t e r n s
MATERIALS AND METHODS
Trypsin/EDTA. The c e l l  sample is  then resuspended in an 
equal volume of fresh medium when separate ex trac tions  
are to  be performed.
P r io r  to  manipulation o f samples, a l l  the glassware 
to  be used fo r  the e x tra c t io n  is  precoated w ith  4 pg of 
the ra d io in e r t  s te ro id  used in  the incubation. Cell 
plus medium or c e l l  samples were homogenised in 
g lass/g lass homogenisers fo r  3 x 5  sec bu rs ts ; the 
temperature is  kept constant at 4°C.
2 .1 .1 . Oestrogens
Sodium ascorbate is  added to the medium at a f in a l  
concentration of 10 pg/ml in  order to  prevent the 
ox ida tion  of the hydroxy oestrogens eventua lly  formed. 
Cells  are incubated in  the presence o f e i th e r  
rad ioac tive  E2 ( [ 6 9733H-E2, s .a . :  60 Ci/mmole; Amersham) 
or El ([6,7]3H-E1, s .a . :  58 Ci/mmole; [4-14C1E1, s .a . :
55 mCi/mmole; Amersham) at the f in a l  concentrations of
a) 3H-E2 -  8.3xlO(-8)M (5 pC i/m l);
b) 3H-E1 -  8.6xlO(-8)M (5 pC i/m l);
c) 14C-E1 -  2.8xlO(-5)M (0.8 pC i/m l).
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For the double label experiments a s ing le  so lu t ion  
composed o f 3H-E2 and 14C-E1 is  used, at the same 
concentrations as before, i f  not otherwise s ta ted . 
Before homogenization 10 mg/ml of ascorbic acid is  added 
to lower pH value below 4.0 and prevent ox ida tion  of 
metabolites.
2 .1 .2 . Androgens
Cells  are incubated in the presence o f T 
( [ 1 ,2 ,6 ,713H-T, s .a . :  82 Ci/mmole; Amersham) a t the
f in a l  concentration of 4.9xlO(-9)M (0.4 pC i/m l). To 
improve recovery, 20 p l/m l o f sodium hydroxide (NaOH, 
2N) is  added to bring pH above 10.0 p r io r  to e x tra c t io n .
2 .2 . S tero id  Tissue Content
Oestrogen t issue  content has been studied on normal 
and neop lastic  breast and endometrial t issues . A ll 
tissues were processed immediately a f te r  surgery or 
stored at ~20°C in  a buffered system (Sucrose 250mM, 
Hepes lQmM, MgCl2 1.5mM, Glycerol 50% (v /v ) ,  pH 7 .4 ) .
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MATERIALS AND METHODS
One gramme of t issue  is  thoroughly minced and put in to  a 
g lass/g lass homogeniser. Tissues are homogenized in  3 
ml pe rch lo r ic  acid 0.01N plus 3 ml of T r is  b u f fe r  0.1M, 
pH 8.6. To recover free' oestrogens and 
catecholoestrogens, ascorbic acid is  added as in  section
2 .1 .1 . A ll procedures are ca rr ied  out a t 4°C or as 
otherwise sta ted .
2.3 . Breast Cyst Fluid
Breast cyst f l u id  was obtained by f in e  needle 
a sp ira t io n  of cyst content [Z a jicek , 1974]. A l l  l iq u id  
is  cen tr ifuged and the p e l le t  u t i l i z e d  fo r  cyto logy 
s tud ies . The supernatant is  measured, subdivided in 
a liq uo ts  of 1 ml each and processed immediately or 
stored in  a deep freezer at -80°C. BCF an ion ic and 
c a t io n ic  content is  ca rr ied  out on 0 .1-0 .2  ml samples by 
means o f po ten tiom etr ic  d i re c t  determination w ith  a 
f u l l y  automated a n a ly t ica l system (Beckman Astra 8 -
I.S .E . module) which ensures re p e a t ib i ly  and 
re p ro d u c ib i l i t y  o f re s u lts .
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2.4 . E x trac tion  Procedures
2 .4 .1 . Cell cu ltu res
A 1 ml a l iq u o t  of c e l l  homogenate is  set in to  a 
s c i n t i l l a t i o n  v ia l  fo r  reading the to ta l  r a d io a c t iv i t y  
per ml processed (TT). The homogenate is  then spun at 
lOOOg fo r  5 min. The supernatant is  co lle c te d  in  a 
separate tube and used fo r  the ex tra c t io ns  (see Fig. 
2 .03). The p e l le t  o f c e n tr i fu g a t io n  is  resuspended w ith 
1 ml d i s t i l l e d  water and put in to  a s c i n t i l l a t i o n  v ia l  
(PP) fo r  reading ra d io a c t iv i t y  s t i l l  bound to  c e l l  
s tru c tu re s . 3 x 1 ml a l iq u o ts  of supernatant are 
sampled in to  glass s c i n t i l l a t i o n  v ia ls  (AA).
For oestrogens, e x tra c t io n  is  ca rr ied  out w ith  10 
ml of d ie thy l etherjacetone (9:1 v /v ) .
For androgens 10 ml o f cold d ie thy l ether are used. 
20 pi of concentrated g la c ia l  ace tic  acid is  a liquoted  
to n e u tra l ize  the NaOH present in  the sample before 
adding s c in t i l l a t i o n  c o c k ta i l .
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Figure 2.03.
Flow chart of s te ro id  e x trac t ion  in in  v i t r o  
systems.
CELL HARVESTING
HOMOGENISATION
I
CENTRIFUGATION TOTAL RADIOACTIVITY 
COUNTING (VIAL TT)
SUPERNATANT PELLET
COUNT RADIOACTIVITY 
(VIAL PP)
EXTRACTION
OESTROGENS 
(DIETHYL ETHER:ACETONE)
ETHER PHASE 
DRIED UNDER N2 STREAM
ANDROGENS 
(DIETHYL ETHER)
COUNT AQUEOUS PHASE 
FOR NON EXTRACTED 
RADIOACTIVITY (VIAL BB)
DESSICATED EXTRACT 
RESUSPENDED IN ACETONE
COUNT RADIOACTIVITY 
ADHERED TO GLASS WALLS 
(VIAL AA)
DRY DOWN UNDER N2 STREAM
STORE SAMPLES AT 4°C PROCESS IMMEDIATELY
RESUSPEND WITH ACETONITRILE
i
INJECT ALIQUOT FOR 
HPLC ANALYSIS
COUNT FINAL EXTRACTED 
RADIOACTIVITY (VIAL CC)
MATERIALS AND METHODS
Samples are thorough ly  mixed f o r  a few seconds and 
l e t  stand f o r  5 min in  a waterbath a t  4°C, The aqueous
phase is  then removed from the glass v ia l  and put in
another one f o r  coun t ing the non ex t rac ted  r a d i o a c t i v i t y  
(BB). The e ther  phase i s  d r ied  down under n i t rogen  
stream; the dessicated e x t ra c t  i s  then removed from the 
v ia l  w i th  3 x 500 pi o f  acetone and put in to  a t e s t
tube, d r ied  again w i th  n i t rogen  and resuspended w i th  30
pi o f  a c e t o n i t r i l e .  20 pi are used f o r  HPLC ana lys is  
and 5 pi are used to  determine t o t a l  ex t rac ted  counts 
(CC). For es t im a t ion  of  percent e x t r a c t i o n  e f f i c i e n c y  
(%EE) the fo l l o w in g  method is  used
CPM(CC) x 6 x 100
%EE -  ---- -------------------------------------- ------------ ------ ---------------
[CPM(CC) x 6] + CPM(AA) + CPM(BB) + CPM(PP)
Read out of  v ia l  (TT) i s  used as in te rn a l  q u a l i t y  
c o n t r o l ,  A t y p ic a l  example of  r a d i o a c t i v i t y  
d i s t r i b u t i o n  i s  given in  Table 2,01,
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Table 2.01,
R a d io a c t iv i ty  values obtained at selected steps 
of s te ro id  e x tra c t io n  procedure. Readings were 
performed in a Beckman LS1801 s c in t i l l a t i o n  
counter. (For abbrevia tions see te x t ) .
TYPICAL DISTRIBUTION OF RADIOACTIVITY 
DURING STEROID.EXTRACTION
OESTROGENS ANDROGENS
V ia l cpm cpm
TT 2.1x10(6) 2 .8x10(5)
PP 2.5x10 (5 ) 1 .1x10 (4 )
AA 6.9x10(3) 3 .5x10(3)
BB 1.5x10(5) 2 .2x10 (4 )
CC 2.4x10(5) 3 .9x10(4)
MATERIALS AND METHODS
2 ,4 ,2 ,  Oestrogens: alurn i num ox idemethod
For t i s s u e  content s tud ie s ,  the homogenate is  
c en t r i f uged  at  lOOOg f o r  5 min and the supernatant is  
decanted in to  a t e s t  tube w i th  40 mg of  alumina (pH 4,0) 
and 8 ml T r i s  b u f f e r  pH 8,6 ,
For 8CF, s te ro id  e x t r a c t i o n  from f resh  or -80 °C 
s tored cys t  f l u i d  was made on 5 ml a l i q u o t ( s ) ,  f o l l o w in g  
the methods p rev ious ly  descr ibed in  sec t ion  2 ,3 .  A f t e r  
a d d i t io n  of  1.5 ml o f  p e r c h lo r i c  acid (0.01M), the 
mixture i s  s t i r r e d  f o r  10 min w i th  a Vortex and 
cen t r i f uged  again (10 min at  2000g). The supernatant  is  
decanted in to  a t e s t  tube con ta in ing  40mg of  alumina pH 
4,0 and 5,5 ml T r i s  b u f f e r  0.1M pH 8,6,
At t h i s  stage, t i s s u e  homogenates and BCF samples 
fo l lowed the same procedure,
The mixture i s  s t i r r e d  f o r  10 min w i th  a vor tex  and 
cen t r i fuged  again 5 min at  lOOOg. Supernatant i s  
removed and ex t rac ted  3 t imes separa te ly  from the 
alumina w i th  d ie th y l  e the r ,  The e ther  e x t r a c t  is  d r ied
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under n itrogen stream on a heating p la te  set a t 37°C 
( f ra c t io n  A ) .
Alumina is  washed three times w ith 2 ml of 
d i s t i l l e d  water and centr ifuged a t lOOOg. At the end 
200 pi o f ace tic  acid 0.2 M are added to the tube and 
mixed fo r  10 min. The sample is  f i n a l l y  cen tr ifuged  5 
min a t lOOOg and the supernatant is  separated and stored 
in  a freezer a t ~20°C ( f ra c t io n  B).
When ready fo r  the chromatographic analys is  
f ra c t io n  A is  redissolved w ith f ra c t io n  B and a l iq u o ts  
o f 5 to 20 pi are used fo r  the chromatography s tud ies . 
Recovery values are reported in Tab. 2.02, whereas in  
Tab. 2.03 the much higher recovery values fo r  20H-E1, 
comparing th is  method w ith  d ie thy l e ther, are shown.
2 .5 . High Pressure L iqu id  Chromatography
Steroids are separated in  Reverse Phase (RP) High 
Pressure L iqu id  Chromatography (HPLC), u t i l i z i n g  
111trasphere-ODS or Spherisorb II-0DS (p a r t ic le  s ize  5p - 
4.6 x 250 mm) columns a t 20±1.0°C plus an UV detecto r
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Table 2.02.
L in e a r i ty  o f recovery o f 20H-E1, El and 2MeO~El 
using aluminum oxide [Brockmann, 1936] column 
e x tra c t io n  method. Median values o f n-3 
experiments are reported (see Section 2 .4 .2 ) .  
Values are expressed as % recovered.
RECOVERY PERCENT VALUES USING 
ALUMINUM OXIDE -  ACID (BROCKMANN) 
EXTRACTION METHOD
Mg 20H-E1 Ei 2Me0-Ei
1 82 82 93
0.5 90 84 90
0,05 90 92 80
0.01 84 87 86
Table 2.03.
E f f ic ie n c y  of recovery of 20H-E1, El and 2Me0~ 
El comparing d ie thy l ether and alumina
e x tra c t io n  methods. Range represents values of 
3 series o f n ^  experiments (see Section
2 .4 .2 ) .  Results are expressed as % recovered.
RECOVERY VALUES WITH ETHER PARTITION (a) AND 
ALUMINA (b) EXTRACTION OF MORE AND LESS POLAR
OESTROHE
r .
A B
20H-EJ <50* 83-91
EX 80-85 84-87
2MeO-Ej 80-88 84-93
MATERIALS AND METHODS
and o n - l in e  rad ioac tive  detection  (RD) fo r  the 
rad io !abe lled  compounds or an electrochemical de tec to r. 
Output s igna ls  from both the UV and the RD detectors  are 
in tegra ted  by means o f a personal computer which gives 
the re ten t ion  time and the re la t iv e  re ten t ion  time (RRt) 
fo r  each separated compound. The electrochemical 
detector was connected to a paper recorder (Houston 
Instruments).
Relative re ten t ion  times of oestrogens, using 
e q u i l in  as in te rna l reference, are shown in  Tab. 2.04, 
meanwhile those of androgens, using Epi-A as in te rn a l 
reference, are reported in  Tab. 2.05.
2 .5 .1 . Oestrogens
For oestrogen analys is  an optimized mobile phase o f 
40% a c e to n i t r i le  in  c i t r i c  acid 0.1M at 1.0 ml /min 
flow rate in  is o c ra t ic  cond it ions , was used. The 
op tim iza tion  of mobile phase was performed in  our Labs 
using a computer s im u la tion  approach and 6th degree 
incomplete equations [Castagnetta e t a l . ,  1986d;
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Table 2.04.
Nomenclature and re la t iv e  re ten t ion  times (RRt) 
of oestrogens.
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Table 2.05.
Nomenclature and re la t iv e  re ten tion  times (RRt) 
o f androgens.
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D'Agostino e t a l . ,  1984; D’ Agostino et a l . ,  1985]. To 
overcome coe lu tion  o f 20H-E2 and 40H-E2 (see F ig . 2.04) 
cyc lodex tr in  was also used as suggested by Shimada 
[Shimada e t a l . ,  1988] (see Fig . 2 .05).
2 .5 .2 . Androgens
For androgen ana lys is , a c e to n i t r i le  45% in  H20 or 
a ce to n it r i le : te tra h yd ro fu ra n e :H 2 0  at 33.7:11.3:55 in 
is o c ra t ic  cond it ions at f lo w -ra te  of 1 ml/min were used.
2 .6 . Detection o f S tero ids
2 . 6.1. UV detection
UV detections were performed at 280 nm fo r  
oestrogens (see Fig. 2.06) and e ith e r  at 214 or 280 nm 
fo r  androgens.
2 .6 .2 . Electrochemical de tection
The electrochemical de tec tion  of oestrogens was 
performed w ith the same columns in is o c ra t ic  conditons
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Figure 2.04.
Coelution of 40H-E2 (1) and 20H-E2 (2) in  RP- 
HPLC at standard condit ions (see Section 
2 .5 .1 ) .
i
Figure 2.05.
Separation o f catecholoestrogens.
1 * 40H—E25 2 * 20H-E2; 3 = 40H-E1; 4 -  20H-E1. 
Mobile phases used:
a) ACN/AcONa 0.06M (1 :2 ) ,  pH 4.0;
b) ACN/AcONa 0.06M (1 :2 ) ,  pH 4.0 plus 
4.4xlO(3)M $-Cyclodextr in ; UV detection  @ 
280nm.
(From Shimada et a l . [1988])
12 (m in)
Figure 2.06.
Oestrogen p r o f i le  by RP-HPLC ( in  v i t r o  
s tu d ie s ) .
Chromatographic conditions? Ultrasphere ODS 
column (4.6 x 250 mm); mobile phase; 
a c e to n i t r i le  40% in C i t r i c  acid 0.1M, pH4.0;
flow Rate; 1 ml/min; UV detection  § 280 nm.
1 = 20H-E2; 2 = 20H-E1; 3 = 40H-E1; 4 = E2;
5 = 4MeO-E2; 6 = 2MeO-E2; 7 = Eq; 8 -  E l;
9 -  4Me0-El; 10 = 2MeO-El.
4-*
o
© 10 mlnin oo in
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(401 ACM in  C i t r i c  acid 0*01 M; f low ra te  1 ml/min) 
coupled w i th  the elec trochemica l  detect ion*,  
e lec trochemica l  de tec to rs  s e t t i n g s  were? gard c e l l  + 
0*50 V o l t ;  a n a ly t i c a l  c e l l  1° de tec to r  + 0*75 V o l t  and 
2° de tec to r  + 0,70 V o l t ,  L i n e a r i t y  of  e lec trochemica l  
de tec t ion  i s  shown in  F ig ,  2,07; a t y p i c a l  
e lec trochemica l  de tec t ion  p r o f i l e  of  a m ix ture  of  
oestrogens is  shown in  F ig ,  2,08,
2 . 6 , 3 . R a d io a c t i v e D e te c t io n
A l l  v ia l  readings were performed in  Ready-Gel(TM) 
Beckman s c i n t i l l a t i o n  c o c k ta i l  w i th  a Beckman LS1801 
s c i n t i l l a t i o n  p-coun te r .  Reading e f f i c i e n c i e s  f o r  3H 
and 14C were 55% and more than 93% re s p e c t i v e l y .  
Quenching c o r re c t io n s  were a u tom a t ic a l ly  performed,
Flo/One (Radiomat ic I n s t r . ,  USA) r a d io a c t i v e  
de tec to r  was set to  read 3H and 14C (42% and 81%
e f f i c i e n c y  s top - f low  r e s p e c t i v e ly )  f o r  the rad io labe led  
compounds. Rad io labe l led  compounds were detected w i th  
the ra d io a c t iv e  de tec to r  a t  the same s e t t i n g s  as f o r
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Figure 2.07.
L in e a r i ty  of response to  16kOH~E1 by 
electrochemical detector (ECD). A broad range 
o f s e n s i t i v i t y  fo r  several oestrogen 
metabolites was observed, S e n s i t iv i ty  l im i t s  
a tta ined : less than 1.2 pmoles (see Section
2.6.2).
itoOH-Ei (ng)
Figure 2.08.
Oestrogen p r o f i le  by electrochemical detection  
(ECD) on l in e  to RP-HPLC.
Chromatographic cond it ions : Spherisorb ODS-2
(4.6x250 mm); mobile phase: ACN 40% in c i t r i c
acid 0.01M, pH 4.0; flow ra te : 1 ml/min; ECD
s e tt in g s :  po te n tia l  +0.75V, gain 30.
1 = E3; 2 = 2MeO-E3; 3 -  16a0H-El; 4 -  16Epi-E3;
5 = 20H-E2; 6 = 40H-E2; 7 = 2QH-E1; 8 = 40H-E1;
9 = 4Me0~E2; 10 = 2MeO~E2; 11 = El; 12 = 4Me0-El; 
13 = 2MeO-El.
8U U v
1
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oestrogens. The p r o f i le  o f an androgen mixture is  shown 
in  F ig. 2.09.
The e f f ic ie n c y ,  in  continous f low , was determined 
in je c t in g  20pl o f ra d io lab e l le d  s te ro id  a t sca la r known 
rad ioac tive  concentrations in  dpm at a f lo w ra te  o f 1 
ml/min. Readings from Flo/ONE rad ioac tive  de tec to r, on 
l in e  to HPLC, were in  cpm.
The formula
OBSERVED CPM x 100 
KNOWN DPM
gives the percent o f e f f ic ie n c y .  Results are shown in  
Tab. 2.06. L in e a r i ty  can be seen in F ig . 2.10 also 
showing the s e n s i t i v i t y  l im i t s  (2-3 picog in je c te d  
equiva lent to  5 to 10 fmoles) a tta ined by th is  system.
2. 7. Oestrone 3 sulphate and Dehydroepiandrosterone
sulphate RIA methods
[6 ,7-3H (n)]-0estrone 3-sulphate-Na+ ( s .a . :  42
Ci/mmole) (New England Nuclear, USA) was used as t ra c e r .  
Bond-Elut C2 ca r tr idges  500mg (Analytichem I n t . ,  USA)
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Figure 2.09.
Androgen p r o f i le  by RP-HPLC.
Chromatografic cond it ions : Ultrasphere ODS
column (4.6x250 mm); mobile phase: ACN:THF:H20 
(33.7%:11.3%:65.0%); flow ra te : 1 ml/min; UV 
detection  @ 214 nm.
1 = 190H"A-dione; 2 -  T; 3 -  A-dione; 4 ~ Epi~A; 
5 ~ 5a—DHT; 6 ~ E; 7 ~ 5a~A~dione; 8 ~ A.
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Table 2.06.
Calculated continuous flow e f f ic ie n c y  of 
rad ioac tive  detector Tron l i n e ” to RP-HPLC at 
standard cond it ions (see Section 2 .6 ) ,
Mean values o f n=3 experiments are reported. 
S e n s i t iv i ty  l im i t s  a tta ined fo r  3H-E2: <10
fmoles fo r  rad ioac tive  de tec to r, equiva lent to 
2.1 picog, and 1.2 fmoles fo r  electrochemical 
de tec tion , equiva lent to 500 picog. The same 
chromatographic cond it ions were used.
EFFICIENCY AND SENSITIVITY OF RADIOACTIVE DETECTION IN CONTINOUS
FLOW AT STANDARD CONDITIONS
DPM CPM EFFICIENCY
(Theore t ica l)  (Observed) (% Values)
75187 13463 18
37593 6125 16
18798 3097 16
9318 1524 16
4699 987 21
2349 433 18
1174 192 16
587 81 14
294 52 18
Figure 2.10.
Response l in e a r i t y  of FL0~0NE/8eta rad ioac tive  
detector on l in e  HPLC at standard condit ions 
(see Section 2 .5 ) .
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were preactiva ted w ith 1 volume (3 ml) o f methanol (C. 
Erba, I t a ly )  and 2 volumes o f d i s t i l l e d  H20.
Standard E1S was purchased from Sigma (St. Louis, 
MO). The s p e c i f ic  E1S-6-BSA antiserum was obtained from 
G.F. B o le l l i ,  who o r ig in a l l y  set th is  in d i re c t  RIA 
method [C io t t i  e t a l . ,  19893; i t  was employed a f te r  
comparison w ith  a previous one [Wright e t a l , 19783.
The E1S antiserum showed a very high s p e c i f i c i t y ,  
n e g l ig ib ly  c ross-reac t ing  w ith  El (0.4%), E3S (0.2%), 
E2S (0.1%) and El g lucuronide (<0.001%).
B r ie f ly ,  3H-E1S (2000 dpm) is  added to  1 ml BCF 
samples as in te rna l standard; a f te r  add it ion  o f 4 ml 
0.1M NaOH, the mixture is  incubated at 65 °C fo r  15 min, 
kept at room temperature fo r  30 min and then loaded on 
Bond-Elut C2. A fte r  washing w ith 5 ml d i s t i l l e d  H20, 
the ca r tr id g e  is  e luted using 2 x 1 ml methanol. The 
l a t t e r  is  dried under n itrogen stream and the residue 
redissolved in  1 ml phosphate b u f fe r  (0.05M, pH 7 .4 ) .  
0.5 ml are used fo r  recovery estim ation and 200, 100 and 
50 pi are a liquoted fo r  RIA. A fte r  s e t t in g  up an E1S
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c a l ib ra t io n  curve, ranging from 7,8 to  1000 pg/tube, the 
antiserum is  d i lu te d  (1:300) and incubated overnight at 
4 °C in  3.75 mg te s t  tubes of ac tiva ted  charcoal fo r  
bound:free separation.
To measure in t ra c y s t ic  DHAS we used a RIA procedure 
with a rou tine  k i t  commercially ava ilab le  (Medical 
System, Los Angeles, USA), as described elsewhere 
[D o g l io t t i  et a l . ,  1986b]. This method is  characterized 
by both good s e n s i t i v i t y  (lowest detectable amount =
0.05 pmol/ml) and accetable in tra -assay (10%) and in t e r ­
assay (12%) v a r ia b i l i t y .
2 .8 . Steroid Binding Assay -  Dextran-Coated Charcoal 
Method
This methodology im plies a sa tu ra t ion  curve 
obtained incubating overnight a t 4°C f ixe d  amounts [150 
p i ]  o f t issue  homogenate against increasing m o la r i t ie s  
o f rad ioac tive  s te ro id  [oestrogens: oestrad io l a t 1, 
1 .5, 2, 4, 6, 8, 10xl0(~10)M; androgens: mibolerone at
1, 2, 3, 5, 7.5, 10, 20, 30, 50xl0(-10)M] a t
107
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phys io log ica l concentrations plus competit ion p o in t(s )  
w ith 100 fo ld  excess o f non rad ioac tive  competitor 
(oestrogens: po in t 7th ± DES; androgens: po in ts  2nd, 5th 
and 9th ± cold Mibolerone), A 9 po in ts  curve fo r  AR 
assay was employed to b e tte r  d is t in g u ish  both type I and 
I I  b ind ing, In p a r t ic u la r ,  fo r  androgen receptor 
assays, a constant concentration o f 10(-7)M of 
un labelled Triamcinolone Acetonide was used in  order to 
avoid binding to  g lu co co r t ico id  receptors.
In a separate set of experiments, cold 0RG2058 
alone (see Tab, 2 .07), a t a constant concentration o f 
10(-7)M, or in  ad d it ion  to the same concentrations of 
Triamcinolone Acetonide (see Tab. 2.08) fo r  a l l  tubes, 
was used in order to prevent the b inding o f progestin  
and g luco co rt ico id  receptors. The f ig u re s  given in 
these tab les correspond to the readings obtained from 
each s ing le  concentration used from the lowest to  the 
h ighest.
As i t  may be seen from example given in Table 2.07, 
the range o f 3H~Mibolerone uptake using cold
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/Table 2.07.
3H-Mibo1erone binding to  AR in the presence of 
excess (10(-7)M) o f e i th e r  Triamcinolone (TA) 
or 0RG2058. Two out of s ix  separate 
experiments are shown as an example to
i l l u s t r a t e  th a t  the leve l o f re la t iv e
competition by the two un labelled l igands can 
vary. In these experiments the receptor 
preparation was made from human BPH tissues . 
Each l in e  represents the reading (crude cpm) 
obtained from samples w ith rad io ligand at 
d i f fe re n t  concentrations (see te x t ) .
TA vs ORG.
TA ORG.
47.00 52.50
69.50 93.70
95.50 116.0
165.0 203.0
226.0 256.2
373.7 514.0
550.2 670.2
709.0 1061.7
1062.2 1561.0
TA ORG.
40.70 36.50
64.20 66.40
97.20 80.20
166.2 143.5
236.7 195.5
393.2 326.7
544.7 415.5
694.5 686.5
1220.5 1121.2
Table 2.08.
3H-T4ibolerone b inding to AR in the presence of 
excess (10(~7)M) of e i th e r  Triamcinolone (TA) 
or TA plus 0RG2058. Two out o f s ix  separate 
experiments are shown as an example to
i l l u s t r a t e  th a t the leve l o f re la t iv e
competit ion by the two unlabelled l igands can 
vary. In these experiments the receptor
preparation was made from human BPH tissues .
Each l in e  represents the reading (crude cpm) 
obtained from samples with rad io ligand at 
d i f fe re n t  concentrations (see te x t ) .
TA vs TA + ORG.
TA TA+ORG. TA TA+ORG
49...00 63.80 33.00 32.80
74.40 90.00 57.80 51.60
101.8 103.6 92.00 77.60
181.4 173.6 187.8 ~ 107.8
238.4 230.2 245.6 194.4
446.4 343.4 549.8 340.8
450.8 421.4 619.4 470.6
647.4 699,0 1106.0 670.8
1022.8 1378.0 1382.0 963.4
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Triamcinolone Acetonide or cold 0RG2058 excess shows 
minor sca tte r in g  in a l l  experiments (n 6) ca rr ied  out. 
S im ila r  sca tte r in g  is  observed when comparing the 
combination o f cold Triamcinolone Acetonide plus ORG2058 
w ith  cold Triamcinolone Acetonide alone (Tab. 2 .08).
2 .8 .1 .  T issue Storage and Handling
A ll t issues were processed immediately a f te r  
surgery or stored in  a buffered system (Sucrose 250 
mM/Hepes 10 mM/MgC12 1.5 mM/Glycerol 50% (v /v ) ;  pH 7.4) 
at ~20<>C in a i r - t i g h t  v ia ls .  Before the u t i l i z a t i o n  a 
small po rt ion  (200-300 mg) o f t issue  is  d issected from 
a l l  f a t  t issue  and reconditioned in sucrose b u ffe r  
(Sucrose 250 mM/Hepes 10 mM/MgC12 1.5 mM; pH 7.4) fo r  20 
min. Sections o f the reconditioned t issue  are then 
weighed (50-200 mg) and homogenised in b u ffe r  (ER: Hepes 
10 mM/EDTA 1.5 m M /D ith io th re ito ! 5 pM; pH 7.4; ARs Hepes 
10 mM/EDTA 1.5 mM/Sodium Molybdate 10 m M /D ith io th re ito l 
5.0 pM/Glycerol 30% (v /v ) ;  pH 7.4) at the t is s u e ib u f fe r  
r a t io  of 1:20 with a g lass/g lass homogenizer (Kontes— 
Dual 1).
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The homogenate is  spun in a bench-top ce n tr i fu ge  a t 
800xg fo r  5 min to  separate the supernatant from the 
p a r t ic u la te .  The f i r s t  is  intended as the so lub le 
f ra c t io n  or cy to so l,  the second as the crude nuclear 
f r a c t io n .
Further u l t ra c e n t r i fu g a t io n s  a t 100,000xg give a 
more re fined  c y to s o l ic  f ra c t io n s ,  sometimes g iv ing  
s ig n i f ic a n t  d if fe rence s , in  terms of b inding s i te  
concentrations. However, the low speed supernatant was 
used fo r  rou tine  assay procedure in our Labs.
The nuclear p e l le t  is  resuspended in  buffered 
sa line  (Hepes 10 mM/NaCl 150 mM; pH 7.4) three times to 
remove any possib le contamination by d i f fe r e n t  c e l l  
f ra c t io n s .
A ll  steps are ca rr ied  out at 4°C or otherwise 
sta ted .
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2 .8 .2 ,  Soluble  Fract ion
A f te r  incubat ion, a l l  cytosol samples are treated
with 0,9 ml HE bu f fe r  (Hepes 10 mM/EDTA 1.5 mM) to stop
the react ion by d i l u t i o n .  To each of the tubes was then 
added 0.5 ml of Dextran Coated Charcoal (DCC) suspension 
(oestrogens: N or i t  A 0.15% (w/v)/Dextran T70 0.0015%
(w/v)/Sucrose 250 mM/Hepes 10 mM/EDTA~Na2 1.5 mM; 
androgens; N or i t  A 0.5% (w/v)/Dextran T70 0.05%
(w/v)/Sucrose 250 mM/Hepes 10 mM/EDTA-Na2 1.5 mM) and 
thoroughly mixed fo r  15 min to s t r i p  a l l  the unbound 
rad ioact ive  s te ro id .  F in a l l y ,  a l l  samples were 
centr i fuged fo r  5 min at 4°C. A l iquots  of 1 ml of the 
supernatant were then set in separate s c i n t i l l a t i o n
v ia l s  to which s c i n t i l l a t i o n  cock ta i l  has been added and 
counted fo r  r a d io a c t i v i t y  in a ^-counter .
2.8.3_._ Nuclear Fract ion
100 pi from each tube of the nuclear samples were 
added to tubes with 5 ml of sa l ine  and then f i l t e r e d  on 
pre-wetted Whatman glass f i b e r  f i l t e r s  GF/C mounted on a
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M i l l i p o re  f i l t e r i n g  apparatus. The tube was washed once 
and the l i q u i d  decanted on top of f i l t e r .  The funnel of 
M i l l i p o re  was r insed with sa l ine  and removed. F i l t e r s  
were put in s c i n t i l l a t i o n  v ia l s  and l e f t  overnight at 
room temperature to dry. S c i n t i l l a t i o n  cock ta i l  was 
added and v ia l s  counted f o r  r a d io a c t i v i t y .
P lo t t in g  the values of bound s te ro id  vs the bound 
over free  r a t i o ,  we construct a curve g iv ing  the x- 
in te rcep t  or the molar concentrat ion of bound s te ro id  
receptor (BpM, fmole/ml) and the d issoc ia t ion  constant 
(Kd).
From the Scatchard p lo t  i t  is  possible to 
demonstrate a bimodal expression of the s te ro id  receptor 
binding. As prev ious ly  demonstrated by Clark et a l . 
[1978], t h i s  binding is  due to  the presence of two forms 
of s te ro id  receptor:  a) type I ,  a high a f f i n i t y  -  low 
capacity s i t e  and b) type I I ,  a low a f f i n i t y  -  high 
capacity s i t e ,
Type I receptor i s  well represented in the f i r s t  
par t  o f  the curve, namely Kd values in the range
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5 .0 x l0 ( - l l )M  ~ 6.0xl0(~10)M, whereas type I I  is
genera l ly  evidenced by s te ro id  concentrat ions equal to 
or higher than 6.0xl0(-10)M, although there is  obvious 
over!ap.
Due to these comments, in our evaluat ion of receptor 
p o s i t i v i t y  or n e g a t iv i t y  of t i ssues ,  we genera l ly  focus 
our a t te n t io n  to type I s te ro id  receptors exc lus ive ly .  
In f a c t ,  as discussed l a t e r  on, only type I receptors 
seem to co r re la te  with pat ients*  prognosis.
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3. STEROID METABOLISM IN VITRO
3.1 . In Vitro Oestrogen Metabolism
The re levant l i t e r a t u r e  on s te ro id  metabolism in 
reproduct ive t issues has been c i ted  in the In t roduc t ion .  
For example9 Lippman's group showed on long-term 
re ten t ion  of E2 by breast cancer c e l l s  [S trob l and 
Lippman, 1979], Gurpide and colleagues showed the ear ly  
formation of conjugate E2 and El by Ishikawa c e l l s  [Hata 
et a l . ,  1987], Pasqualini  showed rapid conversion from 
conjugate to free oestrogens by several ce l l  l in e s  
[Pasqualini  et a l . ,  1989] and Bradlow's group studied in 
v i t r o  metabolism and b io log ica l  e f fe c ts  of 
catecholoestrogens [Schneider et a l . ,  1984]. Some of 
our own data (s te ro id  metabolism in HEC-1A [Castagnetta 
et a l . ,  1987], in ZR75-1 [Castagnetta et a l . ,  1986a] and 
comparing HEC-1A with Ishikawa c e l l s  [Castagnetta et 
a l . ,  1986c]) is  also publ ished.
To study in v i t r o  metabol ic conversions of 
estrogens by e p i t h e l ia l  breast or endometrial c e l l s  we
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used a) the rad ioac t ive  detect ion on l in e  to HPLC a f te r  
op t im iza t ion  of mobile phase (D'Agost ino et a l . 1984;
D'Agostino et a l . 1985; Castagnetta et a l . 1986d) and b) 
a number of long term ce l l  l in e s  ( fo r  both (a) and (b) 
see Mater ia ls  and Methods Sect ion) .  The breast ce l l  
l in e s  included MCF7, ZR75-1, T47D, EVSA-T, PMC42, BT20, 
MDA-MB231. We used also some endometrial e p i t h e l ia l  ce l l  
l in e s  i . e .  HEC-1A, Ishikawa and HEC-50. A l l  data
reported throughout re fe r  to crude values, i . e .  non
corrected fo r  ca lcu la ted losses. An example in po in t  is  
given in Tab. 3.01.
3.1 .1 .  Oestrogen metabolism inendometr ia l  cancer c e l l s
Early experiments showed tha t  d i f f e r e n t  endometrial 
cancer ce l l  l in e s  in  v i t r o  have qu ite  d i f f e r e n t
a b i l i t i e s  to convert e i th e r  E2 or El. Overa l l ,  a large
conversion [Castagnetta et a l . ,  1987] w i th in  24 hr was 
observed from E2 to El in HEC-1A c e l l s  and a very 
l im i te d  formation [Castagnetta et a l . ,  unpubl ished] of 
El from E2 was seen in Ishikawa c e l l s  under ide n t ica l  
experimental condi t ions (see Fig. 3.01) .
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Table 3.01.
Uncorrected values of conversion from t r i t i a t e d  
oestradio l  by T47D ce l l  l i n e .
1.0x10(6) c e l l s  were incubated with 3H-E2 
(8.3xlO(~8)M) fo r  24 hr;  Extrac t ion E f f ic iency  
was 92%. INTEG s in tegrated area of peak; 
RET = re ten t ion  time at highest po in t  of peak; 
%RUN -  % values of conversion as calcula ted
from INTEG.
Radioact ive p r o f i l e :  (1) E3, (2) unknown, (3)
E2, (4) 2MeO~E2, (5) El.
UV p r o f i l e  § 280nm: (1) ,  (2) ,  (3) u n id e n t i f ied
compounds, poss ib ly  inc lud ing some E3 stereo­
isomers; (4) ,  (5) as from rad ioact ive  p r o f i l e ;  
(6) e q u i l i n ,  in te rna l  standard.
CHART QF FLO/ONE OUTPUT OF RADIOACTIVE AND UV PROFILES
NET CPM 
3H-E2
PEAK INTEG FROM
1 317 4 .1 0
2 381 10 .10
3 .8044 11 .40
4 440 14 .40
5 '1058 16 .90
10240 - - - - - - - -
TO RET Vm
5 .4 0  4 .2 0  3 .10
11 .30  10 .90  3 .7 2
14 .30 12 .40  78 .5 5
16 .40  15.00  4 .30
19 .80  17 .80  10 .33
- - - - - - - - - - - - - - - - - - TOTAi.
PEAK INTEG FROM
1 25318 1.70
2 21081 2 .60
3 2571 3 .3 0
4 2222 4 .5 0
5 . 550 12.20
6 1046 16.10
— 52788
TO RET V.m
,2 .50 1 .90 4 7 .9 6
3 .2 0  2 .8 0  39 .9 4
4 .0 0  3 .4 0  4 .8 7
5 .20  4 .8 0  4 .21
12 .60  12 .4 0  1 ,0 4
16 .60  1 6 .4 0 .  1 .9 8
 - - - - - - - - - - - - - - - - - TOTAL
Figure 3.01.
Metabol ic p r o f i l e s  by RP-HPLC a f te r  24 hr 
incubat ion with 3H-E2 of HEC-1A and Ishikawa 
c e l l s .  Percent conversions were?
HEC-1A: El = 55.3%;
Ishikawa; E3 -  5.3%; 20H-E1 * 0.5%; El * 4.6%. 
Unconverted 3H-E2 was 42 and 85.5% in HEC-1A 
and Ishikawa, respect ive ly .
NE
T 
CP
U 
NE
T 
C
PM
3H
-E
2 
Sc
al
e:
 
25
00
0 
3H
-E
2 
Sc
al
e:
 
12
00
8
HEC-1A
o
OIM UlMO Ul
ISHIKAWA
2'°H -EI
^  i — 1— •— r — t ■ ^ r
©
Al
Hi
gh
est
 
po
int
: 
25
04
3 
Hi
gh
est
 
po
in
t: 
10
95
IN VITRO STUDIES
The time course of conversion in Ishikawa and 
HEC-1A c e l l s  i s  shown in Fig. 3.02. Conversion to  El 
has already reached 50% by 6 hr in HEC-1A c e l l s  (Fig.
3.03) but reached only 20-25% a f te r  24 hr in Ishikawa 
c e l l s  (Fig. 3.04).  In these experiments a d i f f e r e n t  
(though n o n-s ig n i f i ca n t )  d i s t r i b u t i o n  of El and E2 
between c e l l s  and medium was observed (Tab. 3 .02) .  In 
both ce l l  l i n e s ,  conversion product at 24 hr was greater  
in the medium than in the ce l l  homogenates. The 24 hr 
data were supported by data obtained a f te r  96 hr in 
which a fu r th e r  decrease of precursor was observed (Tab.
3.03).  Conversion rates were remarkably enhanced by 
increasing ce l l  number (Tab. 3.04).  In add i t ion ,  in  
HEC-1A c e l l s ,  the increase of ce l l  number resu lted in a 
d i f f e r e n t  d i s t r i b u t i o n  of El production between c e l l s  
and medium by 24 hr (Tab. 3.04) .  In f a c t ,  El amounts 
were greater  in  c e l l s  but s l i g h t l y  lower in medium with 
respect to previous experiments (see Tab. 3 .02).
In another study [Castagnetta et a l . ,  1986c] using 
the same ce l l  l i n e s ,  HEC-1A [Kuramoto et a l . ,  1972] and
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Figure 3.02.
Time course of metabol ic conversion of E2 and 
El by HEC-1A and Ishikawa cancer c e l l s .  
Equimolar amounts of labe l led  oestrogens were 
added to the same number of plated c e l l s .  Both 
degradation of precursor and formation of the 
main product are shown.
For d e ta i l s  see te x t  and Figures 3.03 and 3.04.
100
*— HEC-1A [sH]E2 
—x— HEC-1A [*H]Ei 
- + -  ISHIKAWA [®H]E2 
ISHIKAWA [sH]Ei
. SiV
24 hr
Figures 3.03 and 3.04.
Time course of degradation of 9.8xlO(-8)M 3H-E2 
to labe l led  El in HEC-1A (3.03 -  top) and
Ishikawa (3.04 -  bottom) c e l l s .  Plated ce l l  
number was 8.5x10(5) ce l ls /m l  and 7.3x10(5). 
ce l ls /m l  fo r  HEC-1A and Ishikawa, respect ive ly .  
CR ~ conversion ra te .
0 1.5 3
□  [3H]E2 9 .8*10“8 M
180
0 1.5
M B1BMBffiHa.
3  6
Table 3.02.
Comparison of to ta l  % r a d io a c t i v i t y  detected in 
each f r a c t i o n  as El in c e l l s  (C), medium (M) or 
C+M of endometrial cancer Ishikawa and HEC-1A 
ce l l  cu l tu res .  Equimolar concentrat ion of 
precursor E2 (9.8xlO(~8)M) were given to 
s im i la r  amounts of HEC-1A (9 .0±Q.7x10(5) 
c e l l s /m l )  and Ishikawa (8 .2±0.6x10(5) ce l l s /m l )  
Mean ± SD of 2 series of n=3 experiments in 
t r i p l i c a t e .
COMPARISON OF OESTRADIOL CONUERSION TO 
OESTRONE IN HEC-1A AND ISHIKAHA CELL LINES  
AFTER 24 HOURS INCUBATION
Cells CO Mediura CM) C + M
59.Q ± 2.5 72.5 ± 4.1 65.8 ± 9.5
1.8+ 1.0 5.0 ±0.5  3.1 ± 1 .9t 1
C ell
lin es
HEC-1A
Ish ikaw a
\Table 3.03.
Range values of % conversion of 3H-E2 to El by 
Ishikawa c e l l s  at d i f f e r e n t  incubat ion times. 
Precursor mo la r i ty  was in the range of 
5.5xlO(-9)M and 9.8xlO(-8)M, the number of 
c e l l s  plated was maintained constant at 
1.0±0.1x10(6) c e l l s /m l ;  n” 3 experiments in 
t r i p l i c a t e  were car r ied  out.
EE = Ex trac t ion E f f ic ie n cy ;  CR = Conversion 
Rates; V = V i a b i l i t y .
% CR OF E2 TO El AT 24 AND 96 HR INCUBATION 
BY ISHIKAWA ENDOMETRIAL CANCER CELL LINE
Incub. %E2 remaining %CR at El %EE %V
24 hr 80.1-88.3 6.5-12.4 85-88 80-96
96 hr 72.0-81.4 15.1-22.3 86-90 55-68
i
Table 3.04.
D i f fe re n t  % of conversion of 3H-E2 to El by 
HEC-1A c e l l s  grown as reported in Section 2. 
The number o f plated c e l l s  was kept constant at 
1 .0±0.1x10(6) c e l l s /m l .  Mean ± SD of 2 ser ies 
of n=2 experiments, a l l  in t r i p l i c a t e .
METABOLIC CONVERSION RATES (CR) TO OESTRONE 
BY HEC-1A CELLS AFTER 24 HR
Total cell [3H] added El % Produced % Cell
amounts precursor cells medium viability
3.0±0.1x10(6) 9.8x10(-8)M 71.3+4.6 66.6+5.1 85.0+2.0
2.1±0.1x10(6) 5.6x10(-8)M 41.5±2.1 34.0±5.8 70.0±4.2
From: Castagnetta et al. [1987]
I
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Ishikawa, but using 3H-E1 as a precursor,  large 
d i f fe rences  in metabol ic conversion were again observed. 
As shown by Tab. 3.05 and Fig. 3.05b, the HEC-1A c e l l s  
very rap id ly  converted El to E2 w i th in  24 hr (up to 50%) 
and the Ishikawa c e l l s  had l im i te d  conversion rates, 
never higher than 10% (see Fig. 3.05a). The high percent 
of v i a b i l i t y  of c e l l s  (see Tabs. 3.03 and 3.04) ,  the 
high values of ex t rac t ion  e f f i c ie n c y  (as shown by Tabs. 
3.03 and 3.05),  the s im i la r  numbers of c e l l s  incubated 
and the iden t ica l  amount of precursor added, a l l  
ind ica te  tha t  exact ly  the same experimental condi t ions 
were used and so va l ida te  the comparative re su l t s .
In experiments carr ied  out on HEC-1A c e l l s ,  i t  was 
observed tha t  oestrogen conversions were both time and 
ce l l  number dependent (see Tab. 3.04).  Thus, i t  appears 
tha t  HEC-1A c e l l s ,  which are reported to  be receptor 
negat ive [Shapiro et a l . ,  1975; Castagnetta et a l . ,
1986c] are more able to rap id ly  in te rconver t  E2 and El,  
than are Ishikawa c e l l s .
One explanat ion of the s i g n i f i c a n t  d i f fe rences
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Table 3.05.
14C-E1 (6.0xl0(-7)M) was administered to HEC-1A 
and Ishikawa; to ta l  number of plated c e l l s  
ranged between 2.5 and 4.2x10(6). Conversion 
product were evaluated a f te r  24 hr,
Reproduced from Castagnetta et a l . [1986c].
X CONUERSION RATES <CR> OF E ±TO E 2BV HEC-1A  
AND ISHIKAWA ENDOMETRIAL CANCER CELLS
E Ca NuwJber X E x tr a c t io n  y  f r  to  
c e ll  o f  e f f ic ie n c y  ^
lin e s  e x p e riw e n ts  <ranye> 2
Is h ik a w a
HEC-1A
7
9
<80 -  87> 5 .5 ± 0 .4
<87 -  93> 4 0 .7  ±1.8
Figure 3.05.
RP-HPLC p r o f i l e  of radiometabol i tes in Ishikawa 
(a -  top) and HEC-1A (b -  bottom) c e l l s .
A l im i te d  (5.9) vs a large (40.5) % conversion 
of precursor,  despite equimolar amounts of 
14C-E1 were i n i t i a l l y  added, is  shown by 
Ishikawa and HEC-1A respect ive ly .  Eq -  e q u i l in ,  
in te rna l  standard.
Reproduced from Castagnetta et a l . [1986c].
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IN VITRO STUDIES
observed between HEC-1A and Ishikawa c e l l s  may l i e s  in 
d i f f e r e n t  i n t r a c e l l u l a r  concentrat ions of endogenous 
estrogens, To te s t  t h i s  p o s s i b i l i t y ,  dual - label 
experiments were car r ied  out,  Supraphysiological 
concentrat ions of 14C-E1 (1.76xlO(-5)M) were added to 
HEC-1A c e l l s  simultaneously to near to phys io log ica l 
amount of 3H-E2 (9,8x lO(-8)M). The resu l ts  can be seen 
on Fig. 3.06. Note tha t  conversion rates of El to E2 
and vice versa were s im i la r .  Thus the d is s im i la r  E2 
conversion rates to El by HEC-1A c e l l s  compared with 
Ishikawa c e l l s ,  is  not due to a d i f f e r e n t  endogenous 
oestrogen content.
3 . 1.2. Oestrogen metabolism in breas tca nce r  c e l l s
When examining the breast e p i t h e l ia l  cancer c e l l s ,  
hormone sens i t ive  ce l l  l in e s  l i k e  ZR75-1 and T47D (see 
Fig. 3.07 and Tabs. 3.06 and 3.07) exh ib i ted  low 
conversion rates whereas other ce l l  l i n e s ,  l i k e  PMC42, 
BT20 and MDA-MB231, exh ib i ted a very fa s t  conversion of 
E2 (see Tab. 3.08).  The observat ion of slow conversion
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Figure 3.06.
Double labe l ing  metabol ic RP-HPLC p r o f i l e  by 
HEC-1A a f te r  add i t ion  of higher amount 
(10(-7)M) of both 3H-E2 and 14C-E1 precursors. 
High metabol ic conversion rates were observed: 
37.8% to E2 and 58.2% to El by 1.1±0.5x10(6) 
c e l l s .  At the top the UV p r o f i l e  showing the 
reference standards, inc lud ing Eq =. e q u i l in ,  
in te rna l  standard.
U V 280 nm
2.8
14C-E.
CL*
3H-E
CL
w minin o  • 
•Min
Figure 3.07.
Metabol ic p r o f i l e  by RP-HPLC (bottom) a f te r  24 
hr incubat ion of 8x10(5) ce l ls /m l  T47D breast 
cancer c e l l s  with 7.2xlO(-9)M of 3H-E2.
The fo l low ing  oestrogens were detected:
E3 (3.1%), 40H-E1 (2.8%), 2MeO~E2 (3.4%);
El (8.2%); unconverted E2 was 71.2 %.
At top the UV p r o f i l e  § 280 nm.
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Tables 3.06 and 3.07.
Oestrogen conversion rates in Ishikawa, T47D 
and ZR75-1 c e l ls .
Values o f the % recovery from the i n i t i a l  
labeled E2 are reported. For these experiments 
molar concentrations o f 3H-E2 precursor ranged 
from 5.5xl0(~9) to 9 .8 x l0 (~ 8 ) ; p lated ce l l  
number ranged from 6 .6±0.5x10(5) to 
9 .3±0,7x10(5) c e l ls /m l.  Values represent mean 
± SD of a t lea s t 4 experiments a l l  in 
t r i p l i c a t e .  CCE - cathecoloestrogens.
E2 CONVERSION RATES (C R ) RT 2 4  h r  
BV RESPONSIVE HUMRN CRNCER CELL LINES
ISHIKAHA  
T 47-B  
2R 75-1
Eg
88.0 ±2.5
65.8 +0.6 
63.7 ±2.5
E i
4.8 ±0.3
7.9 ±1.6 
5.1 ±2.7
y. EE
88.2 ±4.6
91.3 ±2.1
89.4 ±4.6
E2 CONVERSION RRTES (CR) RT 2 4  h r  
BV RESPONSIVE HUMAN CRNCER CELL LINES
Ei Es CCE
ISHIKAHA 4.8 ±0.3 1.8 ±1.5 e.4 ±0.3
T 47-B  7.9 ±1.6 5.5 ±1.8 1.6 ±1.3
2R 75-1 5.1 ±2.7 5.9 ±2.1 1.6 ±1.1
Table 3.08.
Metabolic conversion o f 3 unresponsive breast 
cancer c e l l  l in e s  rece iv ing 3H-E2 in the range 
of 5 .2xl0(~8) up to 1.2xlO(~7)M. Plated c e l ls  
ranged between 0.81±0.07 and 1 .2±0,08x10(6). 
Values are ranges o f at lea s t n~3 experiments, 
a l1 in  t r i p ! i c a t e .
RANGE OF ZCR BY SEVERAL UNRESPONSIVE CELL LINES 
AFTER 24 HR INCUBATION WITH %-OESTRADIOL
C e ll lin e XE2 rem aining XCR to  Ea ZEE
PMC-42 25. 8-38. 4 50. 0-58. 4 85. i
BT-20 18. 3-32. 7 53. 8 -6 4 .6 89. 3
MDA-MB231 20. 3-36. 9 55. 8-68. 8 . 87.7
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ra te  to  El by HCF7, ranging between 5 and 151 at 24 hr, 
s im i la r  to th a t in  both ZR75-1 and T47D c e l ls  is  
supported by Strobl and Lippman's [1979] remarks th a t E2 
is  reta ined unconverted over a long time period by MCF7 
oestrogen responsive c e l l  l in e *  Thus, fo r  both breast 
and endometrial cancer c e l ls  in  c u ltu re ,  two types o f E2 
metabolism can be observed: in  some c e l l  l in e s  the
ox ida t ive  pathway o f E2 p re v a i ls .
3*1*3. Other aspects o f oestrogen metabolism i n v i t ro by 
breast and endometrial cancer c e l ls
Further stud ies of the c e l l  l in e s  which s lowly 
convert E2 to E l, l i k e  Ishikawa, T47D and ZR75-1, showed 
ea r ly  formation o f catecholoestrogens (see Fig. 3.07 and 
Tab. 3 .07). The Fig. 3.08 shows th a t  ZR75-1 c e l ls ,  when 
incubated w ith a near phys io log ica l concentration o f E2, 
produced ea r ly  formation o f both 2MeO~E2 and 2Me0~El 
a f te r  24 h r. Levels o f both catechol oestrogen 
metabolites were much higher a f te r  96 hr (Tab. 3 .09).
Tab. 3.07 shows th a t several E2-re ta in ing  c e l l  
l in e s  (namely Ishikawa, T47D, ZR75-1 ~ having high
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Figure 3.08.
Comparison o f metabolic p ro f i le s  at 24 and 96 
hr by responsive ZR75-1 breast cancer c e l ls  
using RP-HPLC.
Amounts o f ind iv idua l metabolites produced were 
resp ec t ive ly :
%C at 24 h r: E3 = 0.7; 2MeO-E2 = 1.8; El = 10.6; 
2MeO-El = 0.3.
%C at 96 h r: E3 = 6.6; 2MeO-E2 = 4 . 6 ;  El = 30.8; 
2MeO"El = 1.8.
3H-E2 was mostly unconverted (>55%) even a f te r  
96 hr by 9.0x10(5) ce lls /m l incubated with 
6xlO(~8)M of 3H-E2. %C = % conversion.
(For abbrev ia tions used see Table 2.04)
UV 280lira
Table 3.09.
24 and 96 hr conversion pa tte rn  of 3H-E2 
studied using 0.8-1.1x10(6) ±. 0.4-0.6x10(4)
plated c e l ls ,  to  which 0 .8-1.67xl0(-8)M  
precursor was . added. % median values and 
in te rq u a r t i le  ranges are reported.
Reproduced from Castagnetta et a l . [1986a].
\K CONVERSION RATES CCR> OF E£
AT 24 AND 96 HOURS INCUBATION 
By 2R 75-1 BREAST CANCER CELLS
Eg 2HeOE£ 2MeOEi E± 
24 0.75 1.84 S.26 10.55
96 hr* 6.62 4.65 1.77 30.78
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le ve ls  o f e x tra c t io n  e f f ic ie n c y  and high le ve ls  of 
v i a b i l i t y  o f c e l l s ) ,  when trea ted  w ith  near 
phys io log ica l concentration of E2, produced r e la t iv e ly  
small amount o f El a f te r  24 hr but a t the same time 
produced s ig n i f ic a n t  amounts of E3 and of 
catecholoestrogens. In almost a l l  cases the 
catecholoestrogens, as detected in c e l ls  + medium, were 
MeO d e r iva t ive s ,  mainly 2MeO-~E2 and to a lesser extent 
2MeO"El (Tab. 3 .09).
Production . rates a f te r  96 hr incubation were 
consis tent w ith those observed a f te r  24 hr (F ig . 3 .08). 
I t  is  in te re s t in g  to note th a t formation o f two 
d i f fe re n t  methoxy oestrogens (Tab. 3.09) were 
p ro p o r t io n a l ly  d is t r ib u te d  in  re la t io n  to the amount of 
respective precursor i . e .  much more 2MeO-E2 in presence 
o f the higher amount o f E2 and less 2MeO~El in  the 
presence of low leve ls  o f converted E l. S u rp r is in g ly ,  
when the 96 hr and the 24 hr le ve ls  were compared, 
2MeO-E2 was increased 2.5 times but 2MeO~El was 
increased more than 5 times. El was increased from 2 to
120
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2.5 times only.
Several d i f f e r e n t  experimental cond it ions were 
tested to  obta in the maximum possib le production rates 
fo r  catecholoestrogens. In qu ite  d i f fe re n t  experimental 
cond it ions than th a t reported in  Section 2, using also 
qu ite  d i f fe r e n t  molar concentration of precursor and 
d i f fe re n t  incubation times, we obtained s ig n i f i c a n t ly  
h igher catechol oestrogen form ation, as shown in  Tab.
3.10.
A fte r  incubation w ith 14C-E1, a l l  catechol oestrogen 
metabolites can be observed (2- and 4-hydroxy and - 
methoxy, -E2 and -E l)  w ith a to ta l  catechol oestrogen 
formation near to 20%, a t 96 hr a s t i l l  unconverted El 
percentage o f more than 65% and a l im i te d  percent 
conversion to E2 and E3 respec t ive ly  (Tab. 3 .10). 
O vera l l,  the re su lts  in  Tab. 3.10 confirm th a t El is  a 
b e tte r  substrate fo r  catechol oestrogen formation than is  
E2 [as p rev ious ly  reported by Li e t a l . ,  1985). The
tab le  also suggests slow E2 degradation and El 
fo rm ation, but fa s t  El degradation and E3 production.
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Table 3.10.
Formation of hydroxy and methoxy metabolites 
from d i f fe re n t  oestrogen precursor (3H-E2 and 
14C-E1) in  p a r t ic u la r  experimental cond it ions , 
M o la r ity  of precursors: 3H-E2: 4.8xlO(~7)M;
14C-E1: 6 .8x l0 (~ 5 ). Number o f p lated c e l ls  were 
2 ,7x l0 (6 )±  1,5X10(5) and 2 . Ix l0 (6 )± 2 .2x10(5)
re sp ec t ive ly . Cells  were incubated fo r  24 hr 
in Biggers-BJG phenol-red and serum free 
medium.
FORMATION OF OH- AND MeO-OESTROGENS 
IN RELATION TO TIME AND MOLAR CONCENTRATION 
OF PRECURSORS IN ZR 75-1 CELL LINE
Conversion frow  
products SH-E2 i4 C-Ei
Es 0.7 5.1
e 2 85.5 5.4
20HE2 — 1.1
40HE2 — 1.4
2MeOE2 1.8 2.3
4MeOE2 — 3.1
Conversion fro n  
products SH-E2 14C-Ei
Et 10.8 66.3
CCE 2.0 18.6
20HEi — 4.3
40HEi — 1.9
2MeOEt 0.3 3.4
4MeOEi — 2.1
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On the other hand, rapid formation of 20H-E2 and 20H-E1 
by the same c e l l  l in e s  has been shown, coupled w ith a 
very quick conversion to methoxy metabolites.
3.2 . Metabolic Activ ity  of Epithelia l Cells "In V itro”
These data susta in  the view th a t slow E2 degrading 
c e l l  types are not necessarily  less m etabo lica l1y ac tive  
than are fast-E2~degrading, fas t-E l-accum ula ting  c e l l  
types. Simply, some metabolic pathways o f oestrogens 
appear to  be enhanced, some others to  be repressed, in  
each c e l l  l in e .  Neither intermediate nor d i f fe r e n t  
metabolic patterns in the same c e l l  l in e  can be 
described.
Appreciable formation o f catecholoestrogens by c e l l  
l in e s  which ra p id ly  converted E2 and ra p id ly  accumulated 
El (e .g . BT20, PMC42, MDA-MB231) was never found.
The observed d if fe rences  r e f le c t  the hormone 
respons iv ity  of the c e l ls .  Slowly converting~E2 c e l ls  
belong to the oestrogen responsive, ER-containing, c e l ls  
(Ishikawa, ZR75-1, T47D, MCF7); whereas fa s t  converting
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E2 c e l ls  belong fo r  the most part to  the oestrogen 
unresponsive, receptor-vo id  c e l ls  (HEC-1A, BT20, PMC42, 
MDA-MB231). A l l  c e l l  l in e s  were tested fo r  ER content 
(see Tabs. 3.11 and 3 .12). High a f f i n i t y ,  low capacity 
s i te  I ER were detected in  both solub le and nuclear 
f ra c t io n s ,  in  a l l  c e l l  l in e s  showing slow E2 conversion 
ra tes, EVSA-T excepted [Lo Casto e t a l . ,  1983]. In most 
cases, the oestrogen unresponsive c e l l  l in e s  also showed 
high a f f i n i t y  -  low capac ity , s i te  1 nuclear ER (or some 
ER in to  the nucleus). However, the same c e l l  l in e s  
types (HEC-1A, BT20, MDA-MB231 and EVSA-T) showed some 
reduced a f f i n i t y  -  high capacity s i te  I I  ER in the 
solub le f r a c t io n .
Thus, the in  v i t r o  system appears to be very useful 
fo r  metabolic stud ies of s te ro ids .  Further, in  a l l  
c e l ls  tes ted , a common fea ture  emerged i . e .  th a t  E2 <-> 
El in te rconvers ion is  the p re v a i l in g  form of oestrogen 
metabolism, at le a s t during the f i r s t  24 hr incubation. 
F in a l ly ,  degradation and formation o f oestrogen 
metabolites appears to be time dependent, c e l l  number
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Table 3.11.
Oestrogen receptor (ER) sta tus of breast long 
term c e l l  l in e s  in  soluble (S) or nuclear (N) 
f ra c t io n  alone and in S+N f ra c t io n s .
( - )  ind ica tes  th a t ,  in  few cases, s i te  I ER 
were absent and (+) ind ica tes th a t receptor was 
occasiona lly  present.
A +/ve ER s ta tus  was stated only when Kd was 
below the threshold values adopted fo r  s i te  I 
b inding (5 .5xl0(~10)M ). The sum S+N ER is  used 
to define the in te g r i t y  of the receptor 
fu n c t io n .
OESTROGEN RECEPTOR STATUS IN BREAST CANCER CELL LINES
Soluble (S) Nuclear (N) S + N 
BT20 - - -/ve
MCF7 + + +/ve
MDA-MB231 - - (+) -/ve
PMC 4 2 - - -/ve
T47D + (-) + +/ve
ZR75-1 + + +/ve
Table 3.12.
Oestrogen receptor (ER) s ta tus o f endometrial 
long term c e l l  l in e s  in  solub le (S) or nuclear 
(N) f ra c t io n  alone and in S+N f ra c t io n s .
( - )  ind ica tes  th a t ,  in  few cases, s i te  I ER 
were absent and (+) ind ica tes th a t  receptor was 
occasiona lly  present.
A +/ve ER s ta tus  was stated only when Kd was 
below the threshold values adopted fo r  s i te  I 
b inding (5 .5xl0(~10)M ). The sum S+N ER is  used 
to define the in te g r i t y  of the receptor 
fun c t io n .
OESTROGEN RECEPTOR STATUS IN
Soluble (S) 
Ishikawa + (-)
HEC-1A
ENDOMETRIAL CANCER CELLS
Nuclear (N) S + N 
+ +/ve
- (+) -/ve
i
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dependent and concentration of precursor dependent.
V ia b i l i t y  o f c e l ls ,  ex tra c t io n  e f f ic ie n c y  and to ta l  
recovery of ra d io a c t iv i t y  added are very good a t 24 hr, 
but less good a f te r  96 h r. This po in t might suggest 
formation of conjugates. The data presented here are 
well in  agreement w ith  published data. For example, 
Abul-Hajj e t a l . [1979b] reported data on E2 176-
dehydrogenase and E2 binding in human mammary tumours 
and showed less than 10% conversion of E2 to El in  12 
out of 15 receptor r ich  tumours. A l l  16 ER-poor 
tumours transformed E2 to El w ith percent conversion 
ranging from 12 to 95%.
3.3 . In V i t ro  Androgen Metabolism 
3._3.1. Growth rates o f prosta te  c e l l  l in e s
For in  v i t r o  s tud ies on p ros ta te , fou r d i f fe r e n t  
c e l l  l in e s  were used; DU145 and PC3 human cancer c e l ls  
and two canine c e l l  l in e s ,  CAPE and CPA, respec t ive ly  
normal and neop las tic .
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F i r s t l y ,  the growth rates o f the four d i f fe re n t  
c e l l  l in e s  were c a re fu l ly  estab lished. As i t  can be 
seen from Fig. 3.09, the canine prosta te  c e l l  l in e s  grow 
in  DMEM apparently fa s te r  in  the f i r s t  24 hr than the 
human prosta te  c e l ls  do. However, both CAPE and CPA, 
a f te r  a rapid p r o l i f e r a t io n  in  the f i r s t  24 hr reduce 
growth rates in  the fo l lo w in g  24 hr to  below th a t of 
DU145 and PC3 (see F ig . 3 .10). This change was observed 
well before any e f fe c ts  of approaching confluence: thus, 
i t  may be due to non-optima! growth cond it ions fo r  
canine c e l ls  a f te r  24 h r, or i t  could be an in t r in s i c  
property o f these c e l ls .  O vera ll,  in  DMEM, CAPE grew 
more ra p id ly  than CPA and, s im i la r ly ,  PC3 grew fa s te r  
than DU145.
3 .3 .2 . V ia b i l i t y  of p ro s ta te  cel 1 1ines and E x trac tion
Eff ic ie n c y  values
In a l l  experiments ca rr ied  out on canine prosta te  
c e l l  l in e s ,  the e x tra c t io n  e f f ic ie n c y  was greater a f te r  
24 than 72 hr incubation. This d if fe re nce , though 
small, may be re la ted  to  the p a r t ic u la r  growth curves of
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Figure 3.09.
Growth curves o f canine CPA and CAPE prostate 
c e l ls  in  DMEM. Values represent mean ± SD of 6 
ser ies  of 3 experiments.
(For d e ta i ls  see te x t  and Section 2).
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these two c e l l  l in e s ,  which are qu ite  d i f fe r e n t  from 
th a t observed by human prosta te  cancer c e l l  l in e s .  
Values o f e x tra c t io n  e f f ic ie n c y  a t 72 h r ,  fo r  CAPE c e l l  
l in e s  ranged between 58% and 88%; the median value was 
80%. For CPA c e l ls  values ranged from 79% to  88%; the 
median value was 84%. V ia b i l i t y  o f canine prosta te  
c e l ls ,  ca lcu la ted  as from F ig . 2.01 (see Section 2 ), was 
qu ite  d i f fe re n t  a f te r  24 and 72 hr experiments. For CPA 
c e l ls ,  v i a b i l i t y  values were between 52% and 94%, a t 72 
hr; fo r  CAPE c e l ls ,  v i a b i l i t y  ranged from 53% to  84% (72 
hr va lues). I t  must be noted th a t ,  fo r  these c e l ls ,  the 
v i a b i l i t y  at 72 hr spans a wide range; on the other 
hand, c e l l  balance, i . e .  p r o l i f e r a t i v e  vs death ra tes , 
is  much more d i f f i c u l t  to quan t ify  than simple 
v i a b i l i t y .  The to ta l  c e l l  number appears to be only 
s l ig h t l y  increased between 24 and 48 and again between 
48 and 72 h r, despite continu ing c e l l  d iv is io n ,  Hence 
canine prostate c e l ls  appear to  be most useful fo r  24 hr 
experiments, during which they grow w ith  a loga r i thm ic  
or exponential growth ra te .
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3.4 . Testosterone Conversion Rates by Canine Cell Lines 
3 .4.1. The prosta te  cancer CPA c e l l  l i n e
A de ta iled  analys is o f androgen metabolism 
experiments in  prosta te  c e l ls  showed th a t the canine 
cancer CPA, qu ite  d i f f e r e n t ly  from CAPE c e l ls ,  produce 
DHT and, concomitantly, re ta in  high le ve ls  of 
unconverted 3H-T, (see Fig, 3.11, where typ ica l 
metabolic conversion p ro f i le s  are shown). In CPA the 
amounts o f de1ta4-A produced were low, as mean less than
10% at 24 hr and ranging from 20.5 to  23.3%, a t 72 hr
(F ig . 3 .12). Looking at formation o f Sa-Adione th is  was 
less than 1% at 24 h r, and 3.5% (ranging from 2.9 to
3.8%), a t 72 hr (F ig . 3 .12). Thus, the mean value of
delta4-A plus 5a~Adione production was about
10% at 24 hr (ranging from 9.5 to 10,9) and 25.6% 
at 72 h r. T was mostly unconverted also a f te r  72 hr 
(F ig . 3.12) in  a l l  experimental cond it ions used, When 
using a reduced c e l l  number (data not shown), in  the 
presence of an excess o f 3H-T, the amount of DHT 
produced was reduced a t 24 h r, but the amounts o f Adione
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Figure 3,11.
Typical RP-HPLC p r o f i le  of androgen 
metabolites measured w ith rad ioactive  
de tec tion , 24 hr a f te r  3H~T adm in is tra t ion  to 
canine CPA and CAPE prostate c e l ls .
1 ==' 3H-T; 2 = Del ta4-A; 3 = Epi~A; 4 = DHT;
5 * 5«” A.
For explanations see te x t  and Section 2.
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Figure 3.12.
HPLC rad ioact ive  p r o f i l e  of metabol ic 
conversion of 3H-T in canine CPA c e l l s ,  
comparing 24 to 72 hr products formation. 
I d e n t i f i c a t i o n  numbers as in legend of Figure
3.11. For explanat ion see te x t .
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and of delta4-A plus 5a~Adione increased to about the 
leve ls  prev ious ly  observed a f te r  72 hr* The incubat ion 
of a reduced ce l l  number («3x l0 (6 ) ) ,  in the presence of 
lower concentrat ions of 3H-T, resulted in a reduced 
formation of DHT, but also in  a reduced conversion of 
the precursor;  72 hr production of e i th e r  delta4~A or 
delta4-A plus Ba-Adione showed values very close to 
those i n i t i a l l y  observed at 24 hr ,  with higher i n i t i a l  
concentrat ion of T. S im i la r ly ,  the percent of T 
conversion was s t rong ly  reduced at 72 hr,  resembling 
values obtained at 24 hr a f t e r  higher T adm in is t ra t ion .  
In a l l  experiments DHT formation was observed; the to ta l  
amount represented about 2%, at 24 hr,  and between 3 and 
4%, at 72 hr.  A p o s i t i ve  c o r re la t io n  between ce l l  number 
and DHT production was found, when the proport ion of 
ce l l  number and molar concentrat ion of added precursor 
was maintained. For these experiments between 4 and 5.2 
m i l l i o n  c e l l s  were used, with 4-6xlO(-9)M 3H-T.
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3.4 .2 ,  Cell number and mo la r i ty  of precursor in canine
prostate c e l l s
In the presence of a reduced number of c e l l s  
(3x10(6)) values of DHT produced at 24 hr were lower 
than tha t  observed in  standard condit ions (about 1,2%), 
although overal l  T degradation was s l i g h t l y  increased. 
In the same experiments, de1ta4-A formation was close to 
mean values observed at 72 hr,  but a l l  values observed 
at 72 hr ( i . e .  T degradat ion, de1ta4-A plus 5K-Adione 
formation,  DHT product ion) were unchanged. In these 
c e l l s ,  in normal cond i t ions,  formation of 5«~reduced 
metabol i tes was two-three times more fo r  DHT than fo r  
5a-Adione, at 24 hr;  but equimolar concentrat ions at 72 
hr,  f o r  the two d i f f e r e n t  products of Sa-reductase 
enzymes, were observed (Fig. 3.12).
3 .4 .3 ,  The normal p ro s ta te CAPE cel 1 1i n e
For experiments on CAPE ce l l  l i n e ,  the ce l l  number 
ranged from 3,6 to 5.8 m i l l i o n s / f l a s k .  The median 
values were 8.0x10(5) ce l ls /m l  ( in  a l l  4 m i l l i o n  c e l l s  
per f la sk )  vs 9.1x10(5) ce l ls /m l  used fo r  CPA ( in  a l l
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4.5 m i l l i o n  c e l l s  per f l a s k ) .  The mo la r i ty  of added 3H- 
s te ro id  ranged from 3.4 to 6 .7x l0(~9) .  When excess of 
precursor was required, 6.7xlO(~9)M s te ro id  was added to 
3.1 m i l l i o n  c e l l s  (3.0 m i l l i o n  c e l l s  in the case of 
CPA). Experiments were there fo re  car r ied  out almost 
exact ly  in the same experimental condi t ions, in terms of 
ce l l  number and s te ro id  m o la r i ty .  In a l l  experiments, 
on CAPE c e l l s ,  the f i n a l  concentrat ion of labeled T was 
less than 6% of the to ta l  label (Tab. 3.13).  At 24 hr T 
was mainly converted to delta4~A (Fig. 3.13) .  The 
concentrat ion of 5«-Adione, much increased with respect 
to CPA, ranged, in d i f f e r e n t  experimental cond i t ions,  
from 4.7 up to 10.9% (Tab. 3.13),  of  the added 
precursor;  t h i s  rose to 14.2 up to 37.8% by 72 hr.  
Corresponding!y, the delta4-A leve ls  were s t rong ly  
decreased at 72 hr with respect to 24 hr.  In most 
experiments, some formation of epiandrosterone (EpiA) 
was observed by 24 hr and s t rong ly  increased at 72 hr 
(Fig. 3.13).  T degradation appears to be a func t ion  of 
the molar concentrat ion of precursor ra ther  than of ce l l  
number; however, 5a-Adione formation corre la ted with
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Table 3.13.
Comparison of labeled Testosterone (3H-T) 
conversion by canine CPA and CAPE prostate 
c e l l s .  Data represent range of percent of 3H 
precursor and products detected a f te r  24 hr of 
n~6 experiments i n t r i p l i c a t e .  For molar 
concentrat ions of 3H-T and ce l l  number see 
t e x t .
RANGES OF 3H-T V. CONUERSION RATES IN  
CPA AND CAPE PROSTATE CANCER CELLS 
AFTER 24 h r  INCUBATION
3H-T Adione 5a Adione 
CPA 75.3-80.1 8 .0 -11 .0  0 .6 -1 .0
CAPE 2.7—5.8 72.0-77.5 4 .7 -1 0 .0
DHT
1.8-2.2
Figure 3.13.
HPLC rad ioac t ive  p r o f i l e  of metabol ic 
conversion of 3H-T in canine CAPE c e l l s  
comparing 24 to 72 hr products formation. 
I d e n t i f i c a t i o n  numbers as in legend of Figure
3.11. For explanat ion see te x t .
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both these l a t t e r .  In f a c t ,  in experiments with reduced 
ce l l  number (3.1 m i l l i o n  c e l l s )  and lower precursor 
m o la r i ty ,  the 5a-Adione product ion was decreased. When 
using an higher ce l l  number, together with an increased 
precursor m o la r i ty ,  5«~Adione formation was 
s i g n i f i c a n t l y  higher.
As evidenced from these experiments, the 5a- 
-reductase a c t i v i t y  was f i v e  times higher in  CAPE than 
in CPA c e l l s .  Even so, no formation of DHT was observed 
in any case, ne i ther  at 24 nor at 72 hr (Fig. 3.13).  
P a r t i c u la r l y  of i n te re s t  i s  tha t  to ta l  amount of 
detected delta4-A plus 5a~Adione remained f a i r l y  
constant (the sum of both of these compounds ranged from
77.5 to 85%, at 24 hr,  and from 74.5 u n t i l  85.3%, at 72 
h r ) .  Median values were 82.0% and 77.4% at 24 and 72 
hr,  respect ive ly .
3 .4 .4 . Cell and medium concentrat ions
Before de ta i led  discussion on the human prostate  
cancer ce l l  l i n e s ,  namely DU145 and PC3, some general
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points should be stressed. F i r s t  of  a l l ,  a f t e r  separate 
analyses of c e l l s  and medium, the experimental evidences 
ind icated th a t ,  at  24 hr,  the most par t  of  r a d io a c t i v i t y  
was in the medium, but androgen metabol i tes were not 
equal ly d is t r ib u te d  between c e l l s  and medium ( fo r  
example DHT is  mainly retained by c e l l s  and the ma jo r i ty  
of 5a~Adione is  released in the medium a f te r  24 h r ) .  T 
i s  p a r t l y  located in the medium, p a r t l y  retained by the 
c e l l s  (data not shown).
In general terms, s te ro id  metabolism, in a l l  four  
d i f f e r e n t  prostate ce l l  l in e s  tested, was very 
reproducib le. Product ion rates of s ing le  metabol i tes,  
however, may be s i g n i f i c a n t l y  inf luenced by large 
v a r ia t ions  in ce l l  number or precursor m o la r i ty .  From 
th i s  po in t of view, CAPE c e l l s  appear to be very 
sens i t ive  to s i g n i f i c a n t  reduct ions in the number of 
incubated c e l l s  or in the f i n a l  molar concentrat ion of 
precursor used; PC3, on the contrary , appears more 
s tab le .
In 24 hr experiments, ce l l  v i a b i l i t y  and e x t rac t ion
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e f f i c ie n c y  percent values respect ive ly  ranged from 73 to 
98 and from 77 to 90 fo r  both CAPE and CPA c e l l s .  
Undetected r a d io a c t i v i t y  was also ca lcu la ted ;  when 
losses over 5% were observed, percent values have been 
p ropo r t iona l !y  corrected fo r .
3.5. Testosterone Metabolism in  Human Cancer Prostate
Cel ls
Experiments car r ied  out on PC3 and DU145 (human 
cancer ce l l  l in e s  o r ig in a t in g  from metasta t ic t issue of 
prostate cancer) show tha t  these c e l l s  metabol ize T 
qu ite  d i f f e r e n t l y .
As shown in Fig. 3.14, PC3 show a very rapid 
conversion of t h i s  hormone to de1ta4-A, Scc-Adione and 
EpiA, and, in some cases, to A; in one occasion only 
traces of DHT were observed. At 24 hr,  the mean percent 
value of unmetabolised 3H-T was 12.6%. Also a f te r  
increasing ce l l  number or precursor m o la r i ty ,  the main 
products of T metabolism, by PC3 at 24 hr,  were delta4-A 
(range 54.7-68.0%) and 5a~Adione (range 5.29-29.9%) (see
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Figure 3.14.
Comparison of androgen radiometabol i te s  
produced 24 hr a f te r  addi t ion  of 3H~T to human 
prostate cancer PC3 and DU145 c e l l s .
Equimolar precursor concentrat ions to an 
approximately equal ce l l  number, in t h i s  case 
lower than fo r  standard condi t ions (see Section 
2),  were given. For explanat ion see te x t .
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Fig. 3.15).  In t h i s  case T was fu r th e r  degraded, as i t  
was at 72 hr (Fig. 3.15) j o i n t l y  with delta4~A, whereas 
5ce~Adione, EpiA and A were increased.
In PC3 c e l l s ,  production of EpiA at 24 hr was also 
detected. T was mostly but not e n t i r e l y  converted by 72 
hr:  only 149 pg/ml (median value, range 102-272 pg/ml)
of to ta l  s te ro id  precursor were retained by the system. 
The delta4~A was the most important product of t h i s  
conversion, fol lowed by 5a-Adione (range 73-128 pg/ml) 
and EpiA (range 27-50 pg/ml).
Comparing 5a-Adione product ion rates by FC3 to 
those prev ious ly  observed in CAPE and CPA c e l l s ,  
a c t i v i t y  of 5a-reductase appears to be the same as tha t  
in CAPE, but much higher than in CPA c e l l s .  Very small 
amounts, i f  any, of Sa-DHT were observed at e i t h e r  24 
(Fig. 3.14 and,Tab. 3.14) or 72 hr (Fig. 3.15 and Tab.
3.15).  In the most par t  of  cases, as in the CAPE ce l l  
l i n e ,  there was no detectable DHT formation;  leve ls  of 
EpiA appear higher with respect to CAPE c e l l s  (Fig. 
3.13) .
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Figure 3.15.
Comparison of HPLC rad ioact ive  p ro f i l e s  
obtained in PC3 human prostate cancer c e l l s  
a f te r  24 and 72 hr from admin is t ra t ion  of 3H-T. 
(see legend of Figure 3.11 fo r  i d e n t i f i c a t i o n  
numbers; 6 ~ Androsterone).
24 hr
Table 3.14.
Comparison of labeled Testosterone (3H-T) 
conversion by human cancer PC3 and DU-145 
prostate c e l l s .  Data represent range of 
percent of 3H precursor and products detected 
a f te r  24 hr of n-5 experiments in  t r i p l i c a t e .  
For molar concentrat ions of 3H-T and ce l l  
number see te x t .
RANGES OF 3H-T X CONVERSION RATES IN  
PC3 AND DU-145 PROSTATE CANCER CELLS 
AFTER 24 h *  INCUBATION
3H-T Adione SaAdiane DHT 
PC3 8.3-21.6 44 .3 -64 .2  5.9-9.V, -----
DU-145 75.6-84.9 0.6-3.S 0 .2 -1 .2  2.3-S .0
Table 3.15.
Comparison of 3H-Testosterone conversion in 
human prostate  cancer PC3 and DU145 c e l l s .  For 
these experiments increased ce l l  numbers and 
increased molar concentrat ions of precursor,  
with respect to standard condi t ions (see t e x t ) ,  
were used. Mean ± SD ce l l  number was 
1.5+0.1x10(6) f o r  PC3 and 1.8+0.3x10(6) fo r  
DU-145; administered 3H-T was 5.2xlO(-9)M fo r  
PC3 and 7.4xlO(-9)M fo r  DU-145.
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IN VITRO STUDIES
T conversion was also very rapid, but we can see 
th a t ,  at  72 hr,  T was not as completely degraded as i t  
was in CAPE c e l l s  (Fig, 3.13) .
For these experiments on PC3, i n i t i a l  ce l l  number 
ranged from 5x10(5) to 1 .7x l0(6) /m l  (mean 8.5x10(5)) .  
The molar concentrat ion of precursor ranged from 1.2 to 
6.4xl0(~9) (mean value 4 .3x l0 (~9 ) ) ,
For experiments with DU145, the number of incubated 
c e l l s  ranged from 9 x l 0 ( 5 ) - l . 3x10(6) (mean value 
1.15x10(6)).  In separate experiments, ca r r ied  out in 
t r i p l i c a t e ,  we used 2.5x10(6) c e l l s .  The m o la r i ty  of 
precursor ranged from 4.9 to 7.4xl0(~9) (mean value 
5 .8x l0 (~9 ) ) ,  The metabol ic conversion pattern  in  DU145 
was completely d i f f e r e n t  from tha t  seen in PC3a c e l l s  at 
24 hr (see Fig. 3.14).  These f i r s t  experiments, reported 
in Tab. 3,14, were ca r r ied  out with a lower number of 
incubated c e l l s  than the remainder.
Despite the increased m o la r i ty  of precursor (T 
i n i t i a l  concentrat ions had been respect ive ly  4.3 f o r
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PC3, 5.2 fo r  CAPE* 5,5 fo r  CPA and 5.8xlO(~9)M here) and 
despite the higher ce l l  number (doubled to 2.5x10(6),
i . e .  much more than any other ce l l  l i n e ) ,  T remained
mainly unmetabolised by DU145 c e l l s .  Total conversion
to de lta4” A, 5a-Adione and DHT never exceeded 10% of the 
a l l  r a d io a c t i v i t y  detected (see Tab. 3.14 and Fig.
3.16).  Unconverted 3H-T was recovered in the range 65%- 
85% in a l l  cases. Using the maximum ce l l  number, T
s t i l l  represented more than 50% of a l l  rad ioact ive  
metabol i tes, even by 72 hr (see Tab. 3.15).  Thus, in
these c e l l s ,  conversion to delta4-A is  very low and is
less than DHT formation,  at 24 hr.  Delta4-A and 5a~
-Adione production are s i g n i f i c a n t l y  lower than tha t
observed in hormone responsive CPA c e l l s  (F ig . 3 .12) .  
DHT leve ls  appear p a r t i c u la r l y  high in these c e l l s  by 24 
hr and they double again by 72 hr (see Fig. 3 .16) .  DHT
product ion is  higher than the sum of delta4-A and 5a-
Adione products and i t  appears s i g n i f i c a n t l y  greater  
than tha t  previously observed in hormone responsive CPA 
c e l l s .  Thus, a close s i m i l a r i t y  ex is ts  between metabol ic 
conversion patterns of T observed in canine CPA
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Figure 3.16.
Comparison of HPLC rad ioact ive  p r o f i l e s  
obtained in DU-145 human prostate cancer c e l l s  
a f te r  24 and 72 hr from admin is t ra t ion  of 3H-T. 
(see legend of Figure 3.11 fo r  i d e n t i f i c a t i o n  
numbers).
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IN VITRO STUDIES
(compared with CAPE) and in human DU145 (compared with 
PC3) prostate ce l l  l i n e s .
The d i f fe rences between canine c e l l s  (see Fig. 
3.11) may be explained on the basis of comparing normal 
with prostate cancer c e l l s .  However, f o r  human DU145 
and PC3 prostate cancer c e l l s ,  the explanat ion of 
d i f f e r e n t  behaviour (see Fig. 3.14) is  more d i f f i c u l t .  
The r e p r o d u c ib i l i t y , the very stab le  values and small 
standard devia t ions a l l  suggested tha t  these d i f fe rences 
were r e a l .
3 .6 . Influence of Changes in In i t ia l  Cell Number and
Molar Concentration of Precursor
Separate experiments were car r ied  out to te s t  the 
v a r i a b i l i t y  of metabol ic conversion and production rates 
of ind iv idua l  androgen metabol i tes fo l low ing  
mod if ica t ion  of ce l l  number or molar concentrat ion of 
precursor.
These experiments car r ied  out in human prosta te  
cancer ce l l  l i n e s ,  showed the same trends observed fo r
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canine prostate c e l l s  (data not shown). For example, in 
DU145, when ce l l  number was doubled and molar 
concentrat ion of labeled T held constant,  the 24 hr 
formation of the DHT was three times more than mean 
values observed in a l l  other experiments. In t h i s  case, 
delta4-A production was in h ib i t e d ,  w h i l s t  formation of 
5a-Adione was not enhanced (Fig. 3.16).  However, a t 72 
hr (see Tab, 3.15) ,  DHT was p ro po r t io n a l l y  less 
increased; 5a-Adione was also increased with respect to 
the range in the other experiments. A f te r  72 hr ,  much 
more degradation of T was observed, with corresponding 
delta4~A degradation, and increased formation of 5a- 
Adione and EpiA (see Tab. 3.15),  The metabol ic 
conversion of T appears to be proport ional  to ce l l  
number, Such experiments were not extens ive ly  ca r r ied  
out fo r  PC3 c e l l s ,  but,  using fewer c e l l s  ( less than 50% 
of standard),  a lower T conversion, together with less 
delta4-A and 5a~Adione fo rmation, was observed by 24 hr.  
PC3 is  an unusual ce l l  l i n e  because of i t s  clonogenic 
and morphological polymorphism. The s t a b i l i t y  of t h i s  
c e l l  l i n e  has s t i l l  to be determined.
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3.7 , 5a-Reduction A c t i v i t y
General ly,  5a-reduced metabol i te production 
appeared to be higher in CAPE with respect to CPA and in 
PC3 with respect to DU145 c e l l s  (see Tab. 3.16a and b).  
However, 5a-reduct ion in CAPE normal canine and PC3 
human cancer c e l l s  was exc lus ive ly  l im i te d  to 5a-Adione 
production (see Tab. 3.16a and b).  I t  i s  of in te re s t  to 
note tha t  DHT formation was re la ted to  increased 5a- 
Adione leve ls  in only one experiment on PC3 c e l l s .  As 
with DHT, 5a~Adione appears p o s i t i v e ly  co rre la ted  with 
both ce l l  number and delta4-A (the subst rate)  
concentra t ion. In the CAPE ce l l  l i n e ,  exponential  
formation rates of 5a-Adione were observed in  d i f f e r e n t  
experiments. Reconversion of de!ta4-A to T by c e l l s  
rap id ly  metabol ising T was u n l i k e ly ,  since very low 
leve ls  of t h i s  hormone were seen at 72 hr in both CAPE 
and PC3 c e l l s .  As in CAPE, the sum of delta4-A + 5a~
Adione + A respresents the ma jo r i ty  of labe l led  s te ro ids  
in PC3, ranging between 63%-78% at 24 hr ,  and from 59% 
to 74% at 72 hr (Tab. 3,15) .  In con tras t ,  in DU145 t h i s
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Table 3.16 (a and b ) .
Table summarizes the d i f fe re n t  a b i l i t y  of 
(a -  top) two canine and (b -  bottom) two human 
prostate c e l ls  in  converting precursor (3H-T) 
and producing d i f fe re n t  amount o f DHT or, 
a l te rn a t iv e ly ,  other androgen metabolites.
(a) mean % values of lab e l le d  androgens 
detected in 24 hr experiments were 
resp ec t ive ly : T ~ 4.2%, A+5aAdione - 82.1%, DHT 
<0.2%, fo r  CAPE c e l ls ;  T = 77.7%, A+5aAdione -  
10.3%, DHT = 2.1%, fo r  CPA c e l ls ,
(b) mean % values of lab e l le d  androgens were 
resp ec t ive ly : T ~ 14.9%, A+5aAdione = 62.1%,
DHT <0.2%, fo r  PC3 c e l ls ;  T ~ 80,3%, A+BaAdione 
= 2.9%, DHT -  3.7%, fo r  DU-145 c e l ls .
ANDROGEN METABOLIC PATTERNS IN  
CAPE AND CPA CANINE PROSTATE CELLS 
AFTER 24 hr* INCUBATION
3H-T A+5<x-Adione DHT
COPE Low HisJ, « •" «
CPA High Low High
ANDROGEN METABOLIC PATTERNS IN  
PC3 AND DU-145 HUMAN PROSTATE CANCER CELLS 
AFTER 24 hr* INCUBATION
3H-T A+5«-Adione DHT
PC3 Low High
DU-145 High Low High
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sum accounted fo r  only 5% at 24 hr (8% at 72 h r ) ,  i . e .  
10 times less .
S u rp r is in g ly ,  EpiA production was very uncommon in 
DU145; i t  was observed only w ith higher c e l l  number. In 
CPA c e l ls ,  th is  metabolite  was seen only a t 72 h r, 
a f te r  i n i t i a l l y  increased molar concentrations of 
precursor. I t  was very usua lly  detected in  CAPE and PC3 
c e l l  l in e s  and p ro p o r t io n a l ly  increased w ith  greater 
concentrations o f precursor. 5a--reduction was h igher in  
CAPE than in CPA (three times more) and in  PC3 than in 
DU145 c e l ls  (two times more). Comparison of th is  enzyme 
a c t i v i t y  in  the four prosta te  c e l l  l in e s  are given in 
Tab. 3.17. I t  is  very su rp r is in g  th a t the hormone- 
responsive c e l ls  e x h ib i t  less to ta l  5<x-reductase 
a c t i v i t y .
3.8 . Oestrogen Metabolism in Prostate Cell Lines
To te s t  whether the d ire c t io n  o f metabolism, i . e .  
more ox ida tive  in  CAPE and in  PC3 and more reductive  in 
CPA and DU145 c e l l  l in e s ,  was l im i te d  only to  androgens,
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Table 3.17.
D if fe re n t  Ba-reductase a c t i v i t ie s  observed in 4 
d i f fe re n t  prosta te  c e l l  l in e s  are schematically 
representend. + f ig u re  is  a q u a l i ta t iv e  more 
than a q u a n t i ta t iv e  in d ic a t io n .  Pmoles/ml 
amounts are ca lcu la ted  as the sum of both DHT 
and 5cf~A 24 hr fo rm ation ,, a f te r  co rrec t ion  fo r  
procedural losses.
5k  re d u c ta s e  enzvm e h c t iu itv  in
PROSTATE CELL LINES
Main products V. 
pmoles/ml 5oc Adione DHT
PC3 >100 + + + +
DU145 >50 + + + +
CPA <30 +  + +
CRPE 175 + + +
Table 3.18.
Oestradiol conversion by PC3 and DU-145 human 
prosta te  cancer c e l ls ,  compared also with the 
non responsive endometrial cancer c e l l  l in e  
HEC-1A (see Section 3 .1 .1 ) .  Equimolar 3H-E2 
was administered to the same number o f PC3 and 
DU-145 ( * 1 .0x10(6)) (see te x t ) .  Values reported 
are mean ± SD of n=4 experiments in  t r i p l i c a t e .
2 4  h r V. CONUERSION RRTES (C R ) OF E2 
BV HUMRN CRNCER CELL LINES
HEC-1A
PC-3
DU-145
TP _ TT*Jlig l i l
27.8 ±5.5 60.2 ±7.5
29.2 ±12.5 56.0 ±6.2
72.1 ±10.3 3.0 ±1.2
V. EE
89.2 ±1.9
83.3 ±10.4
90.1 ±1.5
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stud ies were ca rr ied  out using E2 as precursor. 
Incubation w ith almost phys io log ica l concentrations ( in  
the range of 10(-8) -  10(-7)M: see chapter on Materia l
and Methods) o f 3H-E2 was performed w ith  d i f fe re n t  
prosta te  human and canine c e l l  l in e s .  From these 
experiments ' there is  c lea r evidence th a t E2 is  qu ick ly  
metabolized by PC3 c e l ls  to  the same extent th a t the 
unresponsive, ER negative, HEC-1A endometrial cancer 
c e l ls  do, as predicted from the androgen metabolism. On 
the con tra ry , i t  was only s low ly metabolized by DU145 
c e l l  l in e s  (see Tab. 3 .18).
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4. STEROID RECEPTORS
4.1. Androgen Receptor Status o f Human Prostate Tissues
As ex tens ive ly  reported and discussed by other 
authors s te ro id  receptors may e x h ib i t  two b inding s i te s  
[see fo r  example Clark and Peck, 1979] one o f high 
a f f i n i t y  and l im i te d  capac ity , the other o f lower 
a f f i n i t y  and less re a d i ly  saturated.
This chapter concerns stud ies on AR and ER s ta tus 
in prostate cancer tissues and in benign prosta te  
hypertrophy, as well as in  prostate  c e l l  l in e s .  In 
these systems the presence o f both type I or type I I  
binding pro te ins  fo r  both AR and ER is  described. Type 
I I  oestrogen binding s i te s  (the low a f f i n i t y  s i te s )  are 
much more common than type I .  Moreover, only type I 
b inding s i te s  are c lose ly  re la ted  to the prognosis o f 
breast cancer pa t ien ts  [Castagnetta e t a l . ,  1989; Lopes 
et a l . ,1 9 8 7 ] .  S ite  I is  c le a r ly  defined by a measurable 
Kd value ranging between 1 and 5.5xl0(~10)M, i . e .  by the 
maximum value of 0.55 nM used as a c u t - o f f .  This c u t-
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o f f  value was d e f in i t i v e ly  adopted a f te r  i t  had 
demonstrated to have a good c o r re la t io n  w ith  prognosis 
of breast cancer pa t ien ts  [Castagnetta e t a l . ,  19893.
This was not possib le fo r  prosta te  cancer pa tien ts  
because AR does not have the same prognostic 
s ign if ica nce  [Kyprianou e t a l . ,  1986; Mainwaring and 
Randall, 19843. A rb i t ra ry  c u t - o f f  values were adopted 
as <1 nM fo r  type I [Brinkmann e t a l . ,  1987] and a range 
between 1 nM and 0,9xl0(-8)M fo r  type I I  f o r  Mibolerone 
b ind ing, the pre fe rred  l igand fo r  AR assay.
On the basis o f these a rb i t ra ry  c u t - o f f  values, we 
found th a t  in  most prosta te  cancer tissues S ite  I or 
S ite  I I  or both androgen binding s i te s  are present (Tab. 
4 .01). Moreover, the pa ra l le l ism  was maintained w ith 
breast cancer, in  which both the soluble and the nuclear 
ER must be present to  define a f u l l y  working receptor 
mechanism [Leake e t a l . ,  1979; Leake e t a l . ,  1981; Leake 
and Habib, 1987]. U n t i l  fo l low -up  and c l in ic a l  h is to ry  
of prosta te  cancer pa t ien ts  ind ica te  otherwise, high 
a f f i n i t y  s i te s  plus presence o f both so lub le and nuclear 
AR w i l l  be taken as necessary fo r  a p o s it iv e  eva luation
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of hormone s e n s i t iv i t y  s ta tus o f prosta te  cancer 
t issue s .
Using th is  d e f in i t io n  only about 45% (Tab. 4.01) of 
prosta te  cancer p a t ie n ts ,  and 61% fo r  benign p rosta te  
hypertrophy, showed type I AR in both so lub le  and 
nuclear f ra c t io n s  (see Figs. 4.01 and 4 .02), i . e .  a 
func tiona l receptor s ta tu s . By con tras t,  as i t  can be 
seen from same Table 4.01, nuclear receptors alone were 
present in  the m a jo r i tyo f e i th e r  prostate cancer (83%) 
or benign prosta te  hypertrophy (over 90%) t issues 
s tud ied. Type I I  androgen binding s i te s  are also 
present in  most specimens from prosta te  cancer and 
benign prosta te  hypertrophy t issues , in  both so lub le  and 
nuclear f ra c t io n s  (see Tab. 4 .01).
As f ig u res  4.01 and 4.02 i l l u s t r a t e ,  po in ts  to  
determine type I AR in  both soluble and nuclear 
f ra c t io n s  were selected on the basis of the experimental 
window set and of Kd c u t - o f f  values prev ious ly  (see pag. 
143) adopted.
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Table 4.01.
Androgen receptor sta tus was assessed in n=18 
human Prostate Cancer (PCa) and n~66 Benign 
P ro s ta t ic  Hyperplasia (BPH) cases. S ite  I 
ind ica tes high a f f i n i t y  -  low capacity , S ite  I I  
reduced a f f i n i t y  -  high capacity b indings. 
+/ve ind ica tes  the presence of both S and N 
s i te  I AR, while ~/ve ind ica tes  cases in which 
s i te  I AR were absent in  one or both f ra c t io n s ,  
cyt -  cy toso l,  nuc ~ nuclear.
( fo r  d e ta i ls  see te x t ) .
PRESENCE OF S IT E  1 AND 2 ANDROGEN RECEPTORS 
IN  PROSTATE CANCER <PCa> AND BENIGN  
PROSTATE HVPERPLASIA  CBPH) T IS S U E S
n
+ / v e
- / v e
S i t e
S i t e
PCa BPH
± 8  6 6
8 4 0
± 0  2 6
c y t  ± 0  4 0
n u c  1 5  6 1
c y t  1 5  4 4
n u c  1 7  5 9
Figure 4.01.
Scatchard p lo t  o f s i te  I AR in so lub le f ra c t io n  
from a-p rosta te  adenocarcinoma t issu e . 9 po in ts 
(see Section 2) at various concentrations of 
3H-Mibolerone plus 3 competition po in ts  with 
cold Mibolerone were used. Axes o r ig in  is  zero. 
The l in e a r  f i t  has been obtained p lo t t in g  bound 
picomolar (BpM) concentrations vs the bound 
over free  r a t io  (B/F),
0.025
CVT0S0L
50 
BpM
n points excluded s ite  1 AR
Figure 4.02.
Scatchard p lo t  of s i te  I AR in nuclear f ra c t io n  
from a prosta te  adenocarcinoma t issu e . 9 po in ts  
(see Section 2) at various concentrations of 
3H~Hibolerone plus 3 competit ion po in ts  w ith 
cold Mibolerone were used. Axes o r ig in  is  zero. 
The l in e a r  f i t  has been obtained p lo t t in g  bound 
picomolar (BpM) concentrations vs the bound 
over free  ra t io  (B/F).
0.1
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Table 4.02.
Ranges o f (1) Kd ( lx lO (-lO )M ) and (2) 
concentration (fmoles/mg DNA) values fo r  
so luble (S) and nuclear (N) AR in  n~18 human 
Prostate Cancer (PCa) and n~66 Benign P ros ta t ic  
Hyperplasia (BPH). S ite  I ind ica tes  high 
a f f i n i t y ,  S ite  I I  reduced a f f i n i t y  b indings, 
cyt ~ cy toso l,  nuc = nuclear.
Kd VALUES AND fMOLAR CONCENTRATIONS OP 
SOLUBLE AND NUCLEAR ANDROGEN RECEPTORS IN  
PROSTATE CANCER C PC a) AND BENIGN PROSTATE 
H Y P E R P LA S IA C B P H >TIS S U E S
PCa BPH
0 . ,  , c u t  l . O O -  9 .0O  2 . 7 9 -  6 .4 1  
b l t e l  nuc  1 . 8 8 -  9 .7 5  4 . 0 7 -  9 .6 8
Kd
C -+  c y t  2 1 . 1 1 - 9 1 . 4 0  1 4 . 4 1 - 7 6 . 0 0  
S l t e ^ nuc 1 3 . 9 3 - 8 3 . 2 0  9 . 6 3 - 6 5 . 7 1
e - 4 . • 4  c u t  4 9 -  1 5 8  6 3 -  8 2 6
nuc  3 4 7 -  8 6 5  2 1 2 -  1 0 5 9
fm o le s
_ c u t  3 6 7 - 4 9 5 5  3 4 3 - 3 3 2 3 6
S i t e  Z nuc  1 3 9 8 - 7 5 7 1  5 4 5 -  5 4 4 2
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The high frequence of occurrence reduces the 
d isc r im ina t in g  power and, probably, the c l in ic a l  value 
o f e i th e r  solub le and nuclear type I I  AR, compared w ith  
ER in  breast cancer [Lopes e t a l . ,  19873; a s im i la r
p o s s ib i l i t y  fo r  nuclear type I AR has been also 
p rev ious ly  suggested [Trachtenberg e t a l , ,  1982].
The concentrations fo r  type I binding s i te s  are 
greater fo r  ARn than fo r  ARs, but they never d isp lay  
high le v e ls .  Type I I  concentration values are much
greater than type I s i te s ,  being up to 100 fo ld  higher 
fo r  ARs and to 20 fo ld  fo r  ARn in prosta te  cancer 
tissues and, up to 40 fo ld  fo r  ARs and to 25 fo ld  fo r
ARn in benign prosta te  hypertrophy. As fo r  the
comparison o f benign prosta te  hypertrophy w ith  p rosta te
cancer, AR concentration is  higher in  benign prosta te
\
hypertrophy than in  prosta te  cancer; th is  d if fe re nce  is  
mainly accounted by the so lub le f ra c t io n  (Tab. 4 .02).
The presence o f a double b inding s i te  is  bare ly  
a ffec ted  by the binding o f mibolerone to  g lu c o r t ic o id  
and progesterone receptors s ince, from separate
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experiments ca rr ied  out to th is  end, the ra d io a c t iv i t y  
le ve ls  a t the d i f fe re n t  sca la r concentrations used, 
expressed as raw cpm, in  the presence o f Triamcinolone 
Acetonide alone (Tab. 2.07) or coupled w ith  0RG2058 are 
very close or equal (Tab. 2 .08).
The very recent evidence o f two d i f fe r e n t  genes, 
having d i f fe re n t  sequences and coding fo r  two d i f fe re n t  
AR [Govindan, personal communication], might now be 
in te rp re te d  as the two types representing the two 
d isc re te  func tiona l s tru c tu re s , one having high and one 
low a f f i n i t y .
4 .2 . Androgen Receptors in  Prostate Long Term Cell Lines
In th is  thes is  the hormone s e n s i t i v i t y  of both 
canine (both normal and neop las tic , CAPE and CPA) and 
human prosta te  cancer (PC3a and DU-145) c e l l  l in e s  has 
been stud ied. Not s u rp r is in g !y , considering the data 
ju s t  reported on prosta te  t issues , 3 out o f the 4 c e ll  
l in e s  showed a nuclear type I AR (Tab. 4 .03). This was 
true  in d i f fe re n t  experimental cond it ions , i . e .  in  c e l ls
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Table 4.03
Androgen receptor (AR) s ta tus of prostate long 
term c e l l  l in e s  in so luble (S) or nuclear (N) 
f ra c t io n  alone and in S+N f ra c t io n s .
( - )  ind ica tes  th a t ,  in  few cases, s i te  I AR 
were absent. A +/ve AR sta tus was stated only
when Kd was below the threshold values adopted 
fo r  s i te  I b ind ing . The sum S+N AR is  used to 
define the in t e g r i t y  o f the receptor fu nc t ion .
RR STRTUS IN PROSTRTE CELL LINES
S o lu b le  CS3 n u c l e a r  CN J S + M
PC3 -  +  - Z o e
DU145 + M  +  +^oe
CPR + [ - }  +  + / v e
CRPE -  -  —/v e
]
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growing in  DMEM or in  BJG media. The c e l ls  maintained 
in DMEM showed higher fmolar concentration o f nuclear 
type I AR than c e l ls  maintained in BJG, but th is  
d if fe rence  was not s ig n i f i c a n t  s ince, in  a l l  cases, the 
molar concentrations o f receptors (expressed per DMA 
c e l l  content) were low? frequence of soluble and nuclear 
S ite  I I  AR were less common than in  prosta te  cancer or 
benign prosta te  hypertrophy t issues .
However, w h i ls t  CAPE normal canine and PC3 human 
prosta te  cancer c e l ls  never showed soluble S ite  I AR, 
th is  was present, in  most but not in  a l l  occasions (see 
Tab. 4 .03), in  CPA cancer canine and DU-145 human 
prosta te  cancer c e l l  l in e s ,  Thus, in  most cases, 
func tiona l receptor s ta tus  ( i . e .  the presence o f both 
solub le and nuclear type I AR) was observed in  CPA and 
DU145 suggesting probable hormone s e n s i t i v i t y .
Soluble type I AR was more frequent and a t h igher 
concentrations in  CPA c e l ls  grown in DMEM than those 
mantained in BJG medium (data not shown), However, the 
conclusion is  th a t both so lub le  and nuclear type I
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receptors are not so s tab le  in  these c e l ls ,  at lea s t fo r  
the cu ltu re  cond it ions we used.
These data confirm the previous s tud ies , concerning 
CPA canine cancer c e l ls ,  which have been reported to  be 
hormone sen s it ive  and responsive to T [Eaton and 
P ie rre p o in t ,  1988].
The evidence o f the concomitant presence o f so lub le 
and nuclear type I AR in DU145 should ind ica te  some
hormone s e n s i t iv i t y  fo r  these c e l ls ,  although some
report suggests they are unable to  respond to  T or DHT 
[Stone e t a l . ,  1978].
4 .3 . Oestrogen Receptor Status in  Prostate Long Term
Cell Lines
Type I and I I  oestrogen b inding s i te s  were also 
assayed in prosta te  c e l l  l in e s .  Curious ly , the re s u lts  
were s im i la r  to those obtained on AR sta tus in p rosta te  
c e l ls .  In fa c t ,  type I nuclear ER was a very common 
f in d in g  in  3 out o f 4 d i f fe r e n t  c e l l  l in e s  (CPA, PC3,
DU-145) (see Tab. 4 .04). Type I I  b inding s i te s  were
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Table 4.04.
Oestrogen receptor (ER) sta tus o f prostate long 
term c e l l  l in e s  in solub le (S) or nuclear (N) 
f ra c t io n  alone and in S+N f ra c t io n s .
( - )  ind ica tes  th a t ,  in  few cases, s i te  I ER 
were absent. A +/ve ER sta tus was stated only
when Kd was below the threshold values adopted 
fo r  s i te  I b ind ing. The sum S+N ER is  used to 
define the in te g r i t y  of the receptor fu nc t io n .
ER STATUS IN PROSTRTE CELL LINES
S o lu b le  C S ) N u c le a r  £ N J  S + N
PC3 -  +  - / v e
DU145 + [ - ]  +  + /v e
CPfl +  +  + / w
CAPE -  -  - y v e
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much less common than prev ious ly  observed e i th e r  in 
prosta te  cancer and benign prosta te  hypertrophy, or in  
breast cancer t issues . Once again CPA and DU145 c e ll  
l in e s  o ften contained low amount o f func tiona l ER, as 
ind icated by presence o f E2 s i te  I b inding in both 
solub le and nuclear f ra c t io n s ,  but i t  was never observed 
in CAPE and PC3 c e l ls .  When p o s it iv e  fo r  ER s ta tus , 
these c e l ls  showed an ER content s im i la r  to  th a t  we
prev ious ly  observed in  other in  v i t r o  systems, l i k e  
breast (ZR75-1, T47D) or endometrial cancer (Ishikawa) 
c e l ls ,  in  terms of femtomolar concentration re fe rred  to 
DNA (ranges from 135 to 1087 and from 154 to  1261
fmoles/mg DNA fo r  solub le and nuclear type I ER, 
re sp e c t ive ly ) .
In general terms, the concentration o f type I I
binding s i te s  in  both prosta te  cancer and benign 
prostate hypertrophy tissues is  much greater than th a t 
o f corresponding type I receptors (see Tab. 4 .02); they 
may be present also when type I b inding s i te s  are not 
expressed. In cu ltu red  c e l ls  femtomolar concentra tions 
( re fe rred  to DNA) o f type I I  receptors appear to be
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lower than th a t observed by in vivo systems (cancer 
t is s u e s )»
These data well agree w ith  those from B ren tan i's  
group [Lopes et a l . ,  1987], who showed a strong
c o r re la t io n  o f type I I  oestrogen binding s i te s  w ith  type 
I ER content, the l a t t e r  being higher in  the 
postmenopausal and o lder p a t ie n ts .  On the other hand, 
AR content observed in DU-145 human cancer c e l l  l in e s  
and CPA canine cancer c e l ls  was s ig n i f i c a n t ly  lower than 
th a t reported by Brinkman et a l . [1987] in  PC82
transp lan tab le  human p ro s ta t ic  adenocarcinoma. These 
authors id e n t i f ie d  a high a f f i n i t y  binding p ro te in  w ith 
the same Kd value (0.1 nM), as defined fo r  our high 
a f f i n i t y  AR. Nevertheless, they revealed concentrations 
of about 120 fmoles/mg P ro te in , which are much higher 
than th a t observed in our in  v i t r o  systems. , This 
s trong ly  suggest th a t e p i th e l ia l  c e l ls  should be f u l l y  
able to  express a func tiona l receptor mechanism, but, 
due to the lack o f other (stromal?) components, th is  
expression is  much lower than th a t  observed in v ivo .
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5. IN VIVO STEROID METABOLISM AND CONTENT
5.1 . Oestrogen Patterns of Normal Endometrium and #
Breast Cancer Tissues
Stero id  leve ls  have been determined in a v a r ie ty  of 
ways ( i . e .  u r inary  excret ion patterns, plasma leve ls  and 
product ion rates measurements) but none shows any
consistent d i f fe rence  between healthy women, women at 
high r i s k  and women with breast cancer [Dao, 1979; 
Fishman et a l . ,  1978; Moore et a l . ,  1982]. Our data
[Castagnetta et a l . ,  1977; Castagnetta et a l . ,  1981;
Castagnetta et a l , ,  1983; Castagnetta et a l . ,  1985;
Castagnetta e t a l , ,  1986b] on s te ro id  excret ion p r o f i l e s
and plasma values confirmed t h i s  when observations were
l im i te d  to c lass ica l  oestrogens. In f a c t ,  we showed 
tha t  excret ion leve ls  of c lass ica l  oestrogens ( i . e .  E2,
El and E3) were unable to d iscr im ina te  heal thy women 
from those bearing breast minor pathologies or breast 
and endometrial cancer. Further,  the plasma values of 
c lass ica l  oestrogens showed l i t t l e  d isc r im inant  power. 
However breast cancer pa t ien ts  exh ib i ted  s i g n i f i c a n t l y
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d i f f e r e n t  excret ion p r o f i l e s ,  well c o r re la t in g  with 
t h e i r  hormone s e n s i t i v i t y  [Castagnetta e t a l . ,  1981]
when minor oestrogens were taken in to  account.
The more recent epidemiological s tudies [Henderson 
et a l . ,  1982] favour a ro le  fo r  endogenous s te ro ids  in 
the aet io logy of human breast or endometrial cancer. 
One reason fo r  the f a i l u r e  of plasma leve ls  to r e f l e c t  
epidemiological p red ic t ions  may be tha t  the hormonal 
"m i l ie u "  of the breast is  not re f lec ted  by s te ro id  
plasma values.
5 .1 .1 .  Oestrogen content of normal endometrium
In order to study the physio logical modulation of 
oestrogen p r o f i l e s ,  i . e .  the contents and ra t io s  of some 
selected metabol i tes, several pooled specimens of normal 
endometrium were co l lec ted  in both menstrual cycle 
phases -  ear ly  p r o l i f e r a t i v e  and la te  secretory -  and 
analyzed. Comparative analyses of several pooled plasma 
samples (co l lec ted  on the same day) were also car r ied  
out.
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The resu l ts  obtained ind ica te :
a) h igh ly  s i g n i f i c a n t  d i f fe rences  between ear ly  
p r o l i f e r a t i v e  and la te  secretory phases of 
menstrual cycle, conf irming previous observations 
from Gower [1979] (see Tabs, 5.01 and 5.02) ;
b) to ta l  t issue oestrogen contents appear 
s i g n i f i c a n t l y  higher with respect to plasma values 
(w i th in  the plasma ranges as reported by Gower 
[1979] ~ from 10 up to 100 times (mean ~ 30) in
ear ly  p r o l i f e r a t i v e  and from 8 up to 50 times (mean 
= 20) in la te  secretory phases;
c) very broad ranges of almost a l l  oestrogen 
metabol i tes were observed despi te,  or due to ,  the 
rather  l im i te d  number of samples (Tab. 5.02);
d) large va r ia t ions  in the c lass ica l  oestrogens, 
a t t r i b u ta b le  mainly to  E2 and E3 contents, and of 
hydroxy and methoxy metabol i tes concentrat ions 
were observed;
e) there e x is t  c lear  ind ica t ions  suggesting 
s ig n i f i c a n t  d i f fe rences between pre~ and 
postmenopausal endometrial t i ssue content.
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Table 5.01.
Plasma values of c lass ica l  oestrogens (E l,  E2 ' 
and E3) in re la t io n  to ear ly  p r o ! i f e r a t i v e  and 
la te  secretory phases of menstrual cycle. 
Reproduced from Gower D.B. [19793.
PLASMA UALUES OF OESTROGENS IN THE TWO PHASES 
OF MENSTRUAL CYCLE
CLASSICAL OESTROGENS OESTRADIOL
pg/m l pmoles/ml pg /m l pmoles/ml
Phase
Proliferative 90 0.327 30 0.11
Secretive 850 3.190 400 1.46
Table 5.02.
Plasma values ( l e f t ) ,  as reported by Gower D.B. 
[1979], and normal endometrial t i ssue contents 
( r i g h t )  of c lass ica l  oestrogens (CE). Range 
values obtained from curret tage (Novak’ s needle 
biopsy) of n~7 d i f f e r e n t  pools, from 3-4 
d i f f e r e n t  pa t ien ts  matched fo r  age and 
menstrual cycle phases.
OESTROGEN CONTENT IN PLASMA AND NORMAL 
PROLIFERATIVE AND SECRETORV ENDOMETRIUM
CE in CE in
Flasna. Endow. Tissue
pmoles/ml pmoles/gr*1
P r o l i f .  P h a s e  0.327 2.4 - 21.2
S e c r e t .  P h a s e  3.190 20.5 - 193.6
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Postmenopausal a trophic  endometria were featured by 
1) c lass ica l  oestrogens t issue contents less than 1/3 of 
PreM ear ly  p r o l i f e r a t i v e  phase, t issue to plasma ra t io s  
much higher (see Tab* 5.03) and to ta l  oestrogen content 
at the same level as ear ly  p r o l i f e r a t i v e  phase; 2) the 
average proport ion of c lass ica l  oestrogens was about 10% 
in PostM atrophic  endometrium compared with 35% to 50% 
in ear ly  p r o l i f e r a t i v e  and la te  secretory phases, 
respect ive ly  (see Tab. 5.04).
Classical oestrogens appear s i g n i f i c a n t l y  decreased 
in  Post M and show e i th e r  p ro po r t io n a l l y  or absolute ly  
d i f f e r e n t  values in the d i s t i n c t  menstrual cycle phases, 
accounting fo r  the 50% and 60% of the to ta l  oestrogen 
amount in ear ly  p r o l i f e r a t i v e  and la te  secretory 
respect ive ly .  In fa c t  c lass ica l  oestrogens increased 10 
times but to ta l  oestrogens augmentation was 6.5 times 
only in la te  secretory with respect to ear ly  
p r o ! i f e r a t i v e  phase.
In atrophic  PostM endometrium there is  evidence of
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Table 5.03.
Oestrogen contents of atrophic  postmenopausal 
(ARM) endometrial t issues (top l i n e )  were 
obtained from pools (4-5) of women hosp i ta l ized  
fo r  non-gynaecological disease, matched fo r  PM 
age (top l i n e ) .  Tissue to plasma ra t io s  of 
oestrogens as reported by Vermeulen-Meiners et 
a l . [1984] (centre l in e )  and as ca lcu la ted on
our own data (bottom l i n e ) .  Plasma leve ls  were 
obtained by RIA (commercial k i t )  assays.
TISSUE CONCENTRATIONS IN  AFM ENDOMETRIA 
AND TISSUE TO PLASMA RATIOS OF OESTROGENS
f l t r o p h ic  E n d o m . 0 .20- 1.170.10- 0.37 1.50- 10.4
pm o ie s /g r”1 o f tissue
T is s u e  /  P la s m a  >50 >10 ^
r a t i o s '*
T is s u e  /  P la s m a  25-150 8-30 x
r a t io s
Table 5.04.
Ratios of c lass ica l  (Cl)  to to ta l  (Tot) and of 
catechol -  hydroxy (OH) + methoxy (MeO) -  to 
Tot oestrogens in d i f f e r e n t  phases of menstrual 
cycle and in postmenopausal atrophic  
endometrial t issues.
OESTROGEN RATIO VALUES IN NORMAL FRE- 
AND POST-MENOFAUSAL ENDOMETRIUM
M enopausal S ta tu s
„ , Pre Post
O e s t r o g e n  e a r l y  l f it e
R atio s  F'ROLIF, SECRET, '.h T R jF H I-.i
C l / T o t  0 .2 -0 .5  0 .3 -0 ,6  0 .0 9 -0 .2
OH+MeO
T o t 0 .5 -0 .7  Q.^-O.6 0 .8 -0 .9
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very ac t ive  catabolism at leas t  as regards c lass ica l  
oestrogens, as hinted at by large E3 formation (see Tab. 
5.03).  Conversely, among "minor”  oestrogens -  inc lud ing 
unusual metabol i tes -  the catecholoestrogens appear to 
be the most conspicuous f r a c t io n !  a) hydroxy plus 
methoxy compounds co n s t i tu te  up to 50% of to ta l  
oestrogens in ear ly  p r o ! i f e r a t i v e  menstrual cycle phase 
when the to ta l  oestrogen content of normal endometrium 
appears lower but the maximal p r o ! i f e r a t i v e  a c t i v i t y  is  
reached; b) they s t i l l  r ise  to 45% of to ta l  oestrogen 
during the la te  secretory menstrual cycle . phase, when 
the highest peak of oestrogen content is  detected -  i . e .  
mean of 29.5 picomoles in la te  secretory menstrual cycle 
phase vs mean of 4.8 picomoles in ear ly  p r o l i f e r a t i v e  
menstrual cycle phase; c) in PostM atrophic  endometrium 
catecholoestrogens f ra c t i o n  may a t ta in  as high as 80% of 
to ta l  oestrogens (see Tab. 5.04) .  The p re va i l in g  
components were 20H-E2 and 20H-E1 j o i n t l y  with 
in frequent methoxy compounds d i s t r i b u t i o n ;  w i th in  the 
catecholoestrogens, moreover, some in te re s t in g  
suggestions emerged: 1) 2- and 4-hydroxy compounds seem
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to be qu ite  d i f f e r e n t l y  d is t r ib u te d  not only in Post M 
vs PreM endometrium, but also between ear ly
p r o l i f e r a t i v e  and la te  secretory menstrual cycle phases; 
2-hydroxy subfrac t ion  predominates in la te  secretory
where 4-hydroxy p reva i ls  in ear ly  p r o l i f e r a t i v e  
menstrual cycle phase; 2) methoxy formation was much 
higher in ear ly  p r o l i f e r a t i v e  than in la te  secretory
menstrual cycle phase invo lv ing  e i th e r  2- or 4-hydroxy 
compounds (data not reported) .
5.2. Tissue Content o f Oestrogens in  Human Breast Cancer
A few samples of breast cancer have been examined 
also fo r  t h e i r  oestrogen contents. As reported in 
Mater ia ls  and Methods* Section, simple d ie thy le th e r  
ex t ra c t io n ,  or a combined enzymatic plus ac id hydro lys is  
ex t rac t ion  before p a r t i t i o n  chromatography, were used.
Results can be summarized as fo l lows .
F i r s t l y ,  some t imes, but not always, the to ta l  . 
oestrogen contents were high when examining specimens 
without p r io r  enzymatic hydro lys is ;  t h i s  suggests th a t
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the conjugate oestrogens, not recovered in t h i s  case,
may sometimes be l im i te d  in human cancer t issues and,
then, may represent a n e g l ig ib le  proport ion of the to ta l  
oestrogens extracted.
In the second place, we observed large va r ia t io n s
in the amount of to ta l  and of several classes of
oestrogens recovered, with and without enzyme 
hydro lys is ,  suggesting tha t  the content of oestrogen 
conjugates may be h igh ly  var iab le  in d i f f e r e n t  breast 
cancer t issues (data not shown).
In Tab. 5.05 the free  oestrogen contents of breast
cancer t issues are shown. These are expressed as range
without median values due to  the l im i te d  number of
cases. In sp i te  of t h i s  i t  may be seen tha t  both
hydroxy oestrogens and t h e i r  methoxy metabol i tes 
cons t i tu te  a substant ia l  proport ion of to ta l  f ree 
oestrogens.
As regards the several oestrogen subclasses?
a) a marked d i f fe rence  between ER +/ve vs ER - /ve
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Table 5.05.
Ranges of values (95% confidence l im i t s )  
reported in pmoles/g of t issue .
ER s ta tus :  +/ve ind icates a p o s i t ive  soluble
and nuclear oestrogen receptor;  - /ve  ind icates 
the absence of receptor in one or both 
compartments. Adequate adjacent t issue 
sect ions were confirmed as neoplast ic  by 
pa tho log is ts .
COe -  c lass ica l  oestrogens; OH ~ hydroxy, MeO - 
methoxy compounds; Tot -  to ta l  oestrogens.
ND « not detectable.
□ESTROGEN CONTENT OF POSTMENOPAUSAL BREAST CANCER T IS S U E S  IN  
RELATIO N TO OESTROGEN RECEPTOR STATUS
COe OH MeO T o t
ER + / v e  ND . 61 0 . 5  -  86  ND  2., 1 0 . 6  -  114
( n 6 )
ER • " / v e  ND -  37  0 . 2  -  7 8  1 . 1  -  124 2 . 3  -  168
< n 3)
i
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subgroups was observed only fo r  methoxy oestrogens;
b) to ta l  oestrogens showed a trend to e x h ib i t  higher 
value in  ER - /ve  cases;
c) no appreciable d i f fe rences fo r  e i th e r  c lass ica l  or 
hydroxy oestrogens can be reported, however some 
ra t io s  among selected metabol i tes, mainly 
concerning catecholoestrogens, appear of in te re s t  
and deserve fu r th e r  s tud ies.
In examining also d i f f e r e n t  por t ions of the same 
primary breast tumour a large v a r i a b i l i t y  was observed 
not only with respect to to ta l  oestrogen content but 
also concerning several classes or f r a c t io n s  of 
oestrogens.
An example is  given in Tab. 5.06, showing th a t  two 
almost adjacent separate por t ions of the same tumour 
e x h ib i t  a large v a r i a b i l i t y  not only f o r  the to ta l  
oestrogen content (2.5 times more in one po r t ion  than in 
the o the r ) ,  but also fo r  some oestrogen f r a c t io n s ;  e.g. 
methoxy oestrogens represented a large par t  of  to ta l  
oestrogens in  one po r t ion ,  but were almost absent in  the
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Table 5.06.
Concentrations (picomoles x g(~ l )  of t issue)  of 
several oestrogens in two adjacent t issue 
port ions of a primary breast tumour 
character iz  ed by heterogeneous d i s t r i b u t i o n  of 
oestrogen receptors.
Classical (CE), Hydroxy- (QH-), Methoxy- (MeO-) 
16a-Hydroxy-El (16aOH-El) and to ta l  (Tot) 
oestrogens.
Fraction "y" was positive and fraction "x” 
negative for both soluble and nuclear 
oestrogen receptor.
CONCENTRATIONS OF SEVERAL OESTROGENS 
IN DIFFERENT PORTIONS OF THE SAME BREAST TUMOUR
CE OH MeO i60iO HE! TOT
B 969 x 0.7 2.7 12.4 1.0 16.8
B 969 y 0.5 4.6 0.02 2.5 7.7
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other .
As i t  can be seen from the same Tab. 5.06, as with  
to ta l  oestrogens, very d i f f e r e n t  amounts of minor 
oestrogens, hydroxy and methoxy, and unusual l i k e  
16aOH~El may be observed w i th in  the same tumour mass. 
Meanwhile the content of the c lass ica l  oestrogens 
remained s im i la r  in the two tumour sect ions compared. 
This is  j u s t  a paradigmatic evidence of s te ro id  content 
in re la t io n  to breast cancer t issues .  In these two 
port ions the ER status was d i f f e r e n t ,  being por t ion  one 
(Y) p o s i t ive  and other por t ion  (X) negat ive f o r  both 
solub le and nuclear oestrogen receptors, respec t ive ly .  
Thus, d i f f e r e n t  content of several oestrogen f ra c t io n s  
was associated with d i f f e r e n t  ER status in  two separate 
port ions of the same breast tumour.
These data ind ica te  a large v a r i a b i l i t y  in 
oestrogen p r o f i l e s  of breast cancer t issues.  There may 
be d i f f e r e n t  proport ions of conjugate or free  oestrogen 
metabol i tes and d i f f e r e n t  concentrat ions of ind iv idua l  
oestrogens, w i th in  the same f ree oestrogens f r a c t i o n .
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Total oestrogen content ranged from values lower 
than those prev ious ly  observed in ear ly  p r o ! i f e r a t i v e  
endometrium to several times more than those reported 
fo r  la te  secretory endometrium. Looking exc lus ive ly  at 
the c lass ica l  oestrogen f r a c t i o n ,  the t issue content 
was much higher in breast cancer t issues from PostM 
pat ien ts  compared with normal endometrium from PostM 
women (Tables 5,03 and 5.05),
I t  is  noteworthy, however, tha t  minor oestrogens, 
i . e .  catechol and unusual metabol i tes, cons t i tu ted  a 
large proport ion o f  the to ta l  oestrogen content (see 
Fig. 5.01) in both cases (normal endometrial and breast 
cancer t i ssues ) .  Classical oestrogen leve ls  are, thus, 
not f u l l y  representat ive  of the oestrogen status of 
human t issues,  as was prev ious ly  reported [Castagnetta 
et a l . ,  1981; Castagnetta et a l . ,  1985; Castagnetta et 
a l , ,  1986b] looking at oestrogen excret ion values. A
be t te r  understanding of the oestrogen sta tus of human 
normal and cancer ta rge t  t issues should include these 
addi t ional  oestrogens.
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Figure 5.01.
Chromatographic (RP-HPLC) pattern  using 
Electrochemical Detect ion of a breast cancer 
t issue e x t rac t  (see Section 2).
I d e n t i f i c a t i o n  numbers and quan t i ta t ion  
(picomoles) as fo l low s :
1 -  E3 (6 .9 ) ;  2 * 16«0H~E1 (10.5);  3 * 20H-E2
(10.4) ;  4 = 40H-E2 (10.4) ;  5 = 20H-E1 (20.9);
6 -  40H-E1 (604.9);  7 -  E2 (3 .3 ) ;  8 = in terna l
standard E q u i l in ;  9 -  4Me0-El (36.7) .  
I d e n t i f i c a t i o n  of s ing le  metabol i tes sometimes 
was also car r ied  out with SIM -  Mass Spectral 
Analysis (data not shown). For chromatographic 
condi t ions see te x t .
<25min
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In general,  the oestrogen content of human t issues 
appears to be much higher than respect ive s p e c i f i c  
receptor content w i th in  the same t issues.
These data, l i k e  those prev ious ly  reported by 
others [Thi jssen et a l . ,  1986] disprove the s i m p l i c i s t i c  
view tha t  oestrogen uptake by ta rge t  t issues is  s t r i c t l y  
re la ted to receptor content.  More data are required on 
minor oestrogen and conjugate oestrogen f r a c t io n s ,  and 
also on androgens and other s te ro ids ,  r e la t i v e  to 
respect ive plasma values and to normal t issue contents.
5.3. Stero id  Content o f Breast Cyst F lu id
As reported in In t roduc t ion  Section, Gross Cyst ic  
Disease has been extens ive ly  studied in recent years. 
Many reports  o u t l in e  a bimodal biochemical pa t te rn .  
Thus, breast cyst f l u i d s  (BCF) can be subdivided 
according to t h e i r  e le c t r o l y te  content o f K+ and Na+ 
respect ive ly .  Fol lowing t h i s ,  i t  has been shown tha t  
s te ro id  accumulation w i th in  cysts is  s i g n i f i c a n t l y  
corre la ted to cyst type. Now, evidence suggests tha t
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s te ro ids  in  BCF are mainly represented by sulpho- 
conjugates, at leas t  f o r  some androgens and oestrogens.
Increased concentrat ions of DHA-S, El-S or E3-S 
have been observed and reported to be s i g n i f i c a n t l y  
associated with a pecu l ia r  e le c t ro ly te  pattern  [Bradlow 
et a l . ,  1981; Raju et a l . ,  1981; D o g l io t t i  et a l . ,
1986b]. There are no previous reports  however 
concerning a complete p r o f i l e  of oestrogens in BCF. 
Data hereafter  reported present pre l im inary s tudies on 
oestrogen patterns in BCF, looking mainly at the f ree 
pool and, p a r t i c u l a r l y , at  catecholoestrogens, i . e .  
hydroxy and methoxy compounds.
In these studies the free oestrogen pool was 
compared with the content of some oestrogen conjugates 
in BCF and to the respect ive plasma values fo r  the same 
pa t ien ts .  General features ,  emerging from these 
pre l im inary s tud ies, suggest th a t ;  1) oestrogen to 
androgen r a t i o  values are increased in cyst f l u i d s  with 
respect to plasma leve ls ,  mainly because of the greater  
accumulation of oestrogens in BCF; 2) the three
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c lass ica l  ( f ree  plus conjugate) oestrogens appear 
s i g n i f i c a n t l y  concentrated in cyst f l u id s  with respect 
to plasma; 3) genera l ly ,  c lass ica l  oestrogens appear 
fo r  the most par t  represented by t h e i r  conjugates.
5 .3 .1 .  Free and conjugate oestrogens in breast cyst
.......
Cyst f l u i d s  were studied coming from 89 d i f f e r e n t  
pa t ien ts ,  mostly in PreM, but a few were perimenopausal. 
Categor izat ion of BCF was car r ied  out on the basis of 
both ca t ion ic  (e i th e r  K+ or Na+) and anionic Cl-  content 
of the same cyst.  In 27 out of 89 BCFs, the complete 
oestrogen p r o f i l e  was also studied, comparing t h i s  with 
DHA-S content and also free El with El-S. Plasma values 
of corresponding hormones were not achievable fo r  most 
pa t ien ts  as sera were not properly  co l lec ted .  Because 
of previous observat ions [Angel i et a l . ,  1987], cyst
f l u i d s  were not co l lec ted  in re la t io n  to days of 
menstrual cycles in premenopausal pa t ien ts .  Fol lowing 
data reported by Angeli and coworkers, K+ to Na+ ra t io ,  
c u t - o f f  values of more than 1.5 fo r  high K+ content
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(type I )  and of less than 0.66 fo r  high Na+ content 
( type I I )  cyst f l u i d s  were used; intermediate values 
(between 0.66 and 1.5) were a t t r i b u te d  to type I I I  
cys ts . On t h i s  basis,  as i t  can be seen from Tab. 5.07, 
higher C l-  content was observed in type I I ,  high Na+ 
cys ts ; the s t a t i s t i c a l  comparison was h igh ly  s i g n i f i c a n t  
between type 1 and type I I  cys ts. I n te re s t in g ly ,  the 
Cl-  content was below the detectable level  in more than 
75% of type I cysts.
The main goal was to study the f ree  oestrogen 
p r o f i l e  of BCF, i . e .  to measure a wide spectrum of 
oestrogen metabol i tes by using: 1) RP-HPLC, 2) a
computer-aided op t im iza t ion  of the mobile phase and 3) 
on - l ine  electrochemical detect ion. Mass spectral  
analyses were used to confirm the i d e n t i t y  of s ing le  
peaks in some cases, though not always and not f o r  a l l  
oestrogen metabol i tes.
Another goal was to compare free with conjugate 
oestrogen content of BCF; to t h i s  end, we determined E l -  
S in re la t io n  to El concentrat ions in a l l  these samples.
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Table 5.07.
Potassium (K+), Sodium (Na+) and Chlor ide (C1-) 
expressed as range values in mEq/L.
(*)  non detectable in >75% of cases; (+) non 
detectable in >55% of cases; I vs I I  p<0.005 
(Student 's t  t e s t ) .  D is t r ib u t io n  of cases*, 
type I n~47; type I I  n~35; type I I I  n~7.
CYST CATEGORIZATION IN RELATION 
TO ELECTROLITE CONTENT
Cyst Type K*:Na+ Ratio Cl'content 
I >1.5 ND - 20*
in
< 0.66 
0.66 - 1.5
42 -
ND - 46
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A th i r d  goal was to study the . re la t io n s h ip s ,  i f
any, between oestrogens (p r in c ip a l ly  E l, both free  and
sulphated) and DHA-S content of both BCF and plasma.
Unfo rtuna te ly , at le a s t 6 ml of each BCF was
required in  order to obtain a complete oestrogen p r o f i le  
and to study DHA-S and El-S plus e le c t ro ly te  contents. 
For th is  reason only 27 out o f 89 cyst f lu id s ,  
obtained by f ine-need le  asp ira tes , were studied f u l l y .  
The age range fo r  these p a t ien ts  was between 48 and 52 
years. Cyst type d is t r ib u t io n  was: n~14 belong to  type 
I ,  n = l l  belong to type I I  and only n-2 were considered 
as intermediate values -  type I I I  cysts (see Tab. 5 .07 ).
We are aware o f the possib le in te rfe rence  played by 
sulphate delta5-androgens on assay o f sulphate 
oestrogens. I n t u i t i v e ly ,  th is  may re s u l t  in
p ro po r t io n a l!y  enhanced values g iv ing  up to  40% 
overestimation. This is  ju s t  the case o f BCF, where, 
j o i n t l y  w ith high E1S and E3S le v e ls ,  very high amounts 
of DHAS and other sulphate androgens ( l i k e  de ltaS -
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t r i o l s )  are commonly encountered.
For the assay of these conjugate s te ro id s , two main 
methodological approaches can be proposed. The f i r s t  
consists of a high-temperature s o lv o ly s is ,  s p e c i f ic  fo r  
sulphate delta5-androgens, fo llowed by ether e x tra c t io n  
o f hydrolized s te ro id s .  The second [C io t t i  e t a l . ,  
1989] is  a simple, t ime-saving, solid-phase e x tra c t io n ,  
y ie ld in g  both free  and sulphate El w ith more than 80% 
and 90% recovery, resp ec t ive ly .
As a p re lim ina ry  exerc ise, the free  and conjugate 
El content o f BCF was stud ied. Overall the range of 
free  El was very wide, varying from 0.51 to  more than 21 
pmoles/ml. The same was true  fo r  El-S, which ranged 
from undetectable to more than 23 pmoles/ml (see Tab. 
5 .08).
Both free  and sulphated El content appeared re la ted  
to cyst type. In fa c t ,  median values o f free  El were 
three . times higher in  type I cysts though th is  
d if fe rence  was not s ig n i f i c a n t  (see Table 5 .08), and E l-  
S was concentrated 10 times more and exh ib ited  higher
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Table 5.08.
Type I vs I I :  El p=0.67; E1S p=0.02; E1S/E1 
p-0.02 (Student’ s t  t e s t ) .  Values (pmoles/ml) 
are ranges o f n-14 type I and n ^ l l  type I I  cyst 
f lu id s ,  re sp ec t ive ly . (+) non detectable in 
>30% of cases.
Ei AMD EiS CONTENT AND RATIO IN BCF]
Type E| E^ S EjS/Ej
I 0.78-21.50 2.24-23.44 0.45-2.86 
H 0.51 - 5.60 ND- 1.65 0.09-0.79
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median values in  type I w ith respect to type I I  cysts 
(data not shown). There were too few type I I I  to permit 
any comment. S u rp r is in g !y ,  the El-S to  El r a t io  was also 
s ig n i f i c a n t ly  d i f fe r e n t .  As i t  can be seen from Fig.
5.02, El-S, expressed as Log pmoles/100 ml, was 
constan tly  below 1.0 in  type I -  high K+ cysts (two 
cases excepted) and constan tly  h igher than 1.5 (one case 
excepted) in  type I I  -  high Na+ content cyst f l u id s .  
Besides, El-S concentrations (F ig , 5.03) showed a high 
c o r re la t io n  w ith ca tion  content (r=0.94, p<10(-6)),.
having p ro p o r t io n a l ly  higher values with the increased 
K+ to Na+ ra t io s .  Although free  El content was greater 
in  type I -  high K+ cysts and El-S content was also 
enormously increased in  the same kind of cys t,  a much 
higher El-S to El r a t io  (see Fig. 5.04) was observed in 
type I I  -v high Na+ than in  type I high K+ content cys ts . 
These observations confirm previous reports th a t El-S 
concentrations are increased in  type I cysts [Bradlow et 
a l . ,  1981]. Nevertheless, the re su lts  in  Tab. 5.08
suggest th a t o r ig in  of El-S in  re la t io n  to  El d i f f e r s  in  
d i f fe re n t  cyst populations. I t  is  possib le  th a t
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Figure 5.02.
E1S content ( log  of pmoles/dl) and d is t r ib u t io n  
in two cyst f l u id  subgroups, 
t  -  5.99; p -5x10(-4) (Student’ s t  t e s t ) .
Bars represent mean values.
Figure 5.03.
P os it ive  c o r re la t io n  between FIS content 
(pmoles/ml) and K+ to  Na+ ra t io s  of breast cyst 
f l u id ,  r = 0.94, p<10(~6) (Pearson's te s t ) .
19.8
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15,4 
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Figure 5.04.
D is t r ib u t io n  o f E1S to El r a t io  in  high K+ vs 
high Na+ content breast cyst f lu id s ,  
t  "2 .95; p ~ 0.02 (Student’ s t  t e s t ) .
Bars represent mean values.
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sulphating enzyme a c t i v i t ie s  are much higher in  high K+ 
content cyst types. To fu r th e r  inves t ig a te  th is  aspect, 
El-S to DHA-S content o f two d i f fe re n t  cyst types were 
ca lcu la ted . As seen in F ig. 5.05, the DHA-S to El-S 
ra t io s  d i f f e r  s ig n i f i c a n t ly  in  the two cyst f l u id  types; 
mean values o f roughly 0.5 and higher than 1.75 were 
observed in high K+ -  type I and high Na+ -  type I I  
cys ts , re sp ec t ive ly . Thus, e ith e r  androgen or oestrogen 
conjugates are much higher in  one cyst type than in 
another, as ind ica ted  by previous reports [F le ish e r et 
a l . ,  1973; Bradlow et a l . 1979; Bradlow e t a l . ,  1981;
Raju et a l . ,  1981]. Moreover, there is  d i r e c t  evidence 
th a t accumulation o f oestrogens is  much higher than tha t 
of androgens, in type I cysts (see Fig. 5 .05). In our 
experience, DHA-S concentrations in BCF are lower than 
the respective plasma values. El-S leve ls  appear to be 
p ro p o r t io n a l ly  much increased re la t iv e  to DHA-S. This 
evdence is  supported by the high c o r re la t io n  we observed 
between K+ to  Na+ and El-S to  DHA-S ra t io s  in BCF (see 
F ig . 5 .06).
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Figure 5.05.
Log values of DHAS to E1S ra t io s  in  two main 
(high Na+ and high K+) breast cyst f l u id  types, 
t  -  7.48; p<2xl0(~4) (Student’ s t  t e s t ) .
Bars represent mean values.
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Figure 5.06.
C orre la t ion  between cations content ra t io  (K+ 
to Na+) and E1S to DHAS ( x lO ( - l ) )  
concentrations o f breast cyst f l u id ,  r -  0.92, 
p<10(~6) (Pearson's t e s t ) .
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In conclusion, BCF appears to be featured by: a)
s te ro id  content h igher than plasma values; b) higher 
oestrogen/androgen ra t io s ;  c) higher sulphated than free  
El contents. However, h igh ly  s ig n i f ic a n t  d if fe rences  
emerged in  the free  to  conjugate r a t io ,  according to 
e le c t ro ly te  contents o f the various BCF types.
5 .3 .2 . Catecholoestrogens i n breast cyst f l u id
Free oestrogens, showed no s ig n i f ic a n t  d if fe rences  
between two cyst f l u id  types (see Tab. 5 .09), in  terms 
o f e i th e r  to ta l  or c lass ica l oestrogens. Also 
catecholoestrogens, considered as a whole ( i . e . ’ 2- and 
4-hydroxy plus methoxy compounds), were not 
s ig n i f i c a n t ly  d i f fe r e n t .  But, when comparing to ta l  
catecholoestrogens to  to ta l  oestrogens r a t io  in  
d i f fe re n t  cyst types, h igh ly  s ig n i f ic a n t  d if fe rences  
between groups were seen, as reported in F ig . 5.07 (the 
mean values were less than 0.55 and more than 0.75 fo r  
high Na+ -  type I I  and fo r  high K+ -  type I cys ts , 
re s p e c t ive ly ) .  No overlapping o f values was observed; 
so, s t a t i s t i c a l  d if fe rence 'w as high, despite the very
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Table 5.09.
Total (Tot) of c lass ica l (CE), ca techo l- (CCE) 
and oestrogens (E) in  type I vs I I  BCF. Values 
(pmoles/ml) are ranges of n-14 type I and n ^ l l  
type I I  cyst f lu id s .  No s ig n i f ic a n t  
d if fe rences were found between subgroups.
{FREE OESTROGEH COHTEHT IH BCF;
Type Tot E Tot CE Tot CCE
Figure 5.07.
Catechol (CCE) to  to ta l  oestrogens (Tot E) 
ra t io s  in  two breast cyst f l u id  subpopulations, 
t  = 5.98; p<6x!0(-4) (Student’ s t  t e s t ) .
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l im i te d  number of cases. This f ig u re  suggests also 
th a t ,  in  high Na+ -  type I I  cys ts , more than 50% of a l l  
free  oestrogens are represented by catecholoestrogens 
and th a t ,  in  high K+ - type I I  cys ts , they can represent 
up to 80% of a l l  f ree  oestrogens. F ig. 5.08 shows an 
attempt to ca lcu la te  the formation rates of 
catecholoestrogens from th e i r  best substrate El or 
p o ten t ia l substrate E l-S. Data from th is  f ig u re  
ind ica te  th a t in type I I  -  high Na+ cysts , having less 
El-S and free  E l, the ra t io  between El catechols and 
El+El-S was much higher than th a t observed in type I -  
high K+ content cyst f l u id s ,  where more free  El and much 
more El-S was observed, despite th a t the content o f El 
catechols appears to  be less in  high Na+ than in high K+ 
cysts . This suggests th a t high K+ content cyst f lu id s
e x h ib i t  lower El catechols to  El+El-S ra t io s  mostly
\
because the content o f El+El-S is  much higher in  th is  
cyst type. This view is  also supported by the fa c t  th a t 
the same trend was observed when El catechol products 
were separately re la ted  to  El-S and to  free  El 
f ra c t io n s ,  but th is  implies proportiona l 1y much higher
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Figure 5.08.
D is t r ib u t io n  of Catechol-Oestrone ( i . e .  2- and
4-, OH- and MeO-El -  CCE1) to free  El plus E1S 
ra t io  values in  two breast cyst f l u id  types, 
t  -  3.37; p < 0 .0 2 - (Student’ s t  t e s t ) .
Bars represent mean values.
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f ree  El content and sulphatase a c t i v i t y  in  high Na+
cysts .
The ra t io  o f methoxy to hydroxy oestrogens 
(p rev ious ly  reported to have importance in  breast 
cancer [A ss ico tt  e t a l . ,  1977}) was (F ig . 5.09)
s ig n i f i c a n t ly  greater in high Na+ - type I I  cyst f l u id s .  
In fa c t ,  a l l  cases o f th is  cyst type exh ib ited  Log
values higher than 2 (ranging between 2 and 3 ). In
con tra s t,  lower ranges (between 1 and 2 Log va lues), 
were observed in a l l  high K+ -  type I cys ts . This 
d if fe rence  may be p r in c ip a l ly  ascribed to the 4- 
methoxy:4-hydroxy ra t io s ,  (see Tab. 5 .10). To fu r th e r  
inves t iga te  the d if fe rences in both 4- to 2- and hydroxy 
to methoxy oestrogens in BCF, only the ra t io s  of 4- to 
2~hydroxy + methoxy were ca lcu la ted , as reported in Tab. 
5.11. S u rp r is in g ly ,  a l l  cases (apart from three) o f 
type I I  cysts showed negative Logs values, while a l l
cases (apart from one) o f type I cysts exh ib ited  
p o s it iv e  Log values fo r  th is  r a t io ,  concerning E2 
catechols, i . e .  hydroxy + methoxy E2 (see F ig . 5 .10).
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Figure 5.09.
Methoxy (MeO) to hydroxy (OH) ra t io  o f El plus 
E2 and th e i r  d is t r ib u t io n  in high K+ and in 
high Na+ cyst types.
t  = 4.54? p < 3xl0(~3) (Student’ s t  t e s t ) .
Bars represent mean values.
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Table 5.10.
Type I vs I I :  El + E2 Methoxy to Hydroxy
(Me0:0H) p=0.007; 2MeO- to 20H- NSD; 4MeO- to 
40H~ p-0.003. (S tuden ts  t  t e s t ) .
METHOXY TO HYDROXY OESTROGEN CEt+E2 J
_______________RATIOS IN BCF_______________
t .™  MeO:OH 2Me0:20H 4M e0:40HType
I  0.011-0.076 0.018-1.300 0.001-0.100
H 0.136-0.59^ 0 .0 5 6 -0 .8 3 3  0.182-1.110
Table 5.11.
Type I vs I I :  only 4:2 (OH + MeO) E2 shows
s ig n i f i c a n t  d i f fe rence (p<0.01) (Student ’ s t  
t e s t ) .
4  TO 2  HYDROXY + METHOXY OESTROGEN
RATIOS IN BCF
Cyst
Type
I
H
4 > 2
COH+MeOD
Ei+Ei-
/ i »2
COH+MeOD
Ei
f l ; 2
COH+MeOD
E,
0.14-5.09 0 .0 3 -5 .0 0  0.31-22.18 
0.31- 1.63 0 .5 3 -4 .6 9  0 .0 7 - 4 .0 0
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The main d i f fe rences between cyst types, may be 
summarised as fo l low s :  a) d i f f e r e n t  cysts contain
d i f f e r e n t  amounts of to ta l  catecholoestrogens; b) there 
i s  evidence tha t  hydroxy oestrogens are catabol ized at 
d i f f e r e n t  rates, i . e .  have d i f f e r e n t  methoxy oestrogen 
product ion; c) there are also h igh ly  s i g n i f i c a n t  
d i f fe rences in terms of the ra t io s  between d i f f e r e n t  
hydroxy + methoxy oestrogens, e.g. of the content of 4- 
to 2-hydroxy + methoxy compounds.
General conclusions are: 1) catecholoestrogens are 
the major component of the free oestrogen content by 
BCF; 2) considering the sum of E2+E1, methoxy to hydroxy 
f ra c t io n s  and, above a l l ,  the 4-methoxy to hydroxy E2 
ra t io s ,  appear to be s i g n i f i c a n t l y  d i f f e r e n t  between 
cyst types and to co r re la te  with K+ to Na+ ra t io s ,  but 
not with the El+El-S content.
I f  the presence of 4- and 2-hydroxy oestrogens in 
cyst f l u i d s  r e f le c ts  the metabol ic a c t i v i t y  of cysts , 
hydroxylat ing a c t i v i t i e s  appear very high in both cyst 
types. A d d i t io n a l l y ,  4-hydroxy la t ion appears to be much
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Figure 5.10.
Ratio of 4- to 2-hydroxy plus methoxy (OH+MeO) 
E2 in  two main subgroups of breast cyst f l u i d ,  
t  -  4.25; p<4xl0(-3) (Student’ s t  t e s t ) .
Bars represent mean values.
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more act ive  than 2-hydroxy lat ion and t h i s  is  
p a r t i c u la r l y  t rue fo r  E2 re la t i v e  to El* I f  type I I  
cysts more extensive ly  metabolise hydroxy oestrogens, 
showing a higher content of methoxy compounds, the COMT 
enzyme a c t i v i t i e s  could be d i f f e r e n t  between d i f f e r e n t  
cyst types.
In the l i g h t  of the p ro tec t ive  e f fe c t  of low pH on 
the hydroxy oestrogens against t h e i r  metabolism by COMT 
enzymes, or purely chemical degradat ion, the increased 
hydroxy oestrogen content observed in type 1 cysts 
should be re la ted to lower pH values reported fo r  t h i s  
cyst type. A typ ica l  f ree oestrogen p r o f i l e  of Type I -  
BCF is  shown in Fig. 5.11. By con tras t ,  decreased 
hydroxy to methoxy ra t io s  observed in type 2 cysts 
should be a t t r i b u te d  to the higher pH values of high Na+ 
cyst type, as prev ious ly  reported [Bradlow et a l . ,  
1987].
Las t ly ,  experimental evidence is  reported tha t  
16aOH-El was detected in more than 50% of a l l  cases 
studied. Over 40% (6 out of 14 cases) of type I cyst
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gure 5.11.
Electrochemical detect ion p r o f i l e  o f f ree 
oestrogen content a f t e r  separat ion by RP-HPLC. 
Id e n t i f i c a t i o n  numbers and concentrat ion 
(pmoles) of ind iv idua l  metabol i tes as fo l lows :
1 * E3 (57.8) ;  2 -  16Epi-E3 (73.7) ;  3 -  20H-E2
(66.2);  4 -  40H-E2 (N.M.); 5 * 20H-E1 (9 .9 ) ;
6 * 40H-E1 (5 .2 ) ;  7 -  E2 (N.M.); 8 -  4MeO-E2
(10.6);  9 -  Equ i l in  ( in te rna l  standard).
N.M. ~ not measurable. For other d e ta i l s  see 
te x t  and Figure 5.01.
o ino in
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f l u i d s  had a mean of 4,5 nmoles/100 ml, w h i l s t  over 50% 
( i . e .  6 out of 11 cases) of type I I  cysts have less than 
2 nmoles/100 ml content of t h i s  p a r t i c u la r  metabol i te .  
This observation is  espec ia l ly  i n t r ig u in g  and deserves 
fu r th e r  study in order to be t te r  def ine whether 
oestrogen content and ra t io s  in BCF may be considered as 
add i t iona l  parameters in categoriz ing cysts and 
id e n t i f y in g  pa t ien ts  at high r i s k  of developing breast 
cancer.
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6 . DISCUSSION OF RESULTS
The work described in t h i s  thes is  concentrated on 
in  v i t r o  metabolism of s te ro ids  by e p i t h e l ia l  cancer 
c e l l s .
One ob jec t ive  was to es tab l ish  whether s te ro ids  are 
metabolised d i f f e r e n t l y  in c e l l s  having a d i f f e r e n t  
s te ro id  receptor content,  i . e .  a d i f f e r e n t  hormone- 
- s e n s i t i v i t y  s ta tus .  To t h i s  end long-term ce l l  l in e s  
were selected which had been well character ized at the 
time t h i s  study was conceived. For the above reasons, 
the o r ig in a l  design includes both responsive or 
unresponsive, receptor p o s i t ive  or negat ive c e l l s ,  
derived from the main human endocr ine-re lated tumours, 
namely breast,  endometrial or prostate cancers.
However, a d d i t io n a l ,  p re l im inary  data are included 
on t issue content o f s te ro ids  in  both benign and 
malignant diseases.
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6.1. Stero id  Metabolism " In  V i t r o "
The main observations can be summarised as fo l low s :  
d i f f e r e n t  e p i t h e l ia l  ce l l  l in e s  in v i t r o  may e x h ib i t  
d i f f e r e n t  s te ro id  metabol ic patte rns;  t h i s  is  true fo r  
ce l l  l in e s  derived from breast,  endometrial and prostate 
cancer c e l l s ,  as well as fo r  metabolism of e i th e r  E2 or 
T. Two d i s t i n c t  patterns have been cons is ten t ly  
observed: a) high or low rates of E2 or T degradat ion;
b) high or low rates of oxidised metabol i te formation.
The p re fe ren t ia l  pathways encountered were 
p r in c i p a l l y  e i th e r  ox ida t ive  or reduct ive (see Tab. 
6.01) and the p r inc ipa l  pathway was, in any ce l l  l i n e ,  
always the same. For human prostate cancer c e l l s  or 
canine normal and cancer c e l l s ,  the p r inc ipa l  pathway 
was the same fo r  both T and E2. Metabol ic patterns were 
apparent ly unrelated to ce l l  growth rates, but s t rong ly  
dependent on ce l l  number and molar concentrat ions of 
precursors.
A key aspect concerns the r e l i a b i l i t y  of long term, 
well establ ished ce l l  l in e s  in re la t io n  to studies on
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Table 6.01.
Summary of a l te rn a t iv e  metabolism of 
testosterone cons is ten t ly  observed in human and 
canine long term prostate ce l l  l in e s .
METABOLIC PATHWAYS OF TESTOSTEROHE BY CAHIHE AND 
HUMAN NORMAL AND CANCER PROSTATE CELL LINES
[3H ]-T e s to s te ro n e  P red o m in ant Main Sac-Reduced  
D egradation  M etabolism  P ro d u c t M etab o lites
Fast OHidatiue A 4-H 17-Oho
SIoilp Reductiue 5o;-DHT 17-HydroKy
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s te ro id  metabolism. However, a new d is t i n c t i o n  between 
long term and well establ ished systems should be 
introduced. In general terms the ma jo r i ty  of ce l l  l in e s  
studied seem to be very useful  f o r  studies on s te ro id  
metabolism. Each mantained i t s  ch a ra c te r is t i c s  and 
p roper t ies ,  inc lud ing s te ro id  conversion patterns over 
the passages stud ied.
ER p o s i t i ve  c e l l s ,  showed lower E2 degradation and 
lower ox ida t ive  pathway rates (e.g. El fo rmat ion) ,  
higher reduct ive metabol ic rates (e.g.
catecholoestrogens). However, i t  must be underl ined tha t  
s te ro id  receptor s ta tus i s  not,  on " i n  v i t r o "  systems, a 
re l i a b le  index of the hormone s e n s i t i v i t y  s ta tus of the 
c e l l s .  Factors l i k e  the energet ic  charge ( i . e .  ATP or 
cAMP content) or the ce l l  cycle phases should be taken 
in to  account. Thus, a be t te r  d e f i n i t i o n  of hormone 
responsiveness and/or of hormone s e n s i t i v i t y  s tatus of 
c e l l s  is  needed.
Notwithstanding, most popular breast and 
endometrial cancer ce l l  l i n e s ,  recognized and reported
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to be responsive and ER p o s i t ive  -  l i k e  MCF7, ZR75-1, 
T47D and Ishikawa - c o n s t a n t l y  showed the same metabol ic 
conversion pat terns.  On the other hand, some 
unresponsive and ER negative c e l l s  -  l i k e  PMC42, BT20, 
MDA-MB231 -  cons is ten t ly  exh ib i ted a qu ite  d i f f e r e n t  
conversion of E2, s im i l a r l y  to what observed fo r  
endometrial cancer c e l l s  HEC-1A. Therefore, f o r  breast 
and endometrial cancer ce l l  l in e s  a very good 
co r re la t io n  between responsiveness and receptor s tatus 
of ce l l  l i n e s ,  on one hand, and the pecu l ia r  metabol ic 
conversion pat terns,  on the o ther,  was observed.
In prostate c e l l s  the in te rp re ta t io n  of data i s  a 
l i t t l e  b i t  more d i f f i c u l t ;  CAPE (normal unresponsive) 
and CPA (cancer responsive) canine e p i t h e l ia l  c e l l s  show 
opposed metabol ic a b i l i t i e s ,  as do the human ce l l  l in e s  
PC3 and DU145.
These resu l ts  pose two quest ions: l ) , a r e  the normal 
CAPE t r u l y  unresponsive to androgens?; 2) are the DU145 
re a l l y  androgen unresponsive but AR pos i t ive? .  CAPE 
c e l l s  are another example of normal e p i t h e l ia l  c e l l s
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showing l i t t l e  s e n s i t i v i t y  to s te ro ids  and conta ining 
l i t t l e '  or no solub le AR. In our hands, both PC3 and 
CAPE showed a nuclear but never a soluble AR whereas 
CPA and DU145 mostly showed a funct ional  receptor 
mechanism, i . e .  both solub le and nuclear type 1 ~ high 
a f f i n i t y ,  low capacity receptors. The type 1, solub le 
plus nuclear,  receptor p o s i t i ve  prostate c e l l s  showed 
d i f f e r e n t  patterns of s te ro id  metabolism from the 
receptor negat ive ones. This was true over d i f f e r e n t  
condit ions of precursor concentrat ion and ce l l  number.
In s te ro id  metabolism studies in v i t r o ,  a low (10(~ 
8)M of E2 or 10~(9)M of T) precursor mo la r i ty  was 
chosen, since, fo r  t h i s  purpose, not fa r  from 
physio log ica l concentrat ions should be f i r s t l y  tested.
The d i f f e r e n t  metabol ic conversion rates observed 
cannot be a t t r i b u te d  exc lus ive ly  to a d i f f e r e n t  
metabol ic s ta te  of the c e l l s ;  in other words, the c e l l s  
with low a c t i v i t y  in convert ing some s te ro ids  were very 
ac t ive  in convert ing other b io log ica l  ac t ive  compounds, 
For example, in breast or endometrial cancer c e l l s ,  low
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El formation from E2 was observed, but concomitantly 
there was much more catechol oestrogen and E3 formation. 
In prostate cancer c e l l s  less delta4~A was produced, 
but,  at  the same t ime, much more DHT formation from 3H-T 
was observed (see Tab. 6.01).  I t  was also noted that 
DU145 were slow in convert ing T but, in p a r t i c u la r  
experimental condit ions used, grew qu ick ly ,  fa s te r  than 
the CAPE c e l l s  which were, at the same experimental 
condi t ions,  fa s t  converter of T.
In these " i n  v i t r o "  systems, no large conjugate 
formation,  at leas t  at the molar concentrat ion of 
precursor used, was observed. This has also been 
reported by Gurpide and colleagues [Hata et a l . ,  1987],
who showed tha t  conjugate formation is  c le a r l y  re la ted 
to the molar i ty  of precursor added. The absence of 
conjugate formation,  fo r  both oestrogens and androgens, 
though c lear  at 24hr in the experimental condit ions 
used, cannot be completely ruled out f o r  longer 
incubat ions, since ex t rac t ion  e f f i c ie n c y  values were 
lower than expected at 72 or 96 hr.
180
DISCUSSION
Two main conclusions can now be drawn;
1) the double metabol ic patterns encountered also in 
prostate  cancer c e l l s ,  may account fo r  t issue 
accumulation of DHT, prev ious ly  reported by several 
authors [Gel le r  et a l . ,  1984], but never exhaust ive ly 
explained. The same explanat ion fo r  E2 re ten t ion  by 
responsive c e l l s  may be t rue ,  p a r t i c u la r l y  f o r  the 
higher oestrogen content observed in human cancer 
t issues (breast or endometrium) [Vermeulen-Meiners 
et a l . ,  1986]. In f a c t ,  fa s te r  metabol ic conversion 
rates to DHT may eas i ly  expla in  the higher content of 
DHT by responsive prostate cancer; on the other hand, 
the presence of some DHT, in apparent ly unresponsive 
prostate tumours, may be a t t r i b u te d  to the 
heterogeneity of human cancers;
2) there is  a re la t io n  between s te ro id  receptor status 
and s te ro id  hormone concentra t ions. In f a c t ,  the 
receptor p o s i t ive  c e l l s ,  as breast ZR75-1 and T47D or 
the endometrial Ishikawa, re ta in  high level of 
precursor E2. On the contra ry ,  the receptor negat ive
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c e l l s ,  as endometrial HEC-1A or breast PMC-42, 8T-20
and MDA-MB 231, qu ick ly  convert E2 to El.  This could 
simply ind ica te  tha t  s te ro id  bound to receptor is  not 
ava i lab le  fo r  metabolism. However type 1 -  high
a f f i n i t y ,  low capacity -  receptors are present at 
very low concentrat ions ( in  the range of 10-30 
femtomole x 10(6) c e l l s )  r e la t i v e  to the 
corresponding s te ro id .
6.2. Stero id  Tissue Content
The data from the stud ies on s te ro id  t issue content 
may be summarized as fo l low s .  F i r s t l y ,  human cancers 
are very heterogeneous; secondly, large accumulation of 
s te ro ids  occurs in cancer t issues r e la t i v e  to plasma 
values.
Data suggested also tha t  cancer t issues may 
a c t iv e ly  metabolize s te ro ids  [Varela and Dao, 1978; 
Abul-Haj j  et a l . ,  1979c; Thi jssen et a l . ,  1986]. S im i la r  
to the observat ions in v i t r o ,  the metabol ic d i re c t io n  
and the s te ro id  accumulation can be both qu ite  d i f f e r e n t
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in - d i f f e re n t  human cancers (e.g. h igh ly  vs poorly 
d i f f e r e n t ia te d ;  t h i s  i s  true fo r  breast ,  endometrial and 
prostate tumours). The simplest un i fy ing  hypothesis
allows the existence of two patterns, such as prev ious ly  
observed in the s te ro id  excret ion patterns of breast 
and endometrial cancer pa t ien ts  [Castagnetta et a l . ,  
1977; Castagnetta et a l . ,  1981; Castagnetta et a l . ,  
1983; Castagnetta et a l . ,  1985; Castagnetta et a l . ,  
1986d], This view is  also strengthened by the two 
d i f f e r e n t  oestrogen p r o f i l e s  and a number, of other 
parameters, inc lud ing DHAS, in BCF on the basis of K+ to 
Na+ ra t io s .
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